<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation - Valembois, L - 2019 | Cochrane Library</title> <meta content="Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation - Valembois, L - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005049.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation - Valembois, L - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005049.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD005049.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation" name="citation_title"/> <meta content="Lucie Valembois" name="citation_author"/> <meta content="Groupe Hospitalier Pitié‐Salpêtrière‐Charles Foix, AP‐HP, Université Pierre et Marie Curie" name="citation_author_institution"/> <meta content="Etienne Audureau" name="citation_author"/> <meta content="Hôpital Henri‐Mondor, APHP, Université Paris 12 UPEC" name="citation_author_institution"/> <meta content="Andrea Takeda" name="citation_author"/> <meta content="University College London" name="citation_author_institution"/> <meta content="Witold Jarzebowski" name="citation_author"/> <meta content="Centre Hospitalier de Bastia" name="citation_author_institution"/> <meta content="Joël Belmin" name="citation_author"/> <meta content="Université Pierre et Marie Curie (Paris 6)" name="citation_author_institution"/> <meta content="Carmelo Lafuente‐Lafuente" name="citation_author"/> <meta content="Groupe Hospitalier Pitié‐Salpêtrière‐Charles Foix, AP‐HP, Université Pierre et Marie Curie" name="citation_author_institution"/> <meta content="c.lafuente@nodo3.net" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD005049.pub5" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/09/04" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005049.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005049.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005049.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti‐Arrhythmia Agents [*therapeutic use]; Atrial Fibrillation [*prevention &amp; control]; Electric Countershock; Randomized Controlled Trials as Topic; Recurrence; Secondary Prevention" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005049.pub5&amp;doi=10.1002/14651858.CD005049.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005049.pub5&amp;doi=10.1002/14651858.CD005049.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005049.pub5&amp;doi=10.1002/14651858.CD005049.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005049.pub5&amp;doi=10.1002/14651858.CD005049.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005049.pub5&amp;doi=10.1002/14651858.CD005049.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005049.pub5&amp;doi=10.1002/14651858.CD005049.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005049.pub5&amp;doi=10.1002/14651858.CD005049.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005049.pub5&amp;doi=10.1002/14651858.CD005049.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005049.pub5&amp;doi=10.1002/14651858.CD005049.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005049.pub5&amp;doi=10.1002/14651858.CD005049.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005049.pub5&amp;doi=10.1002/14651858.CD005049.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005049.pub5&amp;doi=10.1002/14651858.CD005049.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005049.pub5&amp;doi=10.1002/14651858.CD005049.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005049.pub5&amp;doi=10.1002/14651858.CD005049.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005049.pub5&amp;doi=10.1002/14651858.CD005049.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005049.pub5&amp;doi=10.1002/14651858.CD005049.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005049.pub5&amp;doi=10.1002/14651858.CD005049.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005049.pub5&amp;doi=10.1002/14651858.CD005049.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005049.pub5&amp;doi=10.1002/14651858.CD005049.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005049.pub5&amp;doi=10.1002/14651858.CD005049.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005049.pub5&amp;doi=10.1002/14651858.CD005049.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005049.pub5&amp;doi=10.1002/14651858.CD005049.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005049.pub5&amp;doi=10.1002/14651858.CD005049.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="l7AWCCEw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD005049\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD005049\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005049\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005049\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","fa","fr","es","zh_HANT","ms","ko","hr","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD005049.pub5",title:"Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation",firstPublishedDate:"Sep 4, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Heart Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=l7AWCCEw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005049.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005049.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD005049.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD005049.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005049.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD005049.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD005049.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD005049.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD005049.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD005049.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>19156 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD005049.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005049.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005049.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005049.pub5/full#CD005049-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005049.pub5/full#CD005049-sec-0142"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005049.pub5/full#CD005049-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005049.pub5/full#CD005049-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005049.pub5/full#CD005049-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005049.pub5/full#CD005049-sec-0043"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005049.pub5/full#CD005049-sec-0067"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005049.pub5/full#CD005049-sec-0136"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005049.pub5/appendices#CD005049-sec-0147"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/table_n/CD005049StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/table_n/CD005049StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005049.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005049.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005049.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005049.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005049.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD005049.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005049.pub5/information#CD005049-cr-0002">Lucie Valembois</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005049.pub5/information#CD005049-cr-0003">Etienne Audureau</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005049.pub5/information#CD005049-cr-0004">Andrea Takeda</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005049.pub5/information#CD005049-cr-0005">Witold Jarzebowski</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005049.pub5/information#CD005049-cr-0006">Joël Belmin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005049.pub5/information#CD005049-cr-0007"><i class="icon corresponding-author fa fa-envelope"></i>Carmelo Lafuente‐Lafuente</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/information/en#CD005049-sec-0169">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 04 September 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD005049.pub5">https://doi.org/10.1002/14651858.CD005049.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD005049-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005049-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005049-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005049-abs-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005049-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD005049-abs-0011">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD005049-abs-0014">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD005049-abs-0001" lang="en"> <section id="CD005049-sec-0001"> <h3 class="title" id="CD005049-sec-0001">Background</h3> <p>Atrial fibrillation is the most frequent sustained arrhythmia. Atrial fibrillation often recurs after restoration of normal sinus rhythm. Antiarrhythmic drugs have been widely used to prevent recurrence. This is an update of a review previously published in 2006, 2012 and 2015. </p> </section> <section id="CD005049-sec-0002"> <h3 class="title" id="CD005049-sec-0002">Objectives</h3> <p>To determine the effects of long‐term treatment with antiarrhythmic drugs on death, stroke, drug adverse effects and recurrence of atrial fibrillation in people who had recovered sinus rhythm after having atrial fibrillation. </p> </section> <section id="CD005049-sec-0003"> <h3 class="title" id="CD005049-sec-0003">Search methods</h3> <p>We updated the searches of CENTRAL<i>,</i> MEDLINE and Embase in January 2019, and ClinicalTrials.gov and WHO ICTRP in February 2019. We checked the reference lists of retrieved articles, recent reviews and meta‐analyses. </p> </section> <section id="CD005049-sec-0004"> <h3 class="title" id="CD005049-sec-0004">Selection criteria</h3> <p>Two authors independently selected randomised controlled trials (RCTs) comparing any antiarrhythmic drug with a control (no treatment, placebo, drugs for rate control) or with another antiarrhythmic drug in adults who had atrial fibrillation and in whom sinus rhythm was restored, spontaneously or by any intervention. We excluded postoperative atrial fibrillation. </p> </section> <section id="CD005049-sec-0005"> <h3 class="title" id="CD005049-sec-0005">Data collection and analysis</h3> <p>Two authors independently assessed quality and extracted data. We pooled studies, if appropriate, using Mantel‐Haenszel risk ratios (RR), with 95% confidence intervals (CI). All results were calculated at one year of follow‐up or the nearest time point. </p> </section> <section id="CD005049-sec-0006"> <h3 class="title" id="CD005049-sec-0006">Main results</h3> <p>This update included one new study (100 participants) and excluded one previously included study because of double publication. Finally, we included 59 RCTs comprising 20,981 participants studying quinidine, disopyramide, propafenone, flecainide, metoprolol, amiodarone, dofetilide, dronedarone and sotalol. Overall, mean follow‐up was 10.2 months. </p> <p><b>All‐cause mortality</b> </p> <p>High‐certainty evidence from five RCTs indicated that treatment with sotalol was associated with a higher all‐cause mortality rate compared with placebo or no treatment (RR 2.23, 95% CI 1.03 to 4.81; participants = 1882). The number need to treat for an additional harmful outcome (NNTH) for sotalol was 102 participants treated for one year to have one additional death. Low‐certainty evidence from six RCTs suggested that risk of mortality may be higher in people taking quinidine (RR 2.01, 95% CI 0.84 to 4.77; participants = 1646). Moderate‐certainty evidence showed increased RR for mortality but with very wide CIs for metoprolol (RR 2.02, 95% CI 0.37 to 11.05, 2 RCTs, participants = 562) and amiodarone (RR 1.66, 95% CI 0.55 to 4.99, 2 RCTs, participants = 444), compared with placebo. </p> <p>We found little or no difference in mortality with dofetilide (RR 0.98, 95% CI 0.76 to 1.27; moderate‐certainty evidence) or dronedarone (RR 0.86, 95% CI 0.68 to 1.09; high‐certainty evidence) compared to placebo/no treatment. There were few data on mortality for disopyramide, flecainide and propafenone, making impossible a reliable estimation for those drugs. </p> <p><b>Withdrawals due to adverse events</b> </p> <p>All analysed drugs increased withdrawals due to adverse effects compared to placebo or no treatment (quinidine: RR 1.56, 95% CI 0.87 to 2.78; disopyramide: RR 3.68, 95% CI 0.95 to 14.24; propafenone: RR 1.62, 95% CI 1.07 to 2.46; flecainide: RR 15.41, 95% CI 0.91 to 260.19; metoprolol: RR 3.47, 95% CI 1.48 to 8.15; amiodarone: RR 6.70, 95% CI 1.91 to 23.45; dofetilide: RR 1.77, 95% CI 0.75 to 4.18; dronedarone: RR 1.58, 95% CI 1.34 to 1.85; sotalol: RR 1.95, 95% CI 1.23 to 3.11). Certainty of the evidence for this outcome was low for disopyramide, amiodarone, dofetilide and flecainide; moderate to high for the remaining drugs. </p> <p><b>Proarrhythmia</b> </p> <p>Virtually all studied antiarrhythmics showed increased proarrhythmic effects (counting both tachyarrhythmias and bradyarrhythmias attributable to treatment) (quinidine: RR 2.05, 95% CI 0.95 to 4.41; disopyramide: no data; flecainide: RR 4.80, 95% CI 1.30 to 17.77; metoprolol: RR 18.14, 95% CI 2.42 to 135.66; amiodarone: RR 2.22, 95% CI 0.71 to 6.96; dofetilide: RR 5.50, 95% CI 1.33 to 22.76; dronedarone: RR 1.95, 95% CI 0.77 to 4.98; sotalol: RR 3.55, 95% CI 2.16 to 5.83); with the exception of propafenone (RR 1.32, 95% CI 0.39 to 4.47) for which the certainty of evidence was very low and we were uncertain about the effect. Certainty of the evidence for this outcome for the other drugs was moderate to high. </p> <p><b>Stroke</b> </p> <p>Eleven studies reported stroke outcomes with quinidine, disopyramide, flecainide, amiodarone, dronedarone and sotalol. High‐certainty evidence from two RCTs suggested that dronedarone may be associated with reduced risk of stroke (RR 0.66, 95% CI 0.47 to 0.95; participants = 5872). This result is attributed to one study dominating the meta‐analysis and has yet to be reproduced in other studies. There was no apparent effect on stroke rates with the other antiarrhythmics. </p> <p><b>Recurrence of atrial fibrillation</b> </p> <p>Moderate‐ to high‐certainty evidence, with the exception of disopyramide which was low‐certainty evidence, showed that all analysed drugs, including metoprolol, reduced recurrence of atrial fibrillation (quinidine: RR 0.83, 95% CI 0.78 to 0.88; disopyramide: RR 0.77, 95% CI 0.59 to 1.01; propafenone: RR 0.67, 95% CI 0.61 to 0.74; flecainide: RR 0.65, 95% CI 0.55 to 0.77; metoprolol: RR 0.83 95% CI 0.68 to 1.02; amiodarone: RR 0.52, 95% CI 0.46 to 0.58; dofetilide: RR 0.72, 95% CI 0.61 to 0.85; dronedarone: RR 0.85, 95% CI 0.80 to 0.91; sotalol: RR 0.83, 95% CI 0.80 to 0.87). Despite this reduction, atrial fibrillation still recurred in 43% to 67% of people treated with antiarrhythmics. </p> </section> <section id="CD005049-sec-0007"> <h3 class="title" id="CD005049-sec-0007">Authors' conclusions</h3> <p>There is high‐certainty evidence of increased mortality associated with sotalol treatment, and low‐certainty evidence suggesting increased mortality with quinidine, when used for maintaining sinus rhythm in people with atrial fibrillation. We found few data on mortality in people taking disopyramide, flecainide and propafenone, so it was not possible to make a reliable estimation of the mortality risk for these drugs. However, we did find moderate‐certainty evidence of marked increases in proarrhythmia and adverse effects with flecainide. </p> <p>Overall, there is evidence showing that antiarrhythmic drugs increase adverse events, increase proarrhythmic events and some antiarrhythmics may increase mortality. Conversely, although they reduce recurrences of atrial fibrillation, there is no evidence of any benefit on other clinical outcomes, compared with placebo or no treatment. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD005049-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005049-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005049-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005049-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005049-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD005049-abs-0013">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ko#CD005049-abs-0012">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD005049-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD005049-abs-0015">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD005049-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD005049-abs-0005" lang="en"> <h3>Antiarrhythmics for maintaining sinus rhythm (normal heartbeat) after reversing atrial fibrillation (correcting an irregular heartbeat) </h3> <p><b>Review question</b> </p> <p>We reviewed the evidence about the effect of antiarrhythmic medicines on mortality (death), stroke, side effects that cause people to stop taking the medicine and recurrences of irregular heartbeat, in people who had recovered normal heart rhythm after having atrial fibrillation (a type of irregular heartbeat). </p> <p><b>Background</b> </p> <p>Atrial fibrillation is a disease where the heart rhythm is irregular (called arrhythmia) and often, but not always, too fast. Atrial fibrillation may produce complications, either in the heart (heart failure, fainting) or in other organs by causing embolisms. Embolisms are blood clots that form in the cavities of the heart which may then travel to other places, for example the brain. </p> <p>Atrial fibrillation can be reverted, restoring normal heart rhythm, by using medicines or a controlled electrical shock. However, a major problem is that atrial fibrillation frequently recurs. A variety of medicines have been used to avoid these recurrences and keep the normal heart rhythm. </p> <p><b>Study characteristics</b> </p> <p>This is an update of a review previously published in 2006, 2012 and 2015, and includes results of a search for new studies in January 2019. We found 59 studies testing various antiarrhythmic drugs and involving 20,981 participants. The average age of participants was 65 years. The most frequent diseases were hypertension (high blood pressure) and diseases of the arteries and valves of the heart. We found studies for nine medicines: quinidine, disopyramide, propafenone, flecainide, metoprolol, amiodarone, dofetilide, dronedarone and sotalol. </p> <p><b>Key results and certainty of the evidence</b> </p> <p>High‐certainty evidence from five studies found that deaths from any cause were twice as high in people taking sotalol compared with people taking a placebo (dummy treatment) or no treatment. We calculated that one extra person would die for every 102 people taking sotalol for one year. Evidence for quinidine was low certainty, but the average effect across six studies suggested that people who took quinidine may have a higher risk of death compared with people taking no treatment or placebo. However, the evidence was not strong enough to rule out the possibility that there was no increased risk of death with quinidine. We found few data on mortality for disopyramide, flecainide and propafenone, meaning that we are uncertain of the effect of these drugs on mortality. We found no clear evidence that the other medicines we studied had any effect on risk of death. </p> <p>We found that people taking any of these medicines were more likely to stop taking them due to side effects, compared with people not taking them. We are less certain of the results for disopyramide, amiodarone, dofetilide and flecainide because the low‐certainty evidence mostly came from small studies with design limitations. Evidence was moderate or high for the other medicines. </p> <p>One particular side effect of antiarrhythmic medications is proarrhythmia, which means that people have new or more frequent problems with irregular heartbeats. We found high‐certainty evidence that people taking quinidine or metoprolol had a higher risk of proarrhythmia than people taking no treatment or placebo. Moderate‐certainty evidence indicated a similar increased risk for flecainide, amiodarone, dofetilide, dronedarone and sotalol. Evidence from these studies was moderate certainty due to problems with study limitations, smaller size or imprecise results. We are uncertain of the effect of propafenone on proarrhythmia as we only had very low‐certainty evidence for this medicine. None of the disopyramide studies reported how many people had proarrhythmia. </p> <p>We found high‐certainty evidence that dronedarone may reduce the risk of stroke. There was no evidence of an effect of sotalol (moderate‐certainty evidence); amiodarone, flecainide, quinidine (all low‐certainty evidence) or disopyramide (very low‐certainty evidence) on risk of stroke. No studies reported risk of stroke with propafenone, metoprolol or dofetilide. </p> <p>Moderate‐ to high‐certainty evidence, except disopyramide which was low certainty, showed that all the medicines we assessed reduced recurrence of atrial fibrillation, compared with not taking any treatment or taking a placebo. However, atrial fibrillation still recurred in about half of participants (43% to 67%) treated with antiarrhythmics. </p> <p>Overall, It is unclear whether long‐term treatment with antiarrhythmic medicines carries benefits that outweigh their risks for this group of people. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD005049-sec-0142" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD005049-sec-0142"></div> <h3 class="title" id="CD005049-sec-0143">Implications for practice</h3> <section id="CD005049-sec-0143"> <p>There is high‐certainty evidence of increased all‐cause mortality associated with sotalol treatment, when used for maintaining sinus rhythm in people who had atrial fibrillation. This evidence may have implications for clinical practice, and careful consideration of prescribing for this population would be prudent. </p> <p>We found low‐certainty evidence suggesting that quinidine may be associated with increased mortality, as well as moderate‐certainty evidence of a marked increase in withdrawals due to adverse events and high‐certainty evidence of increased proarrhythmic events. Therefore, the evidence from this review may have implications for prescribing this drug for maintaining sinus rhythm in people who had atrial fibrillation. </p> <p>Flecainide has been shown to induce an excess of mortality in some trials in other heart conditions (<a href="./references#CD005049-bbs2-0164" title="EchtDS , LiebsonPR , MitchellLB , PetersRW , Obias‐MannoD , BarkerAH , et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. New England Journal of Medicine1991;324:781‐8. [PMID: 1900101] ">CAST 1991</a>). Very few data on mortality were available for this drug when employed for maintaining sinus rhythm, making any reliable estimation of mortality in people with atrial fibrillation impossible. However, we found moderate‐certainty evidence of an important increase in proarrhythmic events with flecainide, which would imply a degree of caution may be necessary in using this drug for this population. </p> <p>Overall, chronic treatment with antiarrhythmics drugs may not be the most appropriate first‐line treatment for people with atrial fibrillation given 1. the concerns regarding increased mortality with several drugs; 2. the modest effectiveness of antiarrhythmic drugs for preventing recurrences of atrial fibrillation; 3. the evidence of increased adverse events with all drugs studied; 4. the evidence of increased proarrhythmic events with most drugs studied, and 5. the absence of evidence of any benefit obtained with these drugs on clinical endpoints. Other treatments, or strategies, with fewer associated adverse events, or higher effectiveness, could be considered before using antiarrhythmics, such as no treatment at all, rate control strategy (<a href="./references#CD005049-bbs2-0162" title="CaldeiraD , DavidC , SampaioC . Rate versus rhythm control in atrial fibrillation and clinical outcomes: updated systematic review and meta‐analysis of randomized controlled trials. Archives of Cardiovascular Diseases2012;105(4):226‐38. [DOI: 10.1016/j.acvd.2011.11.005; PUBMED: 22633297] ">Caldeira 2012</a>; <a href="./references#CD005049-bbs2-0167" title="ChatterjeeS , SardarP , LichsteinE , MukherjeeD , AikatS . Pharmacologic rate versus rhythm‐control strategies in atrial fibrillation: an updated comprehensive review and meta‐analysis. Pacing and Clinical Electrophysiology: PACE2013;36(1):122‐33. [DOI: 10.1111/j.1540‐8159.2012.03513.x; PUBMED: 22978656] ">Chatterjee 2013</a>), pulmonary vein catheter ablation (<a href="./references#CD005049-bbs2-0165" title="MarroucheNF , BrachmannJ , AndresenD , SiebelsJ , BoersmaL , JordaensL , et al. Catheter ablation for atrial fibrillation with heart failure. New England Journal of Medicine2018;378(5):417‐27. [DOI: 10.1056/NEJMoa1707855; PUBMED: 29385358] ">CASTLE‐AF 2018</a>; <a href="./references#CD005049-bbs2-0188" title="KhanAR , KhanS , SheikhMA , KhuderS , GrubbB , MoukarbelGV . Catheter ablation and antiarrhythmic drug therapy as first‐ or second‐line therapy in the management of atrial fibrillation: systematic review and meta‐analysis. Circulation. Arrhythmia and Electrophysiology2014;7(5):853‐60. [DOI: 10.1161/CIRCEP.114.001853; PMID: 25110162] ">Khan 2014</a>), or, in selected people with paroxysmal atrial fibrillation, episodic, very short‐term use of antiarrhythmics (in hospital or as needed approach) (<a href="./references#CD005049-bbs2-0157" title='AlboniP , BottoGL , BaldiN , LuziM , RussoV , GianfranchiL , et al. Outpatient treatment of recent‐onset atrial fibrillation with the "pill‐in‐the‐pocket" approach. New England Journal of Medicine2004;351(23):2384‐91. [MEDLINE: PMID: 15575054; ISSN: 0028‐4793] '>Alboni 2004</a>; <a href="./references#CD005049-bbs2-0201" title="SaboridoCM , HockenhullJ , BagustA , BolandA , DicksonR , ToddD . Systematic review and cost‐effectiveness evaluation of 'pill‐in‐the‐pocket' strategy for paroxysmal atrial fibrillation compared to episodic in‐hospital treatment or continuous antiarrhythmic drug therapy. Health Technology Assessment2010;14(31):iii‐iv, 1‐75. [DOI: 10.3310/hta14310; PUBMED: 20569652] ">Saborido 2010</a>). </p> </section> <h3 class="title" id="CD005049-sec-0144">Implications for research</h3> <section id="CD005049-sec-0144"> <p>Adequate evidence exists for some outcomes (withdrawals, proarrhythmia and atrial fibrillation recurrences) for all drugs included in this review. There is good evidence regarding mortality for several antiarrhythmics, but there is an important lack of data on mortality for some drugs, particularly flecainide and propafenone, and limited data for other drugs, such as amiodarone, which does not exclude the possibility of small increases in mortality with them. </p> <p>Available evidence is limited by the lack of systematic assessment in many studies of important clinical outcomes: stroke, heart failure and functional measures (exercise capacity, quality of life). Trials studying antiarrhythmic drugs should measure their effects on these outcomes in addition to prevention of arrhythmia recurrences. Pending questions include the effects of antiarrhythmics on these clinical outcomes, and their effects in specific subgroups of patients, specifically people with heart failure or reduced left ventricular ejection fraction, and older people. </p> <p>Finally, new drugs or other procedures that are more effective in preventing atrial fibrillation recurrence or are associated with fewer adverse effects, or both, would be desirable. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD005049-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD005049-sec-0036"></div> <div class="table" id="CD005049-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Quinidine compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Quinidine compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults in sinus rhythm after cardioversion of atrial fibrillation<br/> <b>Setting:</b> hospital/community<br/> <b>Intervention:</b> quinidine<br/> <b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with quinidine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b><br/> follow‐up: median 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.01</b><br/> (0.84 to 4.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1646<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000<br/> (6 to 36) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Withdrawals due to adverse effects</b><br/> follow‐up: median 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.56</b> (0.87 to 2.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1669<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>c,d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Heterogeneity was high for the main analysis (I<sup>2</sup> = 67%), but the test for subgroup differences indicated that the RR was higher in older studies which used a higher dose. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>163 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>254 per 1000 (142 to 452)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proarrhythmia</b><br/> follow‐up: median 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.05</b><br/> (0.95 to 4.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1676<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b><sup>c,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000<br/> (10 to 48) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stroke</b><br/> follow‐up: median 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.97</b><br/> (0.25 to 3.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1107<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000<br/> (1 to 19) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrence of atrial fibrillation</b><br/> follow‐up: median 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.83</b><br/> (0.78 to 0.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1624<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80.5 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66.8 per 100<br/> (62.8 to 70.8) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for study limitations: majority of studies were at low or unclear risk of bias for at least one of the key domains (allocation concealment, blinding, incomplete outcome data).<br/> <sup>b</sup>Downgraded one level for imprecision: confidence interval included no effect, the possibility of a beneficial effect and a strong harmful effect.<br/> <sup>c</sup>Not downgraded for study limitations, as the two studies contributing majority of weight were at low risk for key domains (allocation concealment, blinding, incomplete outcome data).<br/> <sup>d</sup>Not downgraded for inconsistency: although heterogeneity was high for the main analysis, this was partially explained by subgroup analysis.<br/> <sup>e</sup>Downgraded one level for imprecision: confidence interval included possibility of no effect or small beneficial effect as well as harmful effect.<br/> <sup>f</sup>Not downgraded for imprecision, although CI just included null.<br/> <sup>g</sup>Downgraded one level for imprecision: confidence interval included both important benefits and harms, and event rate was very low. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005049-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Disopyramide compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Disopyramide compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults in sinus rhythm after cardioversion of atrial fibrillation<br/> <b>Setting:</b> hospital/community<br/> <b>Intervention:</b> disopyramide<br/> <b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with disopyramide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b><br/> follow‐up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 5.00</b><br/> (0.25 to 101.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>92<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Anticipated absolute effects per 1000 could not be calculated because there were no deaths in the control group. Risks were the data from the RCT. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0/71</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5/75</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Withdrawals due to adverse effects</b><br/> follow‐up: range 6–12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 3.68</b><br/> (0.95 to 14.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>146<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>104 per 1000<br/> (27 to 401) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proarrhythmia</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stroke</b><br/> follow‐up: range 6–12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.31</b><br/> (0.03 to 2.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>146<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000<br/> (1 to 82) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrence of atrial fibrillation</b><br/> follow‐up: range 6–12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.77</b><br/> (0.59 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>146<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>69.0 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53.1 per 100<br/> (40.7 to 69.7) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for study limitations: both studies had unclear risk of bias for one of the key domains.<br/> <sup>b</sup>Downgraded two levels for imprecision: very small sample size and wide confidence intervals including both important benefits and harms.<br/> <sup>c</sup>Downgraded one level for imprecision: very small sample size. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005049-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Propafenone compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Propafenone compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults in sinus rhythm after cardioversion of atrial fibrillation<br/> <b>Setting:</b> hospital/community<br/> <b>Intervention:</b> propafenone<br/> <b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with propafenone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b><br/> follow‐up: range 6–15 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.19</b><br/> (0.02 to 1.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>212<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Very few data available for this outcome: only 2 deaths reported in 5 included RCTs.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000<br/> (1 to 44) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Withdrawals due to adverse effects</b><br/> follow‐up: range 6–15 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.62</b><br/> (1.07 to 2.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1098<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>61 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>99 per 1000<br/> (65 to 150) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proarrhythmia</b><br/> follow‐up: range 6–15 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.32</b><br/> (0.39 to 4.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>381<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000<br/> (5 to 56) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stroke</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrence of atrial fibrillation</b><br/> follow‐up: range 6–15 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.67</b><br/> (0.61 to 0.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1098<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>73.0 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48.9 per 100<br/> (44.5 to 54.0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for study limitations. All studies had unclear or high risk of bias in at least one of the three key domains (allocation concealment, blinding, incomplete outcome data).<br/> <sup>b</sup>Downgraded two levels for imprecision due to small sample size and confidence interval wide enough to include both important benefit and harm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005049-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Flecainide compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Flecainide compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults in sinus rhythm after cardioversion of atrial fibrillation<br/> <b>Setting:</b> hospital/community<br/> <b>Intervention:</b> flecainide<br/> <b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with flecainide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Withdrawals due to adverse effects</b><br/> follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 15.41</b><br/> (0.91 to 260) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>73<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Anticipated absolute effects per 1000 could not be calculated because there were no withdrawals in the control group. Risks were the data from the RCT. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0/37</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7/36</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proarrhythmia</b><br/> follow‐up: range 6–12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 4.80</b><br/> (1.30 to 17.7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>511<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1000<br/> (8 to 112) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stroke</b><br/> follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.04</b><br/> (0.11 to 39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>362<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Anticipated absolute effects per 1000 could not be calculated because there were no strokes in the control group. Risks were the data from the RCT. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0/81</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3/281</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrence of atrial fibrillation</b><br/> follow‐up: range 6–12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.65</b><br/> (0.55 to 0.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>511<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>69.8 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45.4 per 100<br/> (38.4 to 53.8) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Not downgraded for study limitations. the only included study was at high risk of bias for blinding (less relevant for this outcome) but low risk for other key domains.<br/> <sup>b</sup>Downgraded two levels for imprecision due to small sample size and wide confidence interval that included both possible harm and no effect.<br/> <sup>c</sup>Downgraded one level for study limitations; all studies were at high or unclear risk of bias in at least one of the key domains.<br/> <sup>d</sup>Not downgraded for study limitations. Majority of weight came from 2 largest studies which were at high risk of bias for blinding (less relevant for this outcome) but low risk for other key domains. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005049-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Metoprolol compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Metoprolol compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults in sinus rhythm after cardioversion of atrial fibrillation<br/> <b>Setting:</b> hospital/community<br/> <b>Intervention:</b> metoprolol<br/> <b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Metoprolol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b><br/> follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.02</b><br/> (0.37 to 11.1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>562<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000<br/> (1 to 39) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Withdrawals due to adverse effects</b><br/> follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 3.47</b><br/> (1.48 to 8.1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>562<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000<br/> (31 to 173) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proarrhythmia</b><br/> follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 18.14</b><br/> (2.42 to 135.6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>562<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Anticipated absolute effects per 1000 could not be calculated because there were no events in the control group. Risks are the data from the RCTs. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 / 282</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 / 280</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stroke</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrence of atrial fibrillation</b><br/> follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.83</b> (0.68 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>562<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>72.0 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>59.7 per 100<br/> (49.0 to 73.4) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for imprecision. Confidence intervals included both possible harm and possible benefit.<br/> <sup>b</sup>Downgraded one level for inconsistency: high I<sup>2</sup> statistic (59%) indicated heterogeneity and this could not be explored in subgroup analysis due to only two studies being included. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005049-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Amiodarone compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Amiodarone compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults in sinus rhythm after cardioversion of atrial fibrillation<br/> <b>Setting:</b> hospital/community<br/> <b>Intervention:</b> amiodarone<br/> <b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with amiodarone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b><br/> follow‐up: range 6–12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.66</b><br/> (0.55 to 4.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>444<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>43 per 1000<br/> (14 to 129) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Withdrawals due to adverse effects</b><br/> follow‐up: range 6–16 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 6.70</b><br/> (1.91 to 23.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>319<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49 per 1000<br/> (14 to 172) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proarrhythmia</b><br/> follow‐up: range 6–16 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.22</b><br/> (0.71 to 6.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>673<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000<br/> (6 to 57) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stroke</b><br/> follow‐up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.15</b><br/> (0.30 to 4.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>399<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000<br/> (7 to 100) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrence of atrial fibrillation</b><br/> follow‐up: median 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.52</b><br/> (0.46 to 0.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>812<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>81.2 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42.2 per 100<br/> (37.3 to 47.1) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for imprecision: confidence interval included both possible benefit and harm.<br/> <sup>b</sup>Downgraded one level for study limitations: majority of weight was from studies with unclear or high risk of bias in key domains.<br/> <sup>c</sup>Downgraded one level for imprecision: small sample size.<br/> <sup>d</sup>Not downgraded for study limitations, as the majority weight was from studies at low risk of bias in all key domains.<br/> <sup>e</sup>Downgraded two levels for imprecision: small sample size and wide confidence interval which included both possible benefit and harm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005049-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Dofetilide compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Dofetilide compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults in sinus rhythm after cardioversion of atrial fibrillation<br/> <b>Setting:</b> hospital/community<br/> <b>Intervention:</b> dofetilide<br/> <b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with dofetilide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b><br/> follow‐up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.98</b><br/> (0.76 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1183<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>193 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>189 per 1000<br/> (146 to 245) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Withdrawals due to adverse effects</b><br/> follow‐up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.77</b><br/> (0.75 to 4.2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>677<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>61 per 1000<br/> (26 to 144) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proarrhythmia</b><br/> follow‐up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 5.50</b><br/> (1.33 to 22.8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1183<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000<br/> (3 to 53) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stroke</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrence of atrial fibrillation</b><br/> follow‐up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.72</b> (0.61 to 0.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1183<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>84.2 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60.6 per 100<br/> (51.4 to 71.6) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for study limitations: majority of studies had unclear risk of selection bias.<br/> <sup>b</sup>Downgraded one level for imprecision: confidence interval included both possible benefit and harm.<br/> <sup>c</sup>Not downgraded for study limitations as 51% of weight came from a study with low risk of bias across all domains (but other two studies had unclear risk of selection bias).<br/> <sup>d</sup>Downgraded one level for heterogeneity due to very high I<sup>2</sup> value (79%). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005049-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Dronedarone compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Dronedarone compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults in sinus rhythm after cardioversion of atrial fibrillation<br/> <b>Setting:</b> hospital/community<br/> <b>Intervention:</b> dronedarone<br/> <b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with dronedarone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b><br/> follow‐up: range 6–12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.86</b><br/> (0.68 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6071<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>51 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>44 per 1000<br/> (35 to 56) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Withdrawals due to adverse effects</b><br/> follow‐up: range 6–12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.58</b><br/> (1.34 to 1.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6071<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>122 per 1000<br/> (104 to 143) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proarrhythmia</b><br/> follow‐up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.95</b> (0.77 to 4.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5872<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1000<br/> (14 to 91) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stroke</b><br/> follow‐up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.66</b><br/> (0.47 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5872<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000<br/> (13 to 25) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrence of atrial fibrillation</b><br/> follow‐up: range 6–12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.85</b><br/> (0.80 to 0.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1443<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>76.6 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65.1 per 100<br/> (61.3 to 69.7) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for study limitations: 83% of weight came from a study with unclear blinding, which could be relevant to this outcome.<br/> <sup>b</sup>Downgraded one level for inconsistency due to very high I<sup>2</sup> statistic of 78%.<br/> <sup>c</sup>Downgraded one level for study limitations: most weight came from a study with unclear allocation concealment. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005049-tbl-0009"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Sotalol compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Sotalol compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults in sinus rhythm after cardioversion of atrial fibrillation<br/> <b>Setting:</b> hospital/community<br/> <b>Intervention:</b> sotalol<br/> <b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with sotalol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b><br/> follow‐up: range 6–12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.23</b><br/> (1.03 to 4.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1882<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000<br/> (9 to 40) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Withdrawals due to adverse effects</b><br/> follow‐up: range 6–19 months; median 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.95</b> (1.23 to 3.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2688<br/> (12 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Heterogeneity was high for the main analysis (I<sup>2</sup> = 56%), but the test for subgroup differences indicated that the RR was higher in older studies with sotalol. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>94 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>183 per 1000<br/> (116 to 293) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proarrhythmia</b><br/> follow‐up: median 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 3.55</b><br/> (2.16 to 5.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2989<br/> (12 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 1000<br/> (25 to 68) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stroke</b><br/> follow‐up: range 6–12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.47</b><br/> (0.48 to 4.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1161<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/> (3 to 30) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrence of atrial fibrillation</b><br/> follow‐up: range 6–19 months; median 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.83</b><br/> (0.80 to 0.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3179<br/> (14 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b><sup>a,e,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>78.8 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65.4 per 100<br/> (63.1 to 68.6) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Not downgraded for study limitations. Although the majority of studies had unclear or high risk of bias in at least one of the key domains, the majority of the weight was from studies at low risk of bias in key domains.<br/> <sup>b</sup>Not downgraded for inconsistency. I<sup>2</sup> statistic was 56% for the main analysis, but this was partially explained by subgroup analysis.<br/> <sup>c</sup>Downgraded one level for publication bias: forest plot appeared to be asymmetrical.<br/> <sup>d</sup>Downgraded one level for imprecision: confidence interval included both possible benefit and harm.<br/> <sup>e</sup>Not downgraded for publication bias: funnel plot appears to be broadly symmetrical.<br/> <sup>f</sup>Not downgraded for inconsistency. I<sup>2</sup> statistic was 54% but the forest plot had good overlap in confidence intervals, so a fixed‐effect model was used to maintain the weight of the few larger studies. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD005049-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD005049-sec-0037"></div> <section id="CD005049-sec-0038"> <h3 class="title" id="CD005049-sec-0038">Description of the condition</h3> <p>Atrial fibrillation is the most common sustained arrhythmia and its incidence increases substantially with age (<a href="./references#CD005049-bbs2-0180" title="GoAS , HylekEM , PhillipsKA , ChangY , HenaultLE , SelbyJV , et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA2001;285:2370‐5. [PMID: 11343485] ">Go 2001</a>; <a href="./references#CD005049-bbs2-0189" title="KnuimanM , BriffaT , DivitiniM , ChewD , EikelboomJ , McQuillanB , et al. A cohort study examination of established and emerging risk factors for atrial fibrillation: the Busselton Health Study. European Journal of Epidemiology2014;29(3):181‐90. [DOI: 10.1007/s10654‐013‐9875‐y; PUBMED: 24389686] ">Knuiman 2014</a>; <a href="./references#CD005049-bbs2-0200" title="RuigomezA , JohanssonS , WallanderMA , RodriguezLA . Incidence of chronic atrial fibrillation in general practice and its treatment pattern. Journal of Clinical Epidemiology2002;55:358‐63. [PMID: 11927203] ">Ruigomez 2002</a>). Atrial fibrillation is associated with increased morbidity and mortality, due to stroke, other embolic complications and heart failure (<a href="./references#CD005049-bbs2-0161" title="BenjaminEJ , WolfPA , D'AgostinoRB , SilbershatzH , KannelWB , LevyD . Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation1998;98(10):946‐52. [MEDLINE: PMID: 9737513; ISSN 0009‐7322] ">Benjamin 1998</a>; <a href="./references#CD005049-bbs2-0185" title="HeeringaJ , van derKuipDA , HofmanA , KorsJA , vanHerpenG , StrickerBH , et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. European Heart Journal2006;27(8):949‐53. [PUBMED: 16527828] ">Heeringa 2006</a>; <a href="./references#CD005049-bbs2-0190" title="KrahnAD , ManfredaJ , TateRB , MathewsonFA , CuddyTE . The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow‐Up Study. American Journal of Medicine1995;98:476‐84. [PMID: 7733127] ">Krahn 1995</a>; <a href="./references#CD005049-bbs2-0204" title="StewartS , HartCL , HoleDJ , McMurrayJJ . A population‐based study of the long‐term risks associated with atrial fibrillation: 20‐year follow‐up of the Renfrew/Paisley study. American Journal of Medicine2002;113:359‐64. [PMID: 12401529] ">Stewart 2002</a>). In high‐income countries, atrial fibrillation has grown progressively since the 1990s as a contributing cause of hospitalisation and death (<a href="./references#CD005049-bbs2-0160" title="AyalaC , WattigneyWA , CroftJB , HydukA , MensahGA , DavisH . Atrial fibrillation as a contributing cause of death and Medicare hospitalization – United States, 1999. MMWR. Morbidity and Mortality Weekly Report2003;52(7):128‐31. [PMID: 12617537] ">Ayala 2003</a>; <a href="./references#CD005049-bbs2-0169" title="ChughSS , HavmoellerR , NarayananK , SinghD , RienstraM , BenjaminEJ , et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation2014;129(8):837‐47. [DOI: 10.1161/CIRCULATIONAHA.113.005119; PUBMED: 24345399] ">Chugh 2014</a>; <a href="./references#CD005049-bbs2-0210" title="WattigneyWA , MensahGA , CroftJB . Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation2003;108:711‐6. [PMID: 12885749] ">Wattigney 2003</a>). </p> <p>In people who have atrial fibrillation, normal sinus rhythm is interrupted by periods of atrial fibrillation that may be either symptomatic or asymptomatic. Symptoms can be mild (e.g. palpitations, breathlessness or reduced effort capacity) or severe, causing syncope, heart failure or acute coronary syndrome. Many of the symptoms caused by atrial fibrillation are related to the degree of tachycardia and can be improved by either controlling heart rate (rate control strategy) or converting atrial fibrillation to normal sinus rhythm by electrical or pharmacological means (rhythm control strategy). </p> <p>Most patients alternate between atrial fibrillation and sinus rhythm. The frequency and duration of atrial fibrillation are highly variable, both within patients and between patients, and are employed to classify this arrhythmia (<a href="./references#CD005049-bbs2-0156" title="JanuaryCT , WannLS , AlpertJS , CalkinsH , CigarroaJE , ClevelandJCJr , et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Journal American College Cardiology2014;64(21):e1‐76. [DOI: 10.1016/j.jacc.2014.03.022; MEDLINE: PMID: 24685669] ">AHA/ACC/HRS 2014</a>; <a href="./references#CD005049-bbs2-0174" title="KirchhofP , BenussiS , KotechaD , AhlssonA , AtarD , CasadeiB , et al. ESC Scientific Document Group. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal2016;37(38):2893‐962. [DOI: 10.1093/eurheartj/ehw210; PUBMED: 27567408 ] ">ESC 2016</a>; <a href="./references#CD005049-bbs2-0194" title="National Institute for Health and Care Excellence. Atrial fibrillation: the management of atrial fibrillation. (Clinical Guideline 180), 2014. guidance.nice.org.uk/CG180 (accessed 17 June 2014). ">NICE 2014</a>). If the arrhythmia terminates spontaneously, atrial fibrillation is designated as 'paroxysmal', and it may or may not recur. When atrial fibrillation is sustained beyond seven days, it is designated as 'persistent'. Termination with pharmacological or electrical intervention does not change the designation. When atrial fibrillation is first detected, and it is not known if it will resolve or persist, it is designated 'recent‐onset' or simply 'first‐detected' atrial fibrillation. Finally, 'permanent' atrial fibrillation refers to persistent atrial fibrillation where cardioversion has failed or has not been attempted because it is considered that there is no possibility to restore sinus rhythm. An individual patient can show different classes of atrial fibrillation over time. </p> </section> <section id="CD005049-sec-0039"> <h3 class="title" id="CD005049-sec-0039">Description of the intervention</h3> <p>Many patients recover sinus rhythm spontaneously after an episode of recent‐onset atrial fibrillation, as many as 70% in some studies (<a href="./references#CD005049-bbs2-0179" title="GelerisP , StavratiA , AfthonidisD , KirpizidisH , BoudoulasH . Spontaneous conversion to sinus rhythm of recent (within 24 hours) atrial fibrillation. Journal of Cardiology2001;37:103‐7. [PMID: 11255692] ">Geleris 2001</a>). Electrical and pharmacological cardioversion are very effective in restoring sinus rhythm, even in long‐standing persistent atrial fibrillation. However, one major problem is that recurrence of atrial fibrillation occurs frequently. The risk of recurrence of atrial fibrillation is dependent on age, duration of the atrial fibrillation, and the existence and severity of underlying heart disease (<a href="./references#CD005049-bbs2-0175" title="FlakerGC , FletcherKA , RothbartRM , HalperinJL , Hart RG: Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Clinical and echocardiographic features of intermittent atrial fibrillation that predict recurrent atrial fibrillation. American Journal of Cardiology1995;76:355‐8. [PMID: 7639159] ">Flaker 1995</a>; <a href="./references#CD005049-bbs2-0177" title="FrickM , FrykmanV , Jensen‐UrstadM , OstergrenJ , RosenqvistM . Factors predicting success rate and recurrence of atrial fibrillation after first electrical cardioversion in patients with persistent atrial fibrillation. Clinical Cardiology2001;24:238‐44. [PMID: 11288971] ">Frick 2001</a>). The overall rate of recurrence of atrial fibrillation without treatment is high; of patients who have converted to sinus rhythm, only 20% to 30% will have remained in sinus rhythm one year later (<a href="./references#CD005049-bbs2-0063" title="AFFIRM Investigators, ChungMK , ShemanskiL , ShermanDG , GreeneHL , HoganDB , KellenJC , et al. Functional status in rate‐ versus rhythm‐control strategies for atrial fibrillation: results of the Atrial Fibrillation Follow‐Up Investigation of Rhythm Management (AFFIRM) Functional Status Substudy. Journal of the American College of Cardiology2005;46(10):1891‐9. [PUBMED: PMID: 16286177] AFFIRM Investigators, CorleySD , EpsteinAE , DiMarcoJP , DomanskiMJ , GellerN , GreeneHL , et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow‐Up Investigation of Rhythm Management (AFFIRM) Study. Circulation2004;109(12):1509‐13. [PUBMED: PMID: 15007003] WyseDG , WaldoAL , DiMarcoJP , DomanskiMJ , RosenbergY , SchronEB , et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. New England Journal of Medicine2002;347(23):1825‐33. [MEDLINE: PMID: 12466506; ISSN 0028‐4793] ">AFFIRM 2002</a>; <a href="./references#CD005049-bbs2-0181" title="GolzariH , CebulRD , BahlerRC . Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy. Annals of Internal Medicine1996;125:311‐23. [PMID: 8678396] ">Golzari 1996</a>; <a href="./references#CD005049-bbs2-0208" title="VanGelderIC , CrijnsHJ , TielemanRG , BrugemannJ , DeKamPJ , GosselinkAT , et al. Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. Archives of Internal Medicine1996;156:2585‐92. [PMID: 8951302] ">Van Gelder 1996</a>). </p> <p>Long‐term antiarrhythmic therapy has been widely used to prevent the recurrence of atrial fibrillation. Antiarrhythmic drugs are usually grouped into four classes following the classification by Vaughan Williams (<a href="./references#CD005049-bbs2-0209" title="Vaughan WilliamsEM . A classification of antiarrhythmic actions reassessed after a decade of new drugs. Journal of Clinical Pharmacology1984;24(4):129‐47. [MEDLINE: PMID: 6144698; ISSN: 0091‐2700] ">Vaughan Williams 1984</a>). Class I drugs are those with a direct membrane action (sodium channel blockade), subdivided to Ia, Ib and Ic depending on specific effects on conduction and repolarisation; class II drugs are beta‐blockers; class III drugs are those that prolong repolarisation; and class IV drugs are calcium channel blockers. There is evidence that several class I, class III and maybe class II antiarrhythmic drugs are more effective than placebo for maintaining sinus rhythm (<a href="./references#CD005049-bbs2-0193" title="MillerMR , McNamaraRL , SegalJB , KimN , RobinsonKA , GoodmanSN , et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta‐analysis of clinical trials. Journal of Family Practice2000;49:1033‐46. [PMID: 11093570] ">Miller 2000</a>; <a href="./references#CD005049-bbs2-0195" title="NicholG , McAlisterF , PhamB , LaupacisA , SheaB , GreenM , et al. Meta‐analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation. Heart2002;87:535‐43. [PMID: 12010934] ">Nichol 2002</a>). However, some questions remain concerning the long‐term use of antiarrhythmic drugs. </p> </section> <section id="CD005049-sec-0040"> <h3 class="title" id="CD005049-sec-0040">How the intervention might work</h3> <p>It has been assumed that keeping patients in sinus rhythm would improve their quality of life and reduce the risks of embolism, stroke, heart failure or increased mortality that are associated with atrial fibrillation (<a href="./references#CD005049-bbs2-0158" title="AnterE , CallansDJ , WyseDG . Pharmacological and electrical conversion of atrial fibrillation to sinus rhythm is worth the effort. Circulation2009;120(14):1436‐43. [PUBMED: 19805660] ">Anter 2009</a>). However, this has not been confirmed and, unfortunately, many of the trials with antiarrhythmic drugs have focused only on maintenance of sinus rhythm and have not assessed other relevant outcomes (<a href="./references#CD005049-bbs2-0171" title="ConnollySJ . Appropriate outcome measures in trials evaluating treatment of atrial fibrillation. American Heart Journal2000;139:752‐60. [PMID: 10783204] ">Connolly 2000</a>). Overall, rhythm control strategy, using antiarrhythmics to maintain sinus rhythm, has shown no clear benefit on clinical outcomes (e.g. mortality or stroke) in randomised controlled trials (RCTs) compared to a rate control strategy (<a href="./references#CD005049-bbs2-0162" title="CaldeiraD , DavidC , SampaioC . Rate versus rhythm control in atrial fibrillation and clinical outcomes: updated systematic review and meta‐analysis of randomized controlled trials. Archives of Cardiovascular Diseases2012;105(4):226‐38. [DOI: 10.1016/j.acvd.2011.11.005; PUBMED: 22633297] ">Caldeira 2012</a>; <a href="./references#CD005049-bbs2-0167" title="ChatterjeeS , SardarP , LichsteinE , MukherjeeD , AikatS . Pharmacologic rate versus rhythm‐control strategies in atrial fibrillation: an updated comprehensive review and meta‐analysis. Pacing and Clinical Electrophysiology: PACE2013;36(1):122‐33. [DOI: 10.1111/j.1540‐8159.2012.03513.x; PUBMED: 22978656] ">Chatterjee 2013</a>; <a href="./references#CD005049-bbs2-0202" title="SethiNJ , FeinbergJ , NielsenEE , SafiS , GluudC , JakobsenJC . The effects of rhythm control strategies versus rate control strategies for atrial fibrillation and atrial flutter: a systematic review with meta‐analysis and Trial Sequential Analysis. PloS One2017;12(10):e0186856. [DOI: 10.1371/journal.pone.0186856; PUBMED: 29073191] ">Sethi 2017</a>). </p> <p>Chronic treatment with antiarrhythmic drugs can be associated with severe adverse effects, including the potential induction of life‐threatening arrhythmias (a phenomenon called proarrhythmia). Adverse effects could compromise any benefits of maintaining sinus rhythm, or even outweigh them, leading to worse outcomes overall. In fact, the results of some trials show increased mortality associated with the long‐term use of some antiarrhythmics, as in the case with quinidine (<a href="./references#CD005049-bbs2-0172" title="CoplenSE , AntmanEM , BerlinJA , HewittP , ChalmersTC . Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta‐analysis of randomized control trials. Circulation1990;82:1106‐16. [PMID: 2144796] ">Coplen 1990</a>; <a href="./references#CD005049-bbs2-0203" title="FlakerGC , BlackshearJL , McBrideR , KronmalRA , HalperinJL , HartRG . Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. Journal of the American College of Cardiology1992;20:527‐32. [PMID: 1512329] ">SPAF 1992</a>), or flecainide (<a href="./references#CD005049-bbs2-0164" title="EchtDS , LiebsonPR , MitchellLB , PetersRW , Obias‐MannoD , BarkerAH , et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. New England Journal of Medicine1991;324:781‐8. [PMID: 1900101] ">CAST 1991</a>). Finally, it is not known if all antiarrhythmic drugs are equivalent in their effectiveness and safety in the treatment of atrial fibrillation. </p> </section> <section id="CD005049-sec-0041"> <h3 class="title" id="CD005049-sec-0041">Why it is important to do this review</h3> <p>Many trials have studied long‐term treatment with diverse antiarrhythmic drugs for maintaining sinus rhythm, sometimes compared to placebo and sometimes compared to other antiarrhythmic drugs. Attempts to summarise this evidence in systematic reviews of trials or meta‐analyses have been incomplete. They were combined in one narrative review (<a href="./references#CD005049-bbs2-0181" title="GolzariH , CebulRD , BahlerRC . Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy. Annals of Internal Medicine1996;125:311‐23. [PMID: 8678396] ">Golzari 1996</a>); trials using different antiarrhythmics and with very dissimilar lengths of treatment were pooled together (<a href="./references#CD005049-bbs2-0195" title="NicholG , McAlisterF , PhamB , LaupacisA , SheaB , GreenM , et al. Meta‐analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation. Heart2002;87:535‐43. [PMID: 12010934] ">Nichol 2002</a>); and outcomes other than sinus rhythm maintenance were not evaluated (<a href="./references#CD005049-bbs2-0193" title="MillerMR , McNamaraRL , SegalJB , KimN , RobinsonKA , GoodmanSN , et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta‐analysis of clinical trials. Journal of Family Practice2000;49:1033‐46. [PMID: 11093570] ">Miller 2000</a>). Consequently, we planned to conduct a more exhaustive systematic review of RCTs studying the long‐term use of antiarrhythmic drugs to maintain sinus rhythm and aimed to determine their effects not only on the recurrence of atrial fibrillation but also on other important clinical outcomes. </p> <p>After the first publication of this review, another meta‐analysis on the same subject was published by Freemantle and colleagues (<a href="./references#CD005049-bbs2-0176" title="FreemantleN , Lafuente‐LafuenteC , MitchellS , EckertL , ReynoldsM . Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide and propafenone, for the management of atrial fibrillation. Europace2011;13(3):329‐45. [PUBMED: 21227948] ">Freemantle 2011</a>). The meta‐analysis employed a mixed treatment comparison method, combining the estimates obtained from direct and indirect comparisons in a network of trials. Network meta‐analysis represents an interesting extension of traditional pair‐wise meta‐analyses and can potentially provide a more complete overview of a health set. However, appropriate use of these methods requires strict assumptions and standardisation (<a href="./references#CD005049-bbs2-0163" title="CaldwellDM , DiasS , WeltonNJ . Extending treatment networks in health technology assessment: how far should we go?. Value Health2015;18(5):673‐81. [DOI: 10.1016/j.jval.2015.03.1792] ">Caldwell 2015</a>). Although assumptions underlying classical pair‐wise meta‐analyses are well understood, the conduction of network meta‐analysis still poses multiple challenges that should be carefully considered when using such methods (<a href="./references#CD005049-bbs2-0170" title="CiprianiA , HigginsJP , GeddesJR , SalantiG . Conceptual and technical challenges in network meta‐analysis. Ann Intern Med2013;159(2):130‐137. [DOI: 10.7326/0003‐4819‐159‐2‐201307160‐00008] ">Cipriani 2013</a>; <a href="./references#CD005049-bbs2-0207" title="ToninFS , RottaI , MendesAM , PontaroloR . Network meta‐analysis: a technique to gather evidence from direct and indirect comparisons. Pharmacy Practice2017;15(1):943. ">Tonin 2017</a>). </p> <p>In any case, after the first publication of this review in 2007 and the publication of the meta‐analysis by <a href="./references#CD005049-bbs2-0176" title="FreemantleN , Lafuente‐LafuenteC , MitchellS , EckertL , ReynoldsM . Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide and propafenone, for the management of atrial fibrillation. Europace2011;13(3):329‐45. [PUBMED: 21227948] ">Freemantle 2011</a>, several new RCTs have been published. We have systematically searched, assessed and, when found adequate, included any new trial in this domain in the successive updates of this review. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD005049-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD005049-sec-0042"></div> <p>To determine the effects of long‐term treatment with antiarrhythmic drugs on death, stroke, drug adverse effects and recurrence of atrial fibrillation in people who have recovered sinus rhythm after having atrial fibrillation. </p> <p>The primary aim was to assess the effects of any antiarrhythmic drug compared with no antiarrhythmic treatment, that is, no treatment, placebo or treatment for rate control. If several antiarrhythmic drugs appeared to be effective the secondary aim was to compare them. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD005049-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD005049-sec-0043"></div> <section id="CD005049-sec-0044"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD005049-sec-0045"> <h4 class="title">Types of studies</h4> <p>RCTs with concealed allocation of participants to intervention or placebo. We excluded studies that were not randomised or that used an overt allocation method, where future assignments could be anticipated (e.g. by date, by entry number, alternating or rotating). We also excluded cross‐over studies (as the recurrence rate of atrial fibrillation is not uniform over time), cluster‐randomised studies (more prone to selection bias and to local variations in other intervention applied to people with atrial fibrillation) and studies where duration of follow‐up was less than six months. </p> </section> <section id="CD005049-sec-0046"> <h4 class="title">Types of participants</h4> <p>Adults (aged more than 16 years) who had atrial fibrillation of any type and duration and in whom sinus rhythm had been restored, spontaneously or by any therapeutic intervention. </p> <p>We excluded people with atrial fibrillation following cardiac surgery and people with any condition causing a life expectancy of less than 12 months. </p> </section> <section id="CD005049-sec-0047"> <h4 class="title">Types of interventions</h4> <p>To be included, studies must have randomly allocated participants to an intervention group or a control group. The intervention group must have received oral long‐term treatment with any available antiarrhythmic drug, at an appropriate dosing regimen, aimed at preventing new episodes of atrial fibrillation and maintaining sinus rhythm. </p> <p>For the primary comparison of the review, the control group was no active treatment, this is, any of the following: placebo, no treatment or drugs for rate control (digoxin, calcium channel blockers, beta‐blockers). </p> <p>For the secondary objective of evaluating differences between antiarrhythmic drugs, the control group could have been any of the other antiarrhythmic drugs that have shown effectiveness compared to no antiarrhythmic treatment. </p> <p>Both groups, intervention and control, had to be similar with regard to cardiac disease (frequency, type and severity) and type of atrial fibrillation (especially duration). Also, both groups must have been treated similarly apart from the experimental therapy, that is: </p> <p> <ol id="CD005049-list-0001"> <li> <p>the guidelines used to manage initiation, discontinuation, dose and surveillance of anticoagulation had to be the same in both the intervention and control groups; </p> </li> <li> <p>management and drugs used for hypertension and heart failure had to be similar.</p> </li> </ol> </p> </section> <section id="CD005049-sec-0048"> <h4 class="title">Types of outcome measures</h4> <section id="CD005049-sec-0049"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD005049-list-0002"> <li> <p>All‐cause mortality</p> </li> <li> <p>Adverse effects: withdrawals from taking the study drug caused by adverse events.</p> </li> <li> <p>Adverse effects: proarrhythmia, including any of the following: sudden death, any new symptomatic arrhythmia (including symptomatic bradycardia), aggravation of existing arrhythmias (i.e. rapid atrial fibrillation) and new appearance on electrocardiogram (ECG) of QRS or QT widening that led to stopping treatment (<a href="./references#CD005049-bbs2-0178" title="FriedmanPL , StevensonWG . Proarrhythmia. American Journal of Cardiology1998;82(8A):50N‐8N. [MEDLINE: PMID: 9809901; ISSN: 0002‐9149] ">Friedman 1998</a>). </p> </li> <li> <p>Stroke, all types.</p> </li> </ol> </p> </section> <section id="CD005049-sec-0050"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD005049-list-0003"> <li> <p>Recurrence of atrial fibrillation (number of participants who had a recurrence of atrial fibrillation during follow‐up). </p> </li> <li> <p>Use of anticoagulation (number of participants started on long‐term treatment with anticoagulants at the end of follow‐up). </p> </li> <li> <p>Heart failure.</p> </li> </ol> </p> <p>We analysed all outcomes at 12 months. If a trial did not measure outcomes at this exact time point then we used the nearest measure point (e.g. at six, nine or 15 months instead of 12 months). </p> </section> </section> </section> <section id="CD005049-sec-0051"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD005049-sec-0052"> <h4 class="title">Electronic searches</h4> <p>We updated the searches from 2005 (<a href="./appendices#CD005049-sec-0148">Appendix 1</a>), 2010 (<a href="./appendices#CD005049-sec-0152">Appendix 2</a>), and 2014 (<a href="./appendices#CD005049-sec-0156">Appendix 3</a>) and reran them on 31 January 2019 (<a href="./appendices#CD005049-sec-0162">Appendix 4</a>). </p> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (2019, Issue 1 of 12), MEDLINE (Ovid, 1946 to 28 January 2019) and Embase (Ovid, 1980 to 2019 week 4). </p> <p>We also searched two clinical trials registers; ClinicalTrials.gov (<a href="https://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>) (up to 7 February 2019) and the World Health Organization International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) (up to 7 February 2019). </p> <p>We applied the RCT filter for MEDLINE was the Cochrane sensitivity‐maximising RCT filter, and for Embase, terms as recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD005049-bbs2-0192" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration. ">Lefebvre 2011</a>). </p> </section> <section id="CD005049-sec-0053"> <h4 class="title">Searching other resources</h4> <p>In addition, we checked the reference lists of retrieved studies and the reference lists of recent guidelines, meta‐analyses and general reviews on atrial fibrillation. </p> <p>We applied no language restrictions.</p> </section> </section> <section id="CD005049-sec-0054"> <h3 class="title" id="CD005049-sec-0054">Data collection and analysis</h3> <section id="CD005049-sec-0055"> <h4 class="title">Selection of studies</h4> <p>Any of the authors read the titles (and abstracts where available) and retrieved any publication that seemed to possibly meet the inclusion criteria. Two authors independently read the full texts of the studies that were retrieved and selected the trials that met the criteria for inclusion. We developed and used a predefined form for this task. We compared the selected trials and resolved any discrepancy by discussion and consensus between the authors. We checked the articles that were finally selected for the review to avoid duplication of data. We kept records of the selection process and prepared a PRISMA flowchart (<a href="./references#CD005049-bbs2-0198" title="PRISMA Group, MoherD , LiberatiA , TetzlaffJ , AltmanDG . Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. PLoS Medicine2009;6(7):e1000097. [PUBMED: 19621072] ">PRISMA 2009</a>). </p> </section> <section id="CD005049-sec-0056"> <h4 class="title">Data extraction and management</h4> <p>Two authors (from LV, WJ, JB, CLL) extracted data independently using a data collection form specifically developed for this task. When necessary, we contacted the authors of primary studies for additional information. We checked the completed data forms for agreement and resolved any differences by discussion and consensus. </p> <p>In addition to data relating to the outcomes of the review, we collected information on the following. </p> <p> <ol id="CD005049-list-0004"> <li> <p>Study methods and design (randomisation, allocation concealment and blinding).</p> </li> <li> <p>Baseline characteristics of participants (age, gender, frequency and type of heart disease, echocardiographic measures, duration and type of atrial fibrillation, as defined in each study and knowing that definitions employed were not always consistent). </p> </li> <li> <p>Details of treatments (method of cardioversion employed, time interval between conversion to sinus rhythm and initiation of intervention, antiarrhythmic drugs used and dose, treatment used in control group, concomitant treatments (beta‐blockers, angiotensin‐converting enzyme inhibitors, antiplatelets and warfarin)). </p> </li> <li> <p>Follow‐up duration, participants lost to follow‐up and withdrawals.</p> </li> </ol> </p> </section> <section id="CD005049-sec-0057"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two authors (from LV, EA, WJ, JB, CLL) independently assessed the risk of bias of the selected studies across the following domains recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD005049-bbs2-0187" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook. Cochrane. ">Higgins 2017</a>): random sequence generation, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and any other source of bias. </p> <p>We resolved any differences of opinion by discussion and consensus.</p> </section> <section id="CD005049-sec-0058"> <h4 class="title">Measures of treatment effect</h4> <p>We determined the risk ratio (RR) with 95% confidence intervals (CI) for all outcomes as they were all dichotomous variables. If evidence of an effect appeared for any outcome and the control group rates of the outcomes were broadly similar, we calculated the number needed to treat for an additional beneficial outcome (NNTB) or number needed to treat for an additional harmful outcome (NNTH) to prevent or produce, respectively, one adverse outcome for the specified duration of treatment. We used the pooled RR and the pooled rate from the control groups. </p> </section> <section id="CD005049-sec-0059"> <h4 class="title">Unit of analysis issues</h4> <p>The review includes no cross‐over trials or cluster randomised trials. For trials with multiple time points, we included only data at one year (or the nearest time point). For trials comparing two antiarrhythmics and placebo or no treatment, we divided the placebo (or no treatment) group into two groups with smaller sample size, to include two different comparisons. </p> </section> <section id="CD005049-sec-0060"> <h4 class="title">Dealing with missing data</h4> <p>We analysed the data on the basis of intention‐to‐treat. By default, we considered missing participants not to have experienced an event and we used the randomised number of participants as the denominator. Nevertheless, we also carried out the worst‐case scenario intention‐to‐treat‐analysis for all outcomes as a sensitivity analysis. </p> </section> <section id="CD005049-sec-0061"> <h4 class="title">Assessment of heterogeneity</h4> <p>We tested heterogeneity using the Mantel‐Haenszel Chi<sup>2</sup> test and the I<sup>2</sup> statistic (<a href="./references#CD005049-bbs2-0186" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). If we found important heterogeneity, we searched for an explanation based on the differences in clinical characteristics of the included studies. If the studies were clinically very dissimilar, they were not statistically combined. </p> </section> <section id="CD005049-sec-0062"> <h4 class="title">Assessment of reporting biases</h4> <p>We used funnel plots to test for the presence of publication bias, based on the data for each primary and secondary outcome. </p> </section> <section id="CD005049-sec-0063"> <h4 class="title">Data synthesis</h4> <p>We pooled data using Review Manager 5 (<a href="./references#CD005049-bbs2-0199" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). If there was no heterogeneity, we calculated Mantel‐Haenszel RRs for all outcomes using a fixed‐effect model. If there was heterogeneity between studies, we calculated RRs using a random‐effects model. </p> <p>We pooled data for all antiarrhythmic drugs and analysed them individually (for each specific drug). </p> <section id="CD005049-sec-0064"> <h5 class="title">'Summary of findings' table</h5> <p>We created 'Summary of findings' tables using the following outcomes: all‐cause mortality, withdrawals due to adverse effects, proarrhythmia, stroke and recurrence of atrial fibrillation<i>.</i> We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the certainty of a body of evidence as it related to the studies which contributed data to the meta‐analyses for the prespecified outcomes. We used methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD005049-bbs2-0186" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>) using <a href="./references#CD005049-bbs2-0182" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed December 2018. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro GDT</a>. We prepared a separate 'Summary of findings' table for each drug. We justified all decisions to downgrade the certainty of studies using footnotes and we made comments to aid reader's understanding of the review where necessary. </p> <p>Two authors (AT, CLL) made GRADE assessments and justified, documented and incorporated their judgements into reporting of results for each outcome. </p> </section> </section> <section id="CD005049-sec-0065"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Predefined subgroup analyses were:</p> <p> <ol id="CD005049-list-0005"> <li> <p>paroxysmal atrial fibrillation and persistent atrial fibrillation;</p> </li> <li> <p>people with heart failure compared to people who had never developed heart failure;</p> </li> <li> <p>studies where warfarin was mandatory versus studies where warfarin was discretionary; and </p> </li> <li> <p>people with a structurally normal heart ('lone' atrial fibrillation).</p> </li> </ol> </p> </section> <section id="CD005049-sec-0066"> <h4 class="title">Sensitivity analysis</h4> <p>Sensitivity analyses were performed by selectively pooling:</p> <p> <ol id="CD005049-list-0006"> <li> <p>studies having low risk of bias in the following domains: allocation concealment, blinding and incomplete outcome data; and </p> </li> <li> <p>studies including more than 200 participants.</p> </li> </ol> </p> <p>In addition, we carried out the worst‐case scenario intention‐to‐treat‐analysis (i.e. considering all missing participants as having events) for all outcomes to test if any potential difference might have arisen due to losses to follow‐up. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD005049-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD005049-sec-0067"></div> <section id="CD005049-sec-0068"> <h3 class="title">Description of studies</h3> <section id="CD005049-sec-0069"> <h4 class="title">Results of the search</h4> <p>We found 6332 references and assessed 205 articles in more detail for the previous publication of this review (<a href="./references#CD005049-bbs2-0213" title="Lafuente‐LafuenteC , ValemboisL , BergmannJF , BelminJ . Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD005049.pub4] ">Lafuente‐Lafuente 2015</a>). We retrieved, translated, when needed, and assessed articles in Chinese, English, French, German, Italian, Spanish and Swedish. Finally, 59 studies fulfilled the inclusion criteria and had useable data. They comprised 20,981 participants in total. </p> <p>Compared with the previous publication of this review in 2015, which searched the medical literature until January 2014, we read 2185 additional references (LV, CLL, AT), assessed in detail 22 new articles (LV, EA, CLL, WJ), included one new RCT (<a href="./references#CD005049-bbs2-0014" title="ChunKJ , ByeonK , ImSI , ParkKM , ParkSJ , KimJS , et al. Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion. Clinical Therapeutics2014;36(9):1169‐75. [DOI: 10.1016/j.clinthera.2014.07.013; PUBMED: 25134972] ">Chun 2014</a>), and identified one ongoing study (<a href="./references#CD005049-bbs2-0155" title="ParkYM , ChaMS , KangWC , HanSH , KohKK , AhnT , et al. Efficacy of short‐ and long‐term antiarrhythmic use (flecainide) in maintaining sinus rhythm in patients with first developed paroxysmal atrial fibrillation; prospective‐randomized study, interim analysis. Heart Rhythm2017;14(5 Suppl 1):S304. ParkYM , ChaMS , KangWC , HanSH , KohKK , AhnT , et al. Efficacy of short‐and long‐term anti‐arrhythmic use in maintaining sinus rhythm in patients with first developed paroxysmal atrial fibrillation; prospective‐randomized study, interim analysis. Europace2017;19(Suppl 3):iii46. ">Park 2017</a>). The new included trial compared dronedarone and propafenone, added 100 more participants and reported only atrial fibrillation recurrence rates, but not mortality or adverse events. </p> <p>During our process of checking papers for duplicate publications, we became aware that the data from one study we had previously included by the SVA‐4 Investigators (SVA‐4 2008a), was already reported in another included publication (<a href="./references#CD005049-bbs2-0006" title='ConnollySJ , SchnellDJ , PageRL , WilkinsonWE , MarcelloSR , PritchettEL . Dose‐response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. American Journal of Cardiology2001;88(9):974‐9. [MEDLINE: PMID: 11703992; ISSN 0002‐9149] ConnollySJ , SchnellDJ , PageRL , WilkinsonWE , MarcelloSR , PritchettEL , Azimilide Supraventricular Arrhythmia Program Investigators. Symptoms at the time of arrhythmia recurrence in patients receiving azimilide for control of atrial fibrillation or flutter: results from randomized trials. American Heart Journal2003;146(3):489‐93. [MEDLINE: PMID: 12947368; ISSN: 0002‐8703] PageRL , ConnollySJ , WilkinsonWE , MarcelloSR , SchnellDJ , PritchettEL , Azimilide Supraventricular Arrhythmia Program (ASAP) Investigators. Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and dose‐response. American Heart Journal2002;143(4):643‐9. [MEDLINE: PMID: 11923801; ISSN 0002‐8703] PageRL , TilschTW , ConnollySJ , SchnellDJ , MarcelloSR , WilkinsonWE , et al. Azimilide Supraventricular Arrhythmia Program (ASAP) Investigators. Asymptomatic or "silent" atrial fibrillation: frequency in untreated patients and patients receiving azimilide. Circulation2003;107(8):1141‐5. [MEDLINE: PMID: 12615792; ISSN 0009‐7322] PritchettEL , PageRL , ConnollySJ , MarcelloSR , SchnellDJ , WilkinsonWE . Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose‐response. Azimilide Supraventricular Arrhythmia Program 3 (SVA‐3) Investigators. Journal of the American College of Cardiology2000;36(3):794‐802. [MEDLINE: PMID: 10987602; ISSN 0735‐1097] SVA‐4 Investigators, PageRL , PritchettEL , ConnollyS , WilkinsonWE . Azimilide for the treatment of atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia: results of a randomized trial and insights on the concordance of symptoms and recurrent arrhythmias. Journal of Cardiovascular Electrophysiology2008;19(2):172‐7. [PUBMED: PMID: 17916138] '>ASAP 2003</a>). Therefore, we removed this study from the analysis, and listed it with the main <a href="./references#CD005049-bbs2-0006" title='ConnollySJ , SchnellDJ , PageRL , WilkinsonWE , MarcelloSR , PritchettEL . Dose‐response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. American Journal of Cardiology2001;88(9):974‐9. [MEDLINE: PMID: 11703992; ISSN 0002‐9149] ConnollySJ , SchnellDJ , PageRL , WilkinsonWE , MarcelloSR , PritchettEL , Azimilide Supraventricular Arrhythmia Program Investigators. Symptoms at the time of arrhythmia recurrence in patients receiving azimilide for control of atrial fibrillation or flutter: results from randomized trials. American Heart Journal2003;146(3):489‐93. [MEDLINE: PMID: 12947368; ISSN: 0002‐8703] PageRL , ConnollySJ , WilkinsonWE , MarcelloSR , SchnellDJ , PritchettEL , Azimilide Supraventricular Arrhythmia Program (ASAP) Investigators. Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and dose‐response. American Heart Journal2002;143(4):643‐9. [MEDLINE: PMID: 11923801; ISSN 0002‐8703] PageRL , TilschTW , ConnollySJ , SchnellDJ , MarcelloSR , WilkinsonWE , et al. Azimilide Supraventricular Arrhythmia Program (ASAP) Investigators. Asymptomatic or "silent" atrial fibrillation: frequency in untreated patients and patients receiving azimilide. Circulation2003;107(8):1141‐5. [MEDLINE: PMID: 12615792; ISSN 0009‐7322] PritchettEL , PageRL , ConnollySJ , MarcelloSR , SchnellDJ , WilkinsonWE . Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose‐response. Azimilide Supraventricular Arrhythmia Program 3 (SVA‐3) Investigators. Journal of the American College of Cardiology2000;36(3):794‐802. [MEDLINE: PMID: 10987602; ISSN 0735‐1097] SVA‐4 Investigators, PageRL , PritchettEL , ConnollyS , WilkinsonWE . Azimilide for the treatment of atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia: results of a randomized trial and insights on the concordance of symptoms and recurrent arrhythmias. Journal of Cardiovascular Electrophysiology2008;19(2):172‐7. [PUBMED: PMID: 17916138] '>ASAP 2003</a> reference in the list of <a href="./references#CD005049-bbs1-0001" title="">Included studies</a>. </p> <p><a href="#CD005049-fig-0001">Figure 1</a> illustrates the selection of articles, following the PRISMA model. Agreement between authors was good for both selecting studies and extracting the data. Details of each included study are shown in the <a href="./references#CD005049-sec-0175" title="">Characteristics of included studies</a> table, and the reasons for exclusion are shown in the <a href="./references#CD005049-sec-0176" title="">Characteristics of excluded studies</a> table. </p> <div class="figure" id="CD005049-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Selection of studies for inclusion. AF: atrial fibrillation." data-id="CD005049-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Selection of studies for inclusion. AF: atrial fibrillation.</p> </div> </div> </div> </section> <section id="CD005049-sec-0070"> <h4 class="title">Included studies</h4> <section id="CD005049-sec-0071"> <h5 class="title">Participants</h5> <p>Entry criteria differed between studies in several aspects. In some trials, atrial fibrillation was documented in the history but participants were in sinus rhythm at the time of inclusion, while in other trials, participants were in atrial fibrillation and needed to be converted to sinus rhythm (only those converted were included in the review). The duration of atrial fibrillation when persistent, or the time from the last documented episode of atrial fibrillation when paroxysmal, was highly variable (from one month to one year, or no time limit in some studies). Some of the studies required atrial fibrillation to be symptomatic while others did not. Six studies enrolled both people with atrial fibrillation and people with atrial flutter. When available, we used only data from people with atrial fibrillation. </p> <p>Regarding the type of atrial fibrillation, eight studies included exclusively paroxysmal or recent‐onset atrial fibrillation, 28 studies included only persistent atrial fibrillation (i.e. lasting more than seven days), and the remaining 23 studies included both types. Overall, 48% of the pooled population had persistent or permanent atrial fibrillation. </p> <p>The mean age of participants varied from 46 to 72 years in the included studies and was 65 years in the pooled population. The proportion of participants having underlying heart disease varied widely, from 29% to 100%, with only one study selectively including people without structural heart disease (<a href="./references#CD005049-bbs2-0022" title="ChimientiM , CullenMTJr , CasadeiG . Safety of flecainide versus propafenone for the long‐term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. European Heart Journal1995;16(12):1943‐51. [MEDLINE: PMID: 8682031; ISSN: 0195‐668X] ChimientiM , CullenMTJr , CasadeiG . Safety of long‐term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators. American Journal of Cardiology1996;77(3):60A‐75A. [MEDLINE: PMID: 8607393; ISSN: 0002‐9149] ">FAPIS 1996</a>). The most frequent diseases were coronary artery disease (5% to 50% of participants), hypertension, and valvular abnormalities (less frequent in recent studies). The mean left ventricle ejection fraction was greater than 50% in almost all trials (exceptions being <a href="./references#CD005049-bbs2-0017" title="MollerM , Torp‐PedersenCT , KoberL . Dofetilide in patients with congestive heart failure and left ventricular dysfunction: safety aspects and effect on atrial fibrillation. The Danish Investigators of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group. Congestive Heart Failure2001;7(3):146‐50. [MEDLINE: PMID: 11828153; ISSN 1527‐5299] PedersenOD , BaggerH , KellerN , MarchantB , KoberL , Torp‐PedersenC . Efficacy of dofetilide in the treatment of atrial fibrillation‐flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (DIAMOND) substudy. Circulation2001;104(3):292‐6. [MEDLINE: PMID: 11457747; ISSN 0009‐7322] Torp‐PedersenC , MollerM , Bloch‐ThomsenPE , KoberL , SandoeE , EgstrupK , et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. New England Journal of Medicine1999;341(12):857‐65. [MEDLINE: PMID: 10486417; ISSN 0028‐4793] Torp‐PedersenCT , MollerM , Bloch‐ThomsenPE , KoberL , SandoeE , EgstrupK , et al. Dofetilide to patients with heart failure and left ventricular dysfunction [Dofetilid til patienter med hjerteinsufficiens og darligt fungerende venstre ventrikel]. Ugeskrift for Laeger2000;10(44):5948‐53. [MEDLINE: PMID: 11094565; ISSN: 0041‐5782] ">DIAMOND 2001</a>; <a href="./references#CD005049-bbs2-0028" title="KaluscheD , StockingerJ , BetzP , RoskammH . Sotalol and quinidine/verapamil (Cordichin) in chronic atrial fibrillation – conversion and 12‐month follow‐up – a randomized comparison [Sotalol und Chinidin/Verapamil (Cordichin) bei chronischem Vorhoflimmern – Konversion und 12‐Monats‐Follow‐up – ein randomisierter Vergleich]. Zeitschrift fur Kardiologie1994;83 Suppl 5:109‐16. [MEDLINE: PMID: 7846939; ISSN: 0300‐5860] ">Kalusche 1994</a>; <a href="./references#CD005049-bbs2-0036" title="NergårdhAK , RosenqvistM , NordlanderR , FrickM . Maintenance of sinus rhythm with metoprolol CR initiated before cardioversion and repeated cardioversion of atrial fibrillation: a randomized double‐blind placebo‐controlled study. European Heart Journal2007;28(11):1351‐7. [PUBMED: PMID: 17329409] ">Nergårdh 2007</a>; <a href="./references#CD005049-bbs2-0041" title="PlewanA , LehmannG , NdrepepaG , SchreieckJ , AltEU , SchomigA , et al. Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol. European Heart Journal2001;22(16):1504‐10. [MEDLINE: PMID: 11482924; ISSN: 0195‐668X] ">Plewan 2001</a>; <a href="./references#CD005049-bbs2-0057" title="VijayalakshmiK , WhittakerVJ , SuttonA , CampbellP , WrightRA , HallJA , et al. A randomized trial of prophylactic antiarrhythmic agents (amiodarone and sotalol) in patients with atrial fibrillation for whom direct current cardioversion is planned. American Heart Journal2006;151(4):863.e1‐6. [PUBMED: 16569550] ">Vijayalakshmi 2006</a>). </p> </section> <section id="CD005049-sec-0072"> <h5 class="title">Interventions</h5> <p>Twenty‐nine trials (with 13,443 participants) compared an antiarrhythmic with a control, 12 trials (4536 participants) compared two different antiarrhythmics and a control, and 18 trials (3,002 participants) compared two or more antiarrhythmics with each other. The comparator used in the 41 trials with control groups was a placebo in 32 trials, a beta‐blocker in two trials (<a href="./references#CD005049-bbs2-0016" title="DAPHNE Study Investigators, CapucciA , BottoG , MolonG , SpampinatoA , FavaleS , et al. The Drug And Pace Health cliNical Evaluation (DAPHNE) study: a randomized trial comparing sotalol versus beta‐blockers to treat symptomatic atrial fibrillation in patients with brady‐tachycardia syndrome implanted with an antitachycardia pacemaker. American Heart Journal2008;156(2):373.e1‐8. [PUBMED: PMID: 18657671] ">DAPHNE 2008</a>; <a href="./references#CD005049-bbs2-0041" title="PlewanA , LehmannG , NdrepepaG , SchreieckJ , AltEU , SchomigA , et al. Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol. European Heart Journal2001;22(16):1504‐10. [MEDLINE: PMID: 11482924; ISSN: 0195‐668X] ">Plewan 2001</a>), digoxin in one trial (<a href="./references#CD005049-bbs2-0054" title="SteinbeckG , DoliwaR , BachP . Therapy of paroxysmal atrial fibrillation. Cardiac glycosides alone or combined with anti‐arrhythmia agents? [Therapie des paroxysmalen Vorhofflimmerns. Herzglykoside allein oder in Kombination mit Antiarrhythmika?]. Deutsche Medizinische Wochenschrift1988;113(48):1867‐71. [MEDLINE: PMID: 3143539; ISSN: 0012‐0472] ">Steinbeck 1988</a>), and no treatment in six trials (<a href="./references#CD005049-bbs2-0023" title="KirchhofP , AndresenD , BoschR , BorggrefeM , MeinertzT , ParadeU , et al. Short‐term versus long‐term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec‐SL): a prospective, randomised, open‐label, blinded endpoint assessment trial. Lancet2012;380(9838):238‐46. [PUBMED: 22713626] ">Flec‐SL 2012</a>; <a href="./references#CD005049-bbs2-0025" title="HillestadL , BjerkelundC , DaleJ , MaltauJ , StorsteinO . Quinidine in maintenance of sinus rhythm after electroconversion of chronic atrial fibrillation. A controlled clinical study. British Heart Journal1971;33(4):518‐21. [MEDLINE: PMID: 4934041; ISSN 0007‐0769] ">Hillestad 1971</a>; <a href="./references#CD005049-bbs2-0048" title="SantasE , DominguezE , Martinez‐BrotonsA , Ruiz‐GranellR , RuizV , FerreroA , et al. Early withdrawal of amiodarone after cardioversion in atrial fibrillation patients treated with irbesartan. A prospective randomized study. European Heart Journal2012;33 Suppl 1:380. [DOI: 10.1093/eurheartj/ehs282; PUBMED: 23805432] ">Santas 2012</a>; <a href="./references#CD005049-bbs2-0052" title="SodermarkT , JonssonB , OlssonA , OroL , WallinH , EdhagO , et al. Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter. A multicentre study from Stockholm. British Heart Journal1975;37(5):486‐92. [MEDLINE: PMID: 1093559; ISSN 0007‐0769] ">Sodermark 1975</a>; <a href="./references#CD005049-bbs2-0056" title="VanGelderIC , CrijnsHJ , VanGilstWH , VanWijkLM , HamerHP , LieKI . Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. American Journal of Cardiology1989;64(19):1317‐21. [MEDLINE: PMID: 2511744; ISSN: 0002‐9149] VanGelderIC , CrijnsHJ , VanGilstWH , VanWijkLM , HamerHP , LieKI . Efficacy of flecainide to maintain sinus rhythm after cardioversion of chronic atrial fibrillation and flutter. Circulation1988;78(4 Pt 2):III626. [MEDLINE: PMID: 3168202; ISSN: 0009‐7322] ">Van Gelder 1989</a>; <a href="./references#CD005049-bbs2-0057" title="VijayalakshmiK , WhittakerVJ , SuttonA , CampbellP , WrightRA , HallJA , et al. A randomized trial of prophylactic antiarrhythmic agents (amiodarone and sotalol) in patients with atrial fibrillation for whom direct current cardioversion is planned. American Heart Journal2006;151(4):863.e1‐6. [PUBMED: 16569550] ">Vijayalakshmi 2006</a>). </p> <p>Drugs included in this review, for which there was at least one well‐designed RCT, were class IA: quinidine, disopyramide; class IC: flecainide, propafenone; class II (beta‐blockers): metoprolol; and class III: amiodarone, dofetilide, dronedarone and sotalol. </p> </section> <section id="CD005049-sec-0073"> <h5 class="title">Follow‐up</h5> <p>The most frequent length of follow‐up was one year. It was shorter in 17 trials (six to nine months) and longer in six trials (15 to 19 months). Five trials followed participants for two years or more (<a href="./references#CD005049-bbs2-0003" title="AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. Journal of the American College of Cardiology2003;42(1):20‐9. [MEDLINE: PMID: 12849654; ISSN: 0735‐1097] ">AFFIRM Substudy 2003</a>; <a href="./references#CD005049-bbs2-0008" title="ATHENA Investigators, HohnloserSH , CrijnsHJ , vanEickelsM , GaudinC , PageRL , et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. New England Journal of Medicine2009;360(2):668‐78. [PUBMED: PMID: 19213680] ATHENA Investigators, ConnollySJ , CrijnsHJ , Torp‐PedersenC , vanEickelsM , GaudinC , et al. Analysis of stroke in ATHENA: a placebo‐controlled, double‐blind, parallel‐arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death in patients with atrial fibrillation/atrial flutter. Circulation2009;120(13):1174‐80. [PUBMED: PMID: 19752319] ">ATHENA 2009</a>; <a href="./references#CD005049-bbs2-0030" title="KochiadakisGE , IgoumenidisNE , MarketouME , KaleboubasMD , SimantirakisEN , VardasPE . Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. Heart2000;84(3):251‐7. [MEDLINE: PMID: 10956284; ISSN 1355‐6037] KochiadakisGE , IgoumenidisNE , MarketouME , SolomouMC , KanoupakisEM , VardasPE . Low‐dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. American Journal of Cardiology1998;81(8):995‐8. [MEDLINE: PMID: 9576159; ISSN: 0002‐9149] KochiadakisGE , MarketouME , IgoumenidisNE , ChrysostomakisSI , MavrakisHE , KaleboubasMD , et al. Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm?. Pacing and Clinical Electrophysiology2000;23(11 Pt 2):1883‐7. [MEDLINE: PMID: 11139949; ISSN 0147‐8389] ">Kochiadakis 2000</a>; <a href="./references#CD005049-bbs2-0031" title="KochiadakisGE , IgoumenidisNE , HamilosMI , TzerakisPG , KlapsinosNC , ZacharisEA , et al. Long‐term maintenance of normal sinus rhythm in patients with current symptomatic atrial fibrillation: amiodarone vs propafenone, both in low doses. Chest2004;125(2):377‐83. [MEDLINE: PMID: 14769712; ISSN: 0012‐3692] ">Kochiadakis 2004a</a>; <a href="./references#CD005049-bbs2-0032" title="KochiadakisGE , IgoumenidisNE , HamilosME , TzerakisPG , KlapsinosNC , ChlouverakisGI , et al. Sotalol versus propafenone for long‐term maintenance of normal sinus rhythm in patients with recurrent symptomatic atrial fibrillation. American Journal of Cardiology2004;94(12):1563‐6. [MEDLINE: PMID: 15589019; ISSN: 0002‐9149] ">Kochiadakis 2004b</a>). We extracted and pooled all outcomes at one year of follow‐up or the nearest time point available. For studies with shorter duration of follow‐up, we used the last observation available. Overall, the mean follow‐up of the pooled population analysed was 10.2 months. </p> </section> </section> <section id="CD005049-sec-0074"> <h4 class="title">Excluded studies</h4> <p>Main reasons for exclusion of studies were not being controlled or randomised (43 studies), having a follow‐up shorter than six months (16 studies) and including in the control group participants who did not revert to sinus rhythm (10 studies). Additional details on excluded studies are given in the <a href="./references#CD005049-sec-0176" title="">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD005049-sec-0075"> <h3 class="title">Risk of bias in included studies</h3> <p>There was asymmetry in the funnel plot of withdrawals because of adverse effects on treatment with sotalol (<a href="#CD005049-fig-0002">Figure 2</a>). It showed fewer small studies on the left side (i.e. there were more small studies showing a trend to more withdrawals on active treatment). However, funnel plots for other outcomes with sotalol were symmetric, so we think the risk of substantial publication bias was low. Funnel plots for the remaining drugs were symmetric. </p> <div class="figure" id="CD005049-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 9 Sotalol versus placebo/no treatment, outcome: 9.6 Withdrawals due to adverse effects – main analysis." data-id="CD005049-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 9 Sotalol versus placebo/no treatment, outcome: 9.6 Withdrawals due to adverse effects – main analysis. </p> </div> </div> </div> <p>The results of the assessment of the risk of bias of included studies across different domains are showed in <a href="#CD005049-fig-0003">Figure 3</a> and <a href="#CD005049-fig-0004">Figure 4</a>. </p> <div class="figure" id="CD005049-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD005049-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD005049-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD005049-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD005049-sec-0076"> <h4 class="title">Allocation</h4> <p>All included studies were described as RCTs. However, only a minority detailed how the random number sequence was generated (18 studies, 30.5%) or how the allocation of participants was concealed (17 studies, 28.8%). Because of lack of details, the risk of bias on these items was unclear for the remaining studies. </p> </section> <section id="CD005049-sec-0077"> <h4 class="title">Blinding</h4> <p>The majority of trials comparing an antiarrhythmic versus a control were described as blinded (of 41 trials: 25 were double‐blind and five single‐blind, the remaining 11 were open‐label). In contrast, most trials comparing two or more different antiarrhythmics were open‐label (15 out of 18). However, only 17 of the 25 studies said to be double‐blind adequately reported the method of blinding (and it was adequate in all cases). Nonetheless, we think that the risk of bias associated to this lack of adequate blinding is not very high because: 1. most outcomes assessed in this review were objective ones: recurrence of atrial fibrillation and proarrhythmia were established by ECG records, mortality and stroke are objective outcomes; 2. results from adequately double‐blind studies and open‐label studies were very consistent; 3. well described, adequate blinding was more frequent in studies comparing an active drug with no active treatment, which is the main comparison of the review. </p> </section> <section id="CD005049-sec-0078"> <h4 class="title">Incomplete outcome data</h4> <p>Most studies adequately reported withdrawals and dropouts. The percentage of participants lost to follow‐up was detailed in 47 of the 59 included trials, was small (5% to 10%) and was well balanced across arms. However, virtually all studies only followed participants until atrial fibrillation recurred or until treatment was stopped for any reason. Therefore, data for some outcomes, such as mortality, were not extensive. </p> </section> <section id="CD005049-sec-0079"> <h4 class="title">Selective reporting</h4> <p>All studies but three (<a href="./references#CD005049-bbs2-0014" title="ChunKJ , ByeonK , ImSI , ParkKM , ParkSJ , KimJS , et al. Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion. Clinical Therapeutics2014;36(9):1169‐75. [DOI: 10.1016/j.clinthera.2014.07.013; PUBMED: 25134972] ">Chun 2014</a>; <a href="./references#CD005049-bbs2-0016" title="DAPHNE Study Investigators, CapucciA , BottoG , MolonG , SpampinatoA , FavaleS , et al. The Drug And Pace Health cliNical Evaluation (DAPHNE) study: a randomized trial comparing sotalol versus beta‐blockers to treat symptomatic atrial fibrillation in patients with brady‐tachycardia syndrome implanted with an antitachycardia pacemaker. American Heart Journal2008;156(2):373.e1‐8. [PUBMED: PMID: 18657671] ">DAPHNE 2008</a>; <a href="./references#CD005049-bbs2-0048" title="SantasE , DominguezE , Martinez‐BrotonsA , Ruiz‐GranellR , RuizV , FerreroA , et al. Early withdrawal of amiodarone after cardioversion in atrial fibrillation patients treated with irbesartan. A prospective randomized study. European Heart Journal2012;33 Suppl 1:380. [DOI: 10.1093/eurheartj/ehs282; PUBMED: 23805432] ">Santas 2012</a>) had data on all‐cause mortality, all but two (<a href="./references#CD005049-bbs2-0006" title='ConnollySJ , SchnellDJ , PageRL , WilkinsonWE , MarcelloSR , PritchettEL . Dose‐response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. American Journal of Cardiology2001;88(9):974‐9. [MEDLINE: PMID: 11703992; ISSN 0002‐9149] ConnollySJ , SchnellDJ , PageRL , WilkinsonWE , MarcelloSR , PritchettEL , Azimilide Supraventricular Arrhythmia Program Investigators. Symptoms at the time of arrhythmia recurrence in patients receiving azimilide for control of atrial fibrillation or flutter: results from randomized trials. American Heart Journal2003;146(3):489‐93. [MEDLINE: PMID: 12947368; ISSN: 0002‐8703] PageRL , ConnollySJ , WilkinsonWE , MarcelloSR , SchnellDJ , PritchettEL , Azimilide Supraventricular Arrhythmia Program (ASAP) Investigators. Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and dose‐response. American Heart Journal2002;143(4):643‐9. [MEDLINE: PMID: 11923801; ISSN 0002‐8703] PageRL , TilschTW , ConnollySJ , SchnellDJ , MarcelloSR , WilkinsonWE , et al. Azimilide Supraventricular Arrhythmia Program (ASAP) Investigators. Asymptomatic or "silent" atrial fibrillation: frequency in untreated patients and patients receiving azimilide. Circulation2003;107(8):1141‐5. [MEDLINE: PMID: 12615792; ISSN 0009‐7322] PritchettEL , PageRL , ConnollySJ , MarcelloSR , SchnellDJ , WilkinsonWE . Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose‐response. Azimilide Supraventricular Arrhythmia Program 3 (SVA‐3) Investigators. Journal of the American College of Cardiology2000;36(3):794‐802. [MEDLINE: PMID: 10987602; ISSN 0735‐1097] SVA‐4 Investigators, PageRL , PritchettEL , ConnollyS , WilkinsonWE . Azimilide for the treatment of atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia: results of a randomized trial and insights on the concordance of symptoms and recurrent arrhythmias. Journal of Cardiovascular Electrophysiology2008;19(2):172‐7. [PUBMED: PMID: 17916138] '>ASAP 2003</a>; <a href="./references#CD005049-bbs2-0040" title="PITAGORA Study Investigators, GuliziaM , MangiameliS , OraziS , ChiarandàG , PiccioneG , et al. A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the PITAGORA trial. American Heart Journal2008;155(1):107.e1. [PUBMED: PMID: 18082498] ">PITAGORA 2008</a>) on atrial fibrillation recurrence rates, and all but three (<a href="./references#CD005049-bbs2-0004" title="The Atrial Fibrillation Investigation with Bidisomide (AFIB) Investigators. Treatment of atrial fibrillation and paroxysmal supraventricular tachycardia with bidisomide. Circulation1997;96(8):2625‐32. [MEDLINE: PMID: 9355903; ISSN 0009‐7322] ">AFIB 1997</a>; <a href="./references#CD005049-bbs2-0014" title="ChunKJ , ByeonK , ImSI , ParkKM , ParkSJ , KimJS , et al. Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion. Clinical Therapeutics2014;36(9):1169‐75. [DOI: 10.1016/j.clinthera.2014.07.013; PUBMED: 25134972] ">Chun 2014</a>; <a href="./references#CD005049-bbs2-0048" title="SantasE , DominguezE , Martinez‐BrotonsA , Ruiz‐GranellR , RuizV , FerreroA , et al. Early withdrawal of amiodarone after cardioversion in atrial fibrillation patients treated with irbesartan. A prospective randomized study. European Heart Journal2012;33 Suppl 1:380. [DOI: 10.1093/eurheartj/ehs282; PUBMED: 23805432] ">Santas 2012</a>) presented data for adverse effects, either withdrawals or proarrhythmia (<a href="#CD005049-tbl-0010">Table 1</a>). Other outcomes were less frequently reported: in studies with a placebo or no treatment arm, 11 trials reported stroke, to trials reported heart failure and none reported the actual frequency of anticoagulation. All studies reported the outcomes they had prespecified in the way they had prespecified. </p> <div class="table" id="CD005049-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Number of studies assessing each primary outcome</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n trials reporting (n participants)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n trials NOT reporting (n participants)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All‐cause mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 (17,586)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3<sup>a</sup> (393) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same as total mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same as total mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (9139)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 (8840)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects (proarrhythmia and withdrawals due to adverse effects)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 (16,558)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3<sup>b</sup> (1421) </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Out of 41 studies comparing an active drug with a control group receiving no antiarrhythmic (total 17,979 participants). </p> <p><sup>a</sup><a href="./references#CD005049-bbs2-0014" title="ChunKJ , ByeonK , ImSI , ParkKM , ParkSJ , KimJS , et al. Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion. Clinical Therapeutics2014;36(9):1169‐75. [DOI: 10.1016/j.clinthera.2014.07.013; PUBMED: 25134972] ">Chun 2014</a>; <a href="./references#CD005049-bbs2-0016" title="DAPHNE Study Investigators, CapucciA , BottoG , MolonG , SpampinatoA , FavaleS , et al. The Drug And Pace Health cliNical Evaluation (DAPHNE) study: a randomized trial comparing sotalol versus beta‐blockers to treat symptomatic atrial fibrillation in patients with brady‐tachycardia syndrome implanted with an antitachycardia pacemaker. American Heart Journal2008;156(2):373.e1‐8. [PUBMED: PMID: 18657671] ">DAPHNE 2008</a>; <a href="./references#CD005049-bbs2-0048" title="SantasE , DominguezE , Martinez‐BrotonsA , Ruiz‐GranellR , RuizV , FerreroA , et al. Early withdrawal of amiodarone after cardioversion in atrial fibrillation patients treated with irbesartan. A prospective randomized study. European Heart Journal2012;33 Suppl 1:380. [DOI: 10.1093/eurheartj/ehs282; PUBMED: 23805432] ">Santas 2012</a>. </p> <p><sup>b</sup><a href="./references#CD005049-bbs2-0004" title="The Atrial Fibrillation Investigation with Bidisomide (AFIB) Investigators. Treatment of atrial fibrillation and paroxysmal supraventricular tachycardia with bidisomide. Circulation1997;96(8):2625‐32. [MEDLINE: PMID: 9355903; ISSN 0009‐7322] ">AFIB 1997</a>; <a href="./references#CD005049-bbs2-0014" title="ChunKJ , ByeonK , ImSI , ParkKM , ParkSJ , KimJS , et al. Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion. Clinical Therapeutics2014;36(9):1169‐75. [DOI: 10.1016/j.clinthera.2014.07.013; PUBMED: 25134972] ">Chun 2014</a>; <a href="./references#CD005049-bbs2-0048" title="SantasE , DominguezE , Martinez‐BrotonsA , Ruiz‐GranellR , RuizV , FerreroA , et al. Early withdrawal of amiodarone after cardioversion in atrial fibrillation patients treated with irbesartan. A prospective randomized study. European Heart Journal2012;33 Suppl 1:380. [DOI: 10.1093/eurheartj/ehs282; PUBMED: 23805432] ">Santas 2012</a>. Others studies did not reported proarrhythmia but reported withdrawals (<a href="./references#CD005049-bbs2-0016" title="DAPHNE Study Investigators, CapucciA , BottoG , MolonG , SpampinatoA , FavaleS , et al. The Drug And Pace Health cliNical Evaluation (DAPHNE) study: a randomized trial comparing sotalol versus beta‐blockers to treat symptomatic atrial fibrillation in patients with brady‐tachycardia syndrome implanted with an antitachycardia pacemaker. American Heart Journal2008;156(2):373.e1‐8. [PUBMED: PMID: 18657671] ">DAPHNE 2008</a>; <a href="./references#CD005049-bbs2-0037" title="NiuF , HuangCX , JiangH , YangB , GuoWL , ChenYX , et al. Effects of amiodarone versus sotalol in treatment of atrial fibrillation: a random controlled clinical study. Zhonghua Yi Xue Za Zhi2006;86(2):121‐3. [PUBMED: PMID: 16620720] ">Niu 2006</a>; <a href="./references#CD005049-bbs2-0058" title="VillaniR , ZolettiF , VenianiM , LocatiF , NavaS . A comparison between amiodarone and disopyramide in a delayed‐release formulation in the prevention of recurrences of symptomatic atrial fibrillation [Confronto fra amiodarone e disopiramide in formulazione retard nella prevenzione delle recidive di fibrillazione atriale sintomatica]. La Clinica Terapeutica1992;140(1 Pt 2):35‐9. [MEDLINE: PMID: 1559321; ISSN: 0009‐9074] ">Villani 1992</a>). </p> </div> </div> </section> <section id="CD005049-sec-0080"> <h4 class="title">Other potential sources of bias</h4> <p>Conflict of interest could exist as almost all the studies included in the review were funded by the company manufacturing the antiarrhythmic drug tested. </p> </section> </section> <section id="CD005049-sec-0081"> <h3 class="title" id="CD005049-sec-0081">Effects of interventions</h3> <p>See: <a href="./full#CD005049-tbl-0001"><b>Summary of findings for the main comparison</b> Quinidine compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</a>; <a href="./full#CD005049-tbl-0002"><b>Summary of findings 2</b> Disopyramide compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</a>; <a href="./full#CD005049-tbl-0003"><b>Summary of findings 3</b> Propafenone compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</a>; <a href="./full#CD005049-tbl-0004"><b>Summary of findings 4</b> Flecainide compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</a>; <a href="./full#CD005049-tbl-0005"><b>Summary of findings 5</b> Metoprolol compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</a>; <a href="./full#CD005049-tbl-0006"><b>Summary of findings 6</b> Amiodarone compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</a>; <a href="./full#CD005049-tbl-0007"><b>Summary of findings 7</b> Dofetilide compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</a>; <a href="./full#CD005049-tbl-0008"><b>Summary of findings 8</b> Dronedarone compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</a>; <a href="./full#CD005049-tbl-0009"><b>Summary of findings 9</b> Sotalol compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</a> </p> <p>We calculated all outcomes at one year of follow‐up or the nearest time point (overall mean follow‐up: 10.2 months). </p> <p>Imputing missing participants as events (the worst‐case intention‐to‐treat scenario) generally did not modify the results, so we reported the best‐case intention‐to‐treat analysis (missing participants counted as being free of events) as the default; where differences existed, we reported details. </p> <p>See <a href="./full#CD005049-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD005049-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD005049-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD005049-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD005049-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD005049-tbl-0006">summary of findings Table 6</a>; <a href="./full#CD005049-tbl-0007">summary of findings Table 7</a>; <a href="./full#CD005049-tbl-0008">summary of findings Table 8</a>; <a href="./full#CD005049-tbl-0009">summary of findings Table 9</a>. </p> <section id="CD005049-sec-0082"> <h4 class="title">All‐cause mortality</h4> <p>The all‐cause mortality rate was low (0% to 5.1% at one year). The only exception to this generally low mortality rate was the DIAMOND study (<a href="./references#CD005049-bbs2-0017" title="MollerM , Torp‐PedersenCT , KoberL . Dofetilide in patients with congestive heart failure and left ventricular dysfunction: safety aspects and effect on atrial fibrillation. The Danish Investigators of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group. Congestive Heart Failure2001;7(3):146‐50. [MEDLINE: PMID: 11828153; ISSN 1527‐5299] PedersenOD , BaggerH , KellerN , MarchantB , KoberL , Torp‐PedersenC . Efficacy of dofetilide in the treatment of atrial fibrillation‐flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (DIAMOND) substudy. Circulation2001;104(3):292‐6. [MEDLINE: PMID: 11457747; ISSN 0009‐7322] Torp‐PedersenC , MollerM , Bloch‐ThomsenPE , KoberL , SandoeE , EgstrupK , et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. New England Journal of Medicine1999;341(12):857‐65. [MEDLINE: PMID: 10486417; ISSN 0028‐4793] Torp‐PedersenCT , MollerM , Bloch‐ThomsenPE , KoberL , SandoeE , EgstrupK , et al. Dofetilide to patients with heart failure and left ventricular dysfunction [Dofetilid til patienter med hjerteinsufficiens og darligt fungerende venstre ventrikel]. Ugeskrift for Laeger2000;10(44):5948‐53. [MEDLINE: PMID: 11094565; ISSN: 0041‐5782] ">DIAMOND 2001</a>). This trial recruited people with advanced heart failure and had an overall all‐cause mortality of 31% at one year. </p> <p>The quantity and quality of data on mortality varied markedly between drugs. We found no data on mortality with flecainide and very few data with disopyramide and propafenone. </p> <p>More data were available for other drugs. We found evidence suggesting an increase in the risk of death with two drugs, quinidine and sotalol. For the remaining drugs studied, available evidence show no apparent effect in mortality. </p> <p>There was no important heterogeneity between studies for all‐cause mortality for any of the drugs studied. </p> <section id="CD005049-sec-0083"> <h5 class="title">Drugs with very few or no data on mortality</h5> <section id="CD005049-sec-0084"> <h6 class="title">Disopyramide</h6> <p>Only one study reported all‐cause mortality in people receiving disopyramide compared with placebo or no treatment. It included only 92 participants and had a very wide CIs for mortality that included both possible benefits and harms (RR 5.00, 95% CI 0.25 to 101.37; I<sup>2</sup> = 0%; very low‐certainty evidence; <a href="./references#CD005049-fig-0030" title="">Analysis 2.1</a>). </p> <p>Counting missing participants as having died did not change this finding (<a href="./references#CD005049-fig-0031" title="">Analysis 2.2</a>). No other sensitivity analysis could be carried out. </p> </section> <section id="CD005049-sec-0085"> <h6 class="title">Propafenone</h6> <p>Of the five included trials (998 participants), only two studies reported any deaths (one each). The CIs were wide, including both possible benefits and harms, and the results varied markedly between the main analysis (RR 0.19, 95% CI 0.02 to 1.68; studies = 2, participants = 212; I<sup>2</sup> = 0%; <a href="./references#CD005049-fig-0038" title="">Analysis 3.1</a>) and the sensitivity analysis which treated missing participants as having died (RR 1.28, 95% CI 0.45 to 3.62; studies = 3, participants = 406; I<sup>2</sup> = 19%; <a href="./references#CD005049-fig-0039" title="">Analysis 3.2</a>). Restricting the analysis to the only study at low risk of bias did not differ from the main analysis (<a href="./references#CD005049-fig-0040" title="">Analysis 3.3</a>). </p> <p>Overall, the evidence for this outcome was very low‐certainty, meaning that we were uncertain of the effect of propafenone on mortality. </p> </section> <section id="CD005049-sec-0086"> <h6 class="title">Flecainide</h6> <p>None of the four trials studying flecainide (511 participants in total) reported any death from any cause. </p> </section> </section> <section id="CD005049-sec-0087"> <h5 class="title">Drugs associated with an increase in mortality</h5> <section id="CD005049-sec-0088"> <h6 class="title">Quinidine</h6> <p>Six studies that compared quinidine with placebo or no treatment reported all‐cause mortality. The GRADE rating was low‐certainty for this outcome. The pooled RR suggested that risk of mortality was higher in people receiving quinidine compared with placebo or no treatment, although the CIs also included the possibility of a lower or similar mortality rate (RR 2.01, 95% CI 0.84 to 4.77; studies = 6, participants = 1646; I<sup>2</sup> = 0%; <a href="./references#CD005049-fig-0006" title="">Analysis 1.1</a>). This corresponded to 8 deaths per 1000 people in the control group and 15 (95% CI 6 to 36) per 1000 people in the quinidine group. </p> <p>Sensitivity analysis which treated missing participants as having died increased the RR slightly, but was not substantially different to the main analysis (RR 2.12, 95% CI 0.96 to 4.67; studies = 6, participants = 1646; I<sup>2</sup> = 0%; <a href="./references#CD005049-fig-0007" title="">Analysis 1.2</a>). </p> <p>Conversely, sensitivity analysis of quinidine studies at low risk of bias (<a href="./references#CD005049-fig-0010" title="">Analysis 1.5</a>), or studies with more than 200 participants (<a href="./references#CD005049-fig-0011" title="">Analysis 1.6</a>), left only two studies (<a href="./references#CD005049-bbs2-0039" title="FetschT , BauerP , EngberdingR , KochHP , LuklJ , MeinertzT , et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. European Heart Journal2004;25(16):1385‐94. [MEDLINE: PMID: 15302102; ISSN: 0195‐668X] FetschT , BurschelG , BreithardtG , EngberdingR , KochHP , LuklJ , et al. Medicamentous prevention after electric cardioversion of chronic atrial fibrillation. Goals and design of the PAFAC Study [Die medikamentöse Prophylaxe nach elektronischer Kardioversion von chronischem Vorhofflimmern. Ziele und Design der PAFAC‐Studie]. Zeitschrift fur Kardiologie1999;88(3):195‐207. [MEDLINE: PMID: 10355070; ISSN 0300‐5860] ">PAFAC 2004</a>; <a href="./references#CD005049-bbs2-0053" title="PattenM , KochHP , SonntagF , LuderitzB , MeinertzT . Medicamentous prevention of symptomatic paroxysmal atrial fibrillation/flutter onset. Goals and design of the SOPAT study. Executive committee of the investigators representing trial physicians [Die medikamentose Anfallsprophylaxe bei symptomatischem paroxysmalem Vorhofflimmern/‐flattern. Ziele und Design der SOPAT‐Studie. Investigators in Vertretung der Prufarzte]. Zeitschrift fur Kardiologie1999;88(3):185‐94. [MEDLINE: PMID: 10355069; ISSN: 0300‐5860] PattenM , MaasR , BauerP , LuderitzB , SonntagF , DluzniewskiM , et al. Suppression of paroxysmal atrial tachyarrhythmias – results of the SOPAT trial. European Heart Journal2004;25(16):1395‐404. [MEDLINE: PMID: 15321697; ISSN: 0195‐668X] ">SOPAT 2004</a>). There was no evidence of a difference in all‐cause mortality compared with controls (RR 1.29, 95% CI 0.34 to 4.92; studies = 2, participants = 1234; I<sup>2</sup> = 0%). These two trials were more recent, employed a lower dose of quinidine (320 mg/day to 480 mg/day) than other studies (800 mg/day to 1800 mg/day) and combined quinidine with verapamil. However, when comparing those two studies against older, higher‐dose studies, the test for subgroup differences did not indicate that the effect differed between those two groups (P = 0.4; <a href="./references#CD005049-fig-0008" title="">Analysis 1.3</a>). </p> <p>The other sensitivity analysis did not differ from the main analysis (<a href="./references#CD005049-fig-0009" title="">Analysis 1.4</a>: persistent atrial fibrillation). </p> </section> <section id="CD005049-sec-0089"> <h6 class="title">Sotalol</h6> <p>High‐certainty evidence from five RCTs indicated that people receiving sotalol had a higher all‐cause mortality rate than those with placebo or no treatment (RR 2.23, 95% CI 1.03 to 4.81; studies = 5, participants = 1882; I<sup>2</sup> = 0%; <a href="./references#CD005049-fig-0127" title="">Analysis 9.1</a>; <a href="#CD005049-fig-0005">Figure 5</a>). This corresponded to 8 deaths per 1000 people in the control group and 19 (95% CI 9 to 40) deaths per 1000 people in the sotalol group. The NNTH for sotalol was 102 (95% CI 33 to 4167) participants treated for one year to have one additional death, with a wide CI<i>.</i> </p> <div class="figure" id="CD005049-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="All‐cause mortality with sotalol compared with placebo/no treatment: main analysis." data-id="CD005049-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>All‐cause mortality with sotalol compared with placebo/no treatment: main analysis.</p> </div> </div> </div> <p>This association with increased mortality persisted in all sensitivity analyses undertaken, either counting missing participants as deaths (RR 2.02, 95% CI 1.28 to 3.20; studies = 10, participants = 2757; I<sup>2</sup> = 0%; <a href="./references#CD005049-fig-0128" title="">Analysis 9.2</a>), restricting to those studies at low risk of bias (RR 2.51, 95% CI 1.06 to 5.98; studies = 3, participants = 1311; I<sup>2</sup> = 0%; <a href="./references#CD005049-fig-0130" title="">Analysis 9.4</a>), or which included only persistent atrial fibrillation (RR 2.51, 95% CI 1.06 to 5.98; studies = 3, participants = 1311; I<sup>2</sup> = 0%; <a href="./references#CD005049-fig-0129" title="">Analysis 9.3</a>). There was an even larger effect when restricting the analysis to just those studies with at least 200 participants (RR 2.65, 95% CI 1.16 to 6.09; studies = 4, participants = 1826; I<sup>2</sup> = 0%; <a href="./references#CD005049-fig-0131" title="">Analysis 9.5</a>). </p> </section> </section> <section id="CD005049-sec-0090"> <h5 class="title">Drugs with no apparent effect on mortality</h5> <p>For the remaining drugs studied, available evidence showed no apparent difference in mortality with respect to placebo or no treatment. However, data for mortality were rarely extensive and the data obtained could have been underpowered to detect mild differences in mortality for several of the drugs studied. </p> <section id="CD005049-sec-0091"> <h6 class="title">Metoprolol</h6> <p>Moderate‐certainty evidence from two studies comparing metoprolol with placebo or no treatment produced very wide CIs (RR 2.02, 95% CI 0.37 to 11.05; studies = 2, participants = 562; I<sup>2</sup> = 47%; <a href="./references#CD005049-fig-0061" title="">Analysis 5.1</a>). Results did not change in any of the sensitivity analyses (<a href="./references#CD005049-fig-0062" title="">Analysis 5.2</a>; <a href="./references#CD005049-fig-0063" title="">Analysis 5.3</a>; <a href="./references#CD005049-fig-0064" title="">Analysis 5.4</a>; <a href="./references#CD005049-fig-0065" title="">Analysis 5.5</a>). </p> </section> <section id="CD005049-sec-0092"> <h6 class="title">Amiodarone</h6> <p>Moderate‐certainty evidence from two studies comparing amiodarone with placebo or no treatment produced wide CIs (RR 1.66, 95% CI 0.55 to 4.99; studies = 2, participants = 444; I<sup>2</sup> = 10%; <a href="./references#CD005049-fig-0078" title="">Analysis 6.1</a>). This finding did not change in any of the sensitivity analyses (<a href="./references#CD005049-fig-0079" title="">Analysis 6.2</a>; <a href="./references#CD005049-fig-0080" title="">Analysis 6.3</a>). </p> </section> <section id="CD005049-sec-0093"> <h6 class="title">Dofetilide</h6> <p>Moderate‐certainty evidence from three RCTs found no evidence of a difference in all‐cause mortality rate between dofetilide and placebo or no treatment groups (RR 0.98, 95% CI 0.76 to 1.27; studies = 3, participants = 1183; I<sup>2</sup> = 0%; <a href="./references#CD005049-fig-0094" title="">Analysis 7.1</a>). Sensitivity analyses did not differ substantially from the main analysis (<a href="./references#CD005049-fig-0095" title="">Analysis 7.2</a>; <a href="./references#CD005049-fig-0096" title="">Analysis 7.3</a>; <a href="./references#CD005049-fig-0097" title="">Analysis 7.4</a>; <a href="./references#CD005049-fig-0098" title="">Analysis 7.5</a>). </p> </section> <section id="CD005049-sec-0094"> <h6 class="title">Dronedarone</h6> <p>High‐certainty evidence from three RCTs showed no clear difference in all‐cause mortality between dronedarone and placebo or no treatment (RR 0.86, 95% CI 0.68 to 1.09; studies = 3, participants = 6071; I<sup>2</sup> = 0%; <a href="./references#CD005049-fig-0110" title="">Analysis 8.1</a>). The <a href="./references#CD005049-bbs2-0008" title="ATHENA Investigators, HohnloserSH , CrijnsHJ , vanEickelsM , GaudinC , PageRL , et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. New England Journal of Medicine2009;360(2):668‐78. [PUBMED: PMID: 19213680] ATHENA Investigators, ConnollySJ , CrijnsHJ , Torp‐PedersenC , vanEickelsM , GaudinC , et al. Analysis of stroke in ATHENA: a placebo‐controlled, double‐blind, parallel‐arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death in patients with atrial fibrillation/atrial flutter. Circulation2009;120(13):1174‐80. [PUBMED: PMID: 19752319] ">ATHENA 2009</a> study dominated this analysis, with 97% of the weight in the meta‐analysis. </p> <p>There was very little difference between this main result and the different sensitivity analyses (<a href="./references#CD005049-fig-0111" title="">Analysis 8.2</a>; <a href="./references#CD005049-fig-0112" title="">Analysis 8.3</a>; <a href="./references#CD005049-fig-0113" title="">Analysis 8.4</a>; <a href="./references#CD005049-fig-0114" title="">Analysis 8.5</a>). </p> </section> </section> <section id="CD005049-sec-0095"> <h5 class="title">Head‐to‐head comparisons</h5> <p>In direct comparisons between antiarrhythmics, there were no differences in mortality (<a href="#CD005049-tbl-0011">Table 2</a>). </p> <div class="table" id="CD005049-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Head‐to‐head trials: all‐cause mortality</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Drug 1 vs drug 2</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Drug 1</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Drug 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Disopyramide vs other class I drugs</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0034" title="LloydEA , GershBJ , FormanR . The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation. A double‐blind study comparing quinidine, disopyramide and placebo. South African Medical Journal1984;65(10):367‐9. [MEDLINE: PMID: 6367096; ISSN: 0038‐2469] ">Lloyd 1984</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.19 (0.01 to 3.86)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0042" title="CrijnsHJ , GosselinkAT , LieKI . Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double‐blind study. Cardiovascular Drugs and Therapy1996;10(2):145‐52. [MEDLINE: PMID: 8842506; ISSN: 0920‐3206] ">PRODIS 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.44 (0.10 to 57.37)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Quinidine vs other class I drugs</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0034" title="LloydEA , GershBJ , FormanR . The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation. A double‐blind study comparing quinidine, disopyramide and placebo. South African Medical Journal1984;65(10):367‐9. [MEDLINE: PMID: 6367096; ISSN: 0038‐2469] ">Lloyd 1984</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.17 (0.26 to 103.18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0045" title="RichiardiE , GaitaF , GrecoC , GaschinoG , Comba CostaG , RosettaniE , et al. Propafenone versus hydroquinidine in long‐term pharmacological prophylaxis of atrial fibrillation [Propafenone versus idrochinidina nella profilassi farmacologica a lungo termine della fibrillazione atriale]. Cardiologia1992;37(2):123‐7. [MEDLINE: PMID: 1600529; ISSN: 0393‐1978] ">Richiardi 1992</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.21 (0.01 to 4.28)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Quinidine vs sotalol</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0027" title="Juul‐MollerS , EdvardssonN , Rehnqvist‐AhlbergN . Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation1990;82(6):1932‐9. [MEDLINE: PMID: 2242519; ISSN: 0009‐7322] ">Juul‐Moller 1990</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 (0.07 to 18.15)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0028" title="KaluscheD , StockingerJ , BetzP , RoskammH . Sotalol and quinidine/verapamil (Cordichin) in chronic atrial fibrillation – conversion and 12‐month follow‐up – a randomized comparison [Sotalol und Chinidin/Verapamil (Cordichin) bei chronischem Vorhoflimmern – Konversion und 12‐Monats‐Follow‐up – ein randomisierter Vergleich]. Zeitschrift fur Kardiologie1994;83 Suppl 5:109‐16. [MEDLINE: PMID: 7846939; ISSN: 0300‐5860] ">Kalusche 1994</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.00 (0.13 to 71.56)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0039" title="FetschT , BauerP , EngberdingR , KochHP , LuklJ , MeinertzT , et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. European Heart Journal2004;25(16):1385‐94. [MEDLINE: PMID: 15302102; ISSN: 0195‐668X] FetschT , BurschelG , BreithardtG , EngberdingR , KochHP , LuklJ , et al. Medicamentous prevention after electric cardioversion of chronic atrial fibrillation. Goals and design of the PAFAC Study [Die medikamentöse Prophylaxe nach elektronischer Kardioversion von chronischem Vorhofflimmern. Ziele und Design der PAFAC‐Studie]. Zeitschrift fur Kardiologie1999;88(3):195‐207. [MEDLINE: PMID: 10355070; ISSN 0300‐5860] ">PAFAC 2004</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>377</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>383</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.70 (0.30 to 1.63)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0051" title="VelosoHH , dePaolaAA . Analysis of atrial fibrillation recurrence during therapy with sotalol or quinidine. Researchers of +SOCESP [Analise da recorrencia de fibrilacao atrial durante terapia com sotalol ou quinidina. Investigadores da SOCESP]. Arquivos Brasileiros de Cardiologia1998;70(1):43‐9. [MEDLINE: PMID: 9629687; ISSN: 0066‐782X] dePaolaAA , VelosoHH . Efficacy and safety of sotalol versus quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation. SOCESP Investigators. American Journal of Cardiology1999;84(9):1033‐7. [MEDLINE: PMID: 10569659; ISSN: 0002‐9149] ">SOCESP 1999</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.31 (0.01 to 7.40)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0053" title="PattenM , KochHP , SonntagF , LuderitzB , MeinertzT . Medicamentous prevention of symptomatic paroxysmal atrial fibrillation/flutter onset. Goals and design of the SOPAT study. Executive committee of the investigators representing trial physicians [Die medikamentose Anfallsprophylaxe bei symptomatischem paroxysmalem Vorhofflimmern/‐flattern. Ziele und Design der SOPAT‐Studie. Investigators in Vertretung der Prufarzte]. Zeitschrift fur Kardiologie1999;88(3):185‐94. [MEDLINE: PMID: 10355069; ISSN: 0300‐5860] PattenM , MaasR , BauerP , LuderitzB , SonntagF , DluzniewskiM , et al. Suppression of paroxysmal atrial tachyarrhythmias – results of the SOPAT trial. European Heart Journal2004;25(16):1395‐404. [MEDLINE: PMID: 15321697; ISSN: 0195‐668X] ">SOPAT 2004</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>518</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>264</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51 (0.07 to 3.60)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Flecainide vs propafenone</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0005" title="AliotE , DenjoyI , The Flecainide AF French Study Group. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out‐patients with symptomatic paroxysmal atrial fibrillation/flutter. American Journal of Cardiology1996;77(3):66A‐71A. [MEDLINE: PMID: 8607394; ISSN: 0002‐9149] ">Aliot 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.34 (0.01 to 8.15)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Amiodarone vs class I drugs</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0003" title="AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. Journal of the American College of Cardiology2003;42(1):20‐9. [MEDLINE: PMID: 12849654; ISSN: 0735‐1097] ">AFFIRM Substudy 2003</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>106</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>116</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.42 (0.21 to 0.83)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0040" title="PITAGORA Study Investigators, GuliziaM , MangiameliS , OraziS , ChiarandàG , PiccioneG , et al. A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the PITAGORA trial. American Heart Journal2008;155(1):107.e1. [PUBMED: PMID: 18082498] ">PITAGORA 2008</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.21 (0.67 to 15.40)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Amiodarone vs dronedarone</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0018" title="LeHeuzeyJY , DeFerrariGM , RadzikD , SantiniM , ZhuJ , DavyJM . A short‐term, randomized, double‐blind, parallel‐group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. Journal of Cardiovascular Electrophysiology2010;21(6):597‐605. [PUBMED: PMID: 20384650 ] ">DIONYSOS 2010</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>255</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>249</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.44 (0.48 to 12.47)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Amiodarone vs sotalol</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0003" title="AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. Journal of the American College of Cardiology2003;42(1):20‐9. [MEDLINE: PMID: 12849654; ISSN: 0735‐1097] ">AFFIRM Substudy 2003</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>131</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>125</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60 (0.33 to 1.08)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0040" title="PITAGORA Study Investigators, GuliziaM , MangiameliS , OraziS , ChiarandàG , PiccioneG , et al. A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the PITAGORA trial. American Heart Journal2008;155(1):107.e1. [PUBMED: PMID: 18082498] ">PITAGORA 2008</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.86 (0.34 to 100.89)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0046" title="SinghBN , SinghSN , RedaDJ , TangXC , LopezB , HarrisCL , et al. Amiodarone versus sotalol for atrial fibrillation. New England Journal of Medicine2005;352(18):1861‐72. [MEDLINE: PMID: 15872201; ISSN: 0028‐4793] SinghSN , SinghBN , RedaDJ , FyeCL , EzekowitzMD , FletcherRD , et al. Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol‐Amiodarone Fibrillation Efficacy Trial [Safe‐T]). American Journal of Cardiology2003;92(4):468‐72. [MEDLINE: PMID: 12914883; ISSN 0002‐9149] ">SAFE‐T 2005</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>267</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>261</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.41 to 1.75)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Sotalol vs class I drugs other than quinidine</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0003" title="AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. Journal of the American College of Cardiology2003;42(1):20‐9. [MEDLINE: PMID: 12849654; ISSN: 0735‐1097] ">AFFIRM Substudy 2003</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.43 to 1.60)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0044" title="ReimoldSC , CantillonCO , FriedmanPL , AntmanEM . Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. American Journal of Cardiology1993;71(7):558‐63. [MEDLINE: PMID: 8438741; ISSN: 0002‐9149] ">Reimold 1993</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.00 (0.25 to 101.58)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Sotalol vs dofetilide</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0020" title="CambellTJ , GreenbaumRA , ChannerKS , DalrympleHW , KingmaJH , SantiniM , et al. Mortality in patients with atrial fibrillation – 1 year follow up of EMERALD (European and Australian multicenter evaluative research on atrial fibrillation dofetilide). Journal of the American College of Cardiology2000;35(2 Suppl A):154A‐5A. DalrympleHW , CambellTJ , ChannerKS , GreenbaumR , KingmaJH , SantiniM , et al. Maintenance of sinus rhythm by dofetilide improves quality of life. The EMERALD (European and Australian multicenter evaluative research on atrial fibrillation dofetilide) study. Circulation1998;98(Suppl 13‐14):66. GreenbaumR , CampbellTJ , ChannerKS , DalrympleHW , KingmaJH , SantiniM , et al. Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide. The EMERALD (European and Australian multicenter evaluative research on atrial fibrillation dofetilide) study. Circulation1998;98(Suppl I‐633):3326. USFood , DrugAdministration . Drug Approval Package: Tikosyn (Dofetilide). Medical Review: Parts 1 and 2 (Study number 345). www.accessdata.fda.gov/drugsatfda_docs/nda/99/20‐931_Tikosyn.cfm (accessed 10 August 2010). ">EMERALD 2000</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.04 to 23.99)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; RR: risk ratio.</p> </div> </div> </section> </section> <section id="CD005049-sec-0096"> <h4 class="title">Withdrawals due to adverse effects</h4> <p>Withdrawals due to adverse effects were more frequent with all studied drugs, compared with placebo or no treatment: </p> <section id="CD005049-sec-0097"> <h5 class="title">Quinidine</h5> <p>Moderate‐certainty evidence suggested a higher number of withdrawals due to adverse events in the quinidine group than in the placebo or no treatment group, although the CIs included the possibilities of a slightly smaller number of withdrawals and also of no difference between groups (RR 1.56, 95% CI 0.87 to 2.78; studies = 7, participants = 1669; I<sup>2</sup> = 67%; <a href="./references#CD005049-fig-0012" title="">Analysis 1.7</a>). This corresponded to 163 withdrawals per 1000 people in the control group and 254 (95% CI 142 to 452) per 1000 people in the quinidine group. </p> <p>There was high heterogeneity in the main analysis, which seemed to be related to two more recent studies that employed lower doses of quinidine and combined it with verapamil (<a href="./references#CD005049-bbs2-0039" title="FetschT , BauerP , EngberdingR , KochHP , LuklJ , MeinertzT , et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. European Heart Journal2004;25(16):1385‐94. [MEDLINE: PMID: 15302102; ISSN: 0195‐668X] FetschT , BurschelG , BreithardtG , EngberdingR , KochHP , LuklJ , et al. Medicamentous prevention after electric cardioversion of chronic atrial fibrillation. Goals and design of the PAFAC Study [Die medikamentöse Prophylaxe nach elektronischer Kardioversion von chronischem Vorhofflimmern. Ziele und Design der PAFAC‐Studie]. Zeitschrift fur Kardiologie1999;88(3):195‐207. [MEDLINE: PMID: 10355070; ISSN 0300‐5860] ">PAFAC 2004</a>; <a href="./references#CD005049-bbs2-0053" title="PattenM , KochHP , SonntagF , LuderitzB , MeinertzT . Medicamentous prevention of symptomatic paroxysmal atrial fibrillation/flutter onset. Goals and design of the SOPAT study. Executive committee of the investigators representing trial physicians [Die medikamentose Anfallsprophylaxe bei symptomatischem paroxysmalem Vorhofflimmern/‐flattern. Ziele und Design der SOPAT‐Studie. Investigators in Vertretung der Prufarzte]. Zeitschrift fur Kardiologie1999;88(3):185‐94. [MEDLINE: PMID: 10355069; ISSN: 0300‐5860] PattenM , MaasR , BauerP , LuderitzB , SonntagF , DluzniewskiM , et al. Suppression of paroxysmal atrial tachyarrhythmias – results of the SOPAT trial. European Heart Journal2004;25(16):1395‐404. [MEDLINE: PMID: 15321697; ISSN: 0195‐668X] ">SOPAT 2004</a>). A subgroup analysis based on the dose used and age of the studies suggested there was a real difference between these two studies and older studies which employed a higher dose of quinidine (test for subgroup differences, P = 0.009; <a href="./references#CD005049-fig-0013" title="">Analysis 1.8</a>). In older, higher‐dose studies, approximately three times more people withdrew due to adverse effects, compared to placebo or no treatment (RR 3.05, 95% CI 1.29 to 7.22; studies = 5, participants = 435; I<sup>2</sup> = 29%). In more‐recent, lower‐dose studies, there was no evidence of a difference in withdrawals (RR 0.88, 95% CI 0.61 to 1.27; studies = 2, participants = 1234; I<sup>2</sup> = 51%). </p> <p>The results of sensitivity analysis varied depending on whether they included mostly older studies, as for the analysis of studies on permanent atrial fibrillation, which showed an increase of withdrawals with quinidine (<a href="./references#CD005049-fig-0014" title="">Analysis 1.9</a>), or whether they included mainly the two more‐recent studies, which showed no difference with controls (<a href="./references#CD005049-fig-0015" title="">Analysis 1.10</a>; <a href="./references#CD005049-fig-0016" title="">Analysis 1.11</a>). </p> </section> <section id="CD005049-sec-0098"> <h5 class="title">Disopyramide</h5> <p>Low‐certainty evidence from two RCTs indicated a more than three‐fold higher risk of withdrawal due to adverse events among people receiving disopyramide compared with placebo or no treatment, although the CIs included the possibility of similar risks of withdrawal due to adverse events (RR 3.68, 95% CI 0.95 to 14.24; studies = 2, participants = 146; I<sup>2</sup> = 0%; <a href="./references#CD005049-fig-0032" title="">Analysis 2.3</a>). This corresponded to 28 withdrawals per 1000 people in the control group and 104 (95% CI 27 to 401) per 1000 people in the disopyramide group. The result of the sensitivity analysis was identical to the main analysis (<a href="./references#CD005049-fig-0033" title="">Analysis 2.4</a>). No further sensitivity analyses were possible. </p> </section> <section id="CD005049-sec-0099"> <h5 class="title">Propafenone</h5> <p>Moderate‐certainty evidence indicated a higher risk of withdrawals due to adverse events in people receiving propafenone compared with people receiving placebo or no treatment (RR 1.62, 95% CI 1.07 to 2.46; studies = 5, participants = 1098; I<sup>2</sup> = 0%; <a href="./references#CD005049-fig-0041" title="">Analysis 3.4</a>). Corresponding numbers of withdrawals due to adverse events were 61 per 1000 people in the control group and 99 (95% CI 65 to 150) per 1000 people in the propafenone group. The NNTH for propafenone was 26 (95% CI 11 to 234) participants treated for one year to have one additional withdrawal. </p> <p>Restricting the analysis to the only study with more than 200 participants indicated a lack of evidence for a difference between groups (RR 1.29, 95% CI 0.79 to 2.11; studies = 1, participants = 523; <a href="./references#CD005049-fig-0042" title="">Analysis 3.5</a>). </p> </section> <section id="CD005049-sec-0100"> <h5 class="title">Flecainide</h5> <p>Only one very small RCT reported withdrawals due to adverse events (RR 15.41, 95% CI 0.91 to 260.19; studies = 1, participants = 73; low‐certainty evidence; <a href="./references#CD005049-fig-0048" title="">Analysis 4.1</a>) (<a href="./references#CD005049-bbs2-0056" title="VanGelderIC , CrijnsHJ , VanGilstWH , VanWijkLM , HamerHP , LieKI . Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. American Journal of Cardiology1989;64(19):1317‐21. [MEDLINE: PMID: 2511744; ISSN: 0002‐9149] VanGelderIC , CrijnsHJ , VanGilstWH , VanWijkLM , HamerHP , LieKI . Efficacy of flecainide to maintain sinus rhythm after cardioversion of chronic atrial fibrillation and flutter. Circulation1988;78(4 Pt 2):III626. [MEDLINE: PMID: 3168202; ISSN: 0009‐7322] ">Van Gelder 1989</a>). Seven people receiving flecainide withdrew due to adverse events, compared with none in the control arm. The RR reflected a higher risk of withdrawal due to adverse events when receiving flecainide, but the CIs were wide enough to include no difference between groups and even a small chance of a lower risk, but the very small number of people in this analysis limited the usefulness of this result. </p> </section> <section id="CD005049-sec-0101"> <h5 class="title">Metoprolol</h5> <p>High‐certainty evidence from two RCTs found that the risk of withdrawing due to adverse events was more than three times higher among people receiving metoprolol than people receiving placebo or no treatment (RR 3.47, 95% CI 1.48 to 8.15; studies = 2, participants = 562; I<sup>2</sup> = 0%; <a href="./references#CD005049-fig-0066" title="">Analysis 5.6</a>). This represented 21 per 1000 people receiving placebo or no treatment withdrawing due to adverse effects compared with 74 (95% CI 31 to 173) per 1000 people receiving metoprolol. The NNTH was 19 (95% CI 7 to 99) participants treated for one year to have one additional withdrawal. </p> <p>All sensitivity analyses were similar to the main results (<a href="./references#CD005049-fig-0067" title="">Analysis 5.7</a>; <a href="./references#CD005049-fig-0068" title="">Analysis 5.8</a>; <a href="./references#CD005049-fig-0069" title="">Analysis 5.9</a>). </p> </section> <section id="CD005049-sec-0102"> <h5 class="title">Amiodarone</h5> <p>Pooled analysis of four RCTs found low‐certainty evidence that the risk of withdrawing due to an adverse event was more than six times higher for people receiving amiodarone than for people receiving placebo or no treatment (RR 6.70, 95% CI 1.91 to 23.45; studies = 4, participants = 319; I<sup>2</sup> = 0%; <a href="./references#CD005049-fig-0081" title="">Analysis 6.4</a>). This corresponded to seven people out of 1000 people receiving placebo or no treatment withdrawing, compared with 49 (95% CI 14 to 172) per 1000 people receiving amiodarone. The NNTH for amiodarone was 25 (95% CI 6 to 157) participants treated for one year to have one additional withdrawal. </p> <p>Sensitivity analysis restricted to the only study at low risk of bias had very wide CIs (RR 4.98, 95% CI 0.65 to 38.29; studies = 1, participants = 99; <a href="./references#CD005049-fig-0082" title="">Analysis 6.5</a>). </p> </section> <section id="CD005049-sec-0103"> <h5 class="title">Dofetilide</h5> <p>Low‐certainty evidence from two RCTs suggested withdrawals due to adverse effects may have been higher in people receiving dofetilide, but the wide CIs also included the possibility that there was the same risk (or a lower risk) as for people receiving placebo or no treatment (RR 1.77, 95% CI 0.75 to 4.18; studies = 2, participants = 677; I<sup>2</sup> = 0%; <a href="./references#CD005049-fig-0099" title="">Analysis 7.6</a>). The risk was 34 per 1000 people in the placebo or no treatment group compared with 61 (95% CI 26 to 144) per 1000 people in the dofetilide group. Sensitivity analyses were identical to the main result (<a href="./references#CD005049-fig-0100" title="">Analysis 7.7</a>; <a href="./references#CD005049-fig-0101" title="">Analysis 7.8</a>). </p> </section> <section id="CD005049-sec-0104"> <h5 class="title">Dronedarone</h5> <p>Three RCTs showed moderate‐certainty evidence of a higher risk of withdrawals due to adverse effects among people receiving dronedarone (RR 1.58, 95% CI 1.34 to 1.85; studies = 3, participants = 6071; I<sup>2</sup> = 31%; <a href="./references#CD005049-fig-0115" title="">Analysis 8.6</a>). This corresponded to a risk of 77 withdrawals per 1000 people in the placebo or no treatment group and 122 (95% CI 104 to 143) withdrawals per 1000 people in the dronedarone group. The NNTH was 22 (95% CI 15 to 38) participants treated for one year to have one additional withdrawal. </p> <p>The <a href="./references#CD005049-bbs2-0008" title="ATHENA Investigators, HohnloserSH , CrijnsHJ , vanEickelsM , GaudinC , PageRL , et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. New England Journal of Medicine2009;360(2):668‐78. [PUBMED: PMID: 19213680] ATHENA Investigators, ConnollySJ , CrijnsHJ , Torp‐PedersenC , vanEickelsM , GaudinC , et al. Analysis of stroke in ATHENA: a placebo‐controlled, double‐blind, parallel‐arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death in patients with atrial fibrillation/atrial flutter. Circulation2009;120(13):1174‐80. [PUBMED: PMID: 19752319] ">ATHENA 2009</a> study had 82.5% of the weight in the main meta‐analysis, so the sensitivity analyses were heavily influenced by this large study. When it was included, they were very similar to the main analysis (<a href="./references#CD005049-fig-0117" title="">Analysis 8.8</a>; <a href="./references#CD005049-fig-0118" title="">Analysis 8.9</a>). The analysis of studies on permanent atrial fibrillation did not include the ATHENA trial and had a very wide CIs (RR 14.51, 95% CI 0.90 to 234.74; <a href="./references#CD005049-fig-0116" title="">Analysis 8.7</a>). </p> </section> <section id="CD005049-sec-0105"> <h5 class="title">Sotalol</h5> <p>The risk of withdrawing due to an adverse event was almost twice as high in people receiving sotalol as in people receiving placebo or no treatment (RR 1.95, 95% CI 1.23 to 3.11; studies = 12, participants = 2688; I<sup>2</sup> = 56%; <a href="./references#CD005049-fig-0132" title="">Analysis 9.6</a>). The risk was 94 withdrawals per 1000 people in the control group and 183 (95% CI 116 to 293) per 1000 people in the sotalol group. The corresponding NNTH was 11 (95% CI 5 to 46) participants treated for one year to have one additional withdrawal. </p> <p>Evidence was rated as moderate‐certainty due to suspected publication bias. Although there was an I<sup>2</sup> statistic of 56%, we did not downgrade for heterogeneity, because subgroup analysis showed a difference between a subgroup containing the <a href="./references#CD005049-bbs2-0039" title="FetschT , BauerP , EngberdingR , KochHP , LuklJ , MeinertzT , et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. European Heart Journal2004;25(16):1385‐94. [MEDLINE: PMID: 15302102; ISSN: 0195‐668X] FetschT , BurschelG , BreithardtG , EngberdingR , KochHP , LuklJ , et al. Medicamentous prevention after electric cardioversion of chronic atrial fibrillation. Goals and design of the PAFAC Study [Die medikamentöse Prophylaxe nach elektronischer Kardioversion von chronischem Vorhofflimmern. Ziele und Design der PAFAC‐Studie]. Zeitschrift fur Kardiologie1999;88(3):195‐207. [MEDLINE: PMID: 10355070; ISSN 0300‐5860] ">PAFAC 2004</a> and <a href="./references#CD005049-bbs2-0053" title="PattenM , KochHP , SonntagF , LuderitzB , MeinertzT . Medicamentous prevention of symptomatic paroxysmal atrial fibrillation/flutter onset. Goals and design of the SOPAT study. Executive committee of the investigators representing trial physicians [Die medikamentose Anfallsprophylaxe bei symptomatischem paroxysmalem Vorhofflimmern/‐flattern. Ziele und Design der SOPAT‐Studie. Investigators in Vertretung der Prufarzte]. Zeitschrift fur Kardiologie1999;88(3):185‐94. [MEDLINE: PMID: 10355069; ISSN: 0300‐5860] PattenM , MaasR , BauerP , LuderitzB , SonntagF , DluzniewskiM , et al. Suppression of paroxysmal atrial tachyarrhythmias – results of the SOPAT trial. European Heart Journal2004;25(16):1395‐404. [MEDLINE: PMID: 15321697; ISSN: 0195‐668X] ">SOPAT 2004</a> studies, and a subgroup containing the other studies (P = 0.009 from test for subgroup differences; <a href="./references#CD005049-fig-0133" title="">Analysis 9.7</a>). </p> <p>Sensitivity analyses all showed an increase in withdrawals on sotalol, giving estimates which were very similar to the main analysis (permanent atrial fibrillation: <a href="./references#CD005049-fig-0134" title="">Analysis 9.8</a>), lower (low risk of bias studies: RR 1.27, 95% CI 1.00 to 1.60; studies = 4, participants = 1686; I<sup>2</sup> = 78%; <a href="./references#CD005049-fig-0135" title="">Analysis 9.9</a>), or slightly lower (studies with at least 200 participants: RR 1.81, 95% CI 0.97 to 3.35; studies = 5, participants = 1900; I<sup>2</sup> = 79%; <a href="./references#CD005049-fig-0136" title="">Analysis 9.10</a>). </p> </section> <section id="CD005049-sec-0106"> <h5 class="title">Head‐to‐head comparisons</h5> <p>In direct comparisons between antiarrhythmics (<a href="#CD005049-tbl-0012">Table 3</a>), quinidine appeared to cause more withdrawals than flecainide or other class I drugs. Amiodarone seemed to produce fewer withdrawals than class I drugs combined, but showed no difference compared with dronedarone or sotalol. Sotalol caused more withdrawals than dofetilide or beta‐blockers. </p> <div class="table" id="CD005049-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Head‐to‐head trials: withdrawals due to adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Drug 1 vs drug 2</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Drug 1</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Drug 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Disopyramide vs other class I drugs</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0034" title="LloydEA , GershBJ , FormanR . The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation. A double‐blind study comparing quinidine, disopyramide and placebo. South African Medical Journal1984;65(10):367‐9. [MEDLINE: PMID: 6367096; ISSN: 0038‐2469] ">Lloyd 1984</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.48 (0.10 to 2.43)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0042" title="CrijnsHJ , GosselinkAT , LieKI . Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double‐blind study. Cardiovascular Drugs and Therapy1996;10(2):145‐52. [MEDLINE: PMID: 8842506; ISSN: 0920‐3206] ">PRODIS 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40 (0.14 to 1.19)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Quinidine vs flecainide</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0035" title="NaccarelliGV , DorianP , HohnloserSH , CoumelP . Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. American Journal of Cardiology1996;77(3):53A‐9A. [MEDLINE: PMID: 8607392; ISSN: 0002‐9149] ">Naccarelli 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>117</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>122</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.66 (1.04 to 2.65)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0054" title="SteinbeckG , DoliwaR , BachP . Therapy of paroxysmal atrial fibrillation. Cardiac glycosides alone or combined with anti‐arrhythmia agents? [Therapie des paroxysmalen Vorhofflimmerns. Herzglykoside allein oder in Kombination mit Antiarrhythmika?]. Deutsche Medizinische Wochenschrift1988;113(48):1867‐71. [MEDLINE: PMID: 3143539; ISSN: 0012‐0472] ">Steinbeck 1988</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.00 (0.26 to 96.13)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Quinidine vs other class I drugs</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0034" title="LloydEA , GershBJ , FormanR . The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation. A double‐blind study comparing quinidine, disopyramide and placebo. South African Medical Journal1984;65(10):367‐9. [MEDLINE: PMID: 6367096; ISSN: 0038‐2469] ">Lloyd 1984</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.07 (0.41 to 10.43)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0035" title="NaccarelliGV , DorianP , HohnloserSH , CoumelP . Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. American Journal of Cardiology1996;77(3):53A‐9A. [MEDLINE: PMID: 8607392; ISSN: 0002‐9149] ">Naccarelli 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>117</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>122</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.66 (1.04 to 2.65)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0045" title="RichiardiE , GaitaF , GrecoC , GaschinoG , Comba CostaG , RosettaniE , et al. Propafenone versus hydroquinidine in long‐term pharmacological prophylaxis of atrial fibrillation [Propafenone versus idrochinidina nella profilassi farmacologica a lungo termine della fibrillazione atriale]. Cardiologia1992;37(2):123‐7. [MEDLINE: PMID: 1600529; ISSN: 0393‐1978] ">Richiardi 1992</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.39 (1.20 to 4.77)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0054" title="SteinbeckG , DoliwaR , BachP . Therapy of paroxysmal atrial fibrillation. Cardiac glycosides alone or combined with anti‐arrhythmia agents? [Therapie des paroxysmalen Vorhofflimmerns. Herzglykoside allein oder in Kombination mit Antiarrhythmika?]. Deutsche Medizinische Wochenschrift1988;113(48):1867‐71. [MEDLINE: PMID: 3143539; ISSN: 0012‐0472] ">Steinbeck 1988</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.00 (0.26 to 96.13)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Quinidine vs sotalol</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0026" title="HohnloserSH , van deLooA , BaedekerF . Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. Journal of the American College of Cardiology1995;26(4):852‐8. [MEDLINE: PMID: 7560608; ISSN: 0735‐1097] ">Hohnloser 1995</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.00 (1.38 to 72.39)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0027" title="Juul‐MollerS , EdvardssonN , Rehnqvist‐AhlbergN . Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation1990;82(6):1932‐9. [MEDLINE: PMID: 2242519; ISSN: 0009‐7322] ">Juul‐Moller 1990</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.31 (1.19 to 4.47)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0028" title="KaluscheD , StockingerJ , BetzP , RoskammH . Sotalol and quinidine/verapamil (Cordichin) in chronic atrial fibrillation – conversion and 12‐month follow‐up – a randomized comparison [Sotalol und Chinidin/Verapamil (Cordichin) bei chronischem Vorhoflimmern – Konversion und 12‐Monats‐Follow‐up – ein randomisierter Vergleich]. Zeitschrift fur Kardiologie1994;83 Suppl 5:109‐16. [MEDLINE: PMID: 7846939; ISSN: 0300‐5860] ">Kalusche 1994</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.33 (0.65 to 8.40)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0039" title="FetschT , BauerP , EngberdingR , KochHP , LuklJ , MeinertzT , et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. European Heart Journal2004;25(16):1385‐94. [MEDLINE: PMID: 15302102; ISSN: 0195‐668X] FetschT , BurschelG , BreithardtG , EngberdingR , KochHP , LuklJ , et al. Medicamentous prevention after electric cardioversion of chronic atrial fibrillation. Goals and design of the PAFAC Study [Die medikamentöse Prophylaxe nach elektronischer Kardioversion von chronischem Vorhofflimmern. Ziele und Design der PAFAC‐Studie]. Zeitschrift fur Kardiologie1999;88(3):195‐207. [MEDLINE: PMID: 10355070; ISSN 0300‐5860] ">PAFAC 2004</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>377</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>383</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.78 to 1.27)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0051" title="VelosoHH , dePaolaAA . Analysis of atrial fibrillation recurrence during therapy with sotalol or quinidine. Researchers of +SOCESP [Analise da recorrencia de fibrilacao atrial durante terapia com sotalol ou quinidina. Investigadores da SOCESP]. Arquivos Brasileiros de Cardiologia1998;70(1):43‐9. [MEDLINE: PMID: 9629687; ISSN: 0066‐782X] dePaolaAA , VelosoHH . Efficacy and safety of sotalol versus quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation. SOCESP Investigators. American Journal of Cardiology1999;84(9):1033‐7. [MEDLINE: PMID: 10569659; ISSN: 0002‐9149] ">SOCESP 1999</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.32 (0.54 to 3.23)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0053" title="PattenM , KochHP , SonntagF , LuderitzB , MeinertzT . Medicamentous prevention of symptomatic paroxysmal atrial fibrillation/flutter onset. Goals and design of the SOPAT study. Executive committee of the investigators representing trial physicians [Die medikamentose Anfallsprophylaxe bei symptomatischem paroxysmalem Vorhofflimmern/‐flattern. Ziele und Design der SOPAT‐Studie. Investigators in Vertretung der Prufarzte]. Zeitschrift fur Kardiologie1999;88(3):185‐94. [MEDLINE: PMID: 10355069; ISSN: 0300‐5860] PattenM , MaasR , BauerP , LuderitzB , SonntagF , DluzniewskiM , et al. Suppression of paroxysmal atrial tachyarrhythmias – results of the SOPAT trial. European Heart Journal2004;25(16):1395‐404. [MEDLINE: PMID: 15321697; ISSN: 0195‐668X] ">SOPAT 2004</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>518</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>264</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84 (0.62 to 1.14)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Flecainide vs propafenone</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0005" title="AliotE , DenjoyI , The Flecainide AF French Study Group. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out‐patients with symptomatic paroxysmal atrial fibrillation/flutter. American Journal of Cardiology1996;77(3):66A‐71A. [MEDLINE: PMID: 8607394; ISSN: 0002‐9149] ">Aliot 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.23 (0.05 to 1.00)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0022" title="ChimientiM , CullenMTJr , CasadeiG . Safety of flecainide versus propafenone for the long‐term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. European Heart Journal1995;16(12):1943‐51. [MEDLINE: PMID: 8682031; ISSN: 0195‐668X] ChimientiM , CullenMTJr , CasadeiG . Safety of long‐term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators. American Journal of Cardiology1996;77(3):60A‐75A. [MEDLINE: PMID: 8607393; ISSN: 0002‐9149] ">FAPIS 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18 (0.50 to 2.78)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Amiodarone vs class I drugs</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0003" title="AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. Journal of the American College of Cardiology2003;42(1):20‐9. [MEDLINE: PMID: 12849654; ISSN: 0735‐1097] ">AFFIRM Substudy 2003</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>154</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.33 (0.21 to 0.53)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0031" title="KochiadakisGE , IgoumenidisNE , HamilosMI , TzerakisPG , KlapsinosNC , ZacharisEA , et al. Long‐term maintenance of normal sinus rhythm in patients with current symptomatic atrial fibrillation: amiodarone vs propafenone, both in low doses. Chest2004;125(2):377‐83. [MEDLINE: PMID: 14769712; ISSN: 0012‐3692] ">Kochiadakis 2004a</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.74 (2.09 to 36.46)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0040" title="PITAGORA Study Investigators, GuliziaM , MangiameliS , OraziS , ChiarandàG , PiccioneG , et al. A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the PITAGORA trial. American Heart Journal2008;155(1):107.e1. [PUBMED: PMID: 18082498] ">PITAGORA 2008</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11 (0.23 to 5.40)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0058" title="VillaniR , ZolettiF , VenianiM , LocatiF , NavaS . A comparison between amiodarone and disopyramide in a delayed‐release formulation in the prevention of recurrences of symptomatic atrial fibrillation [Confronto fra amiodarone e disopiramide in formulazione retard nella prevenzione delle recidive di fibrillazione atriale sintomatica]. La Clinica Terapeutica1992;140(1 Pt 2):35‐9. [MEDLINE: PMID: 1559321; ISSN: 0009‐9074] ">Villani 1992</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.35 (0.10 to 1.18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0059" title="VitoloE , TronciM , LarovereMT , RumoloR , MorabitoA . Amiodarone versus quinidine in the prophylaxis of atrial fibrillation. Acta Cardiologica1981;36(6):431‐44. [MEDLINE: PMID: 7039195; ISSN: 0001‐5385] ">Vitolo 1981</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.06 to 14.09)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Amiodarone vs dronedarone</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0018" title="LeHeuzeyJY , DeFerrariGM , RadzikD , SantiniM , ZhuJ , DavyJM . A short‐term, randomized, double‐blind, parallel‐group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. Journal of Cardiovascular Electrophysiology2010;21(6):597‐605. [PUBMED: PMID: 20384650 ] ">DIONYSOS 2010</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>255</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>249</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.37 (0.90 to 2.09)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Amiodarone vs sotalol</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0003" title="AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. Journal of the American College of Cardiology2003;42(1):20‐9. [MEDLINE: PMID: 12849654; ISSN: 0735‐1097] ">AFFIRM Substudy 2003</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>154</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.47 to 1.47)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0030" title="KochiadakisGE , IgoumenidisNE , MarketouME , KaleboubasMD , SimantirakisEN , VardasPE . Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. Heart2000;84(3):251‐7. [MEDLINE: PMID: 10956284; ISSN 1355‐6037] KochiadakisGE , IgoumenidisNE , MarketouME , SolomouMC , KanoupakisEM , VardasPE . Low‐dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. American Journal of Cardiology1998;81(8):995‐8. [MEDLINE: PMID: 9576159; ISSN: 0002‐9149] KochiadakisGE , MarketouME , IgoumenidisNE , ChrysostomakisSI , MavrakisHE , KaleboubasMD , et al. Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm?. Pacing and Clinical Electrophysiology2000;23(11 Pt 2):1883‐7. [MEDLINE: PMID: 11139949; ISSN 0147‐8389] ">Kochiadakis 2000</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.44 (1.01 to 11.75)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0037" title="NiuF , HuangCX , JiangH , YangB , GuoWL , ChenYX , et al. Effects of amiodarone versus sotalol in treatment of atrial fibrillation: a random controlled clinical study. Zhonghua Yi Xue Za Zhi2006;86(2):121‐3. [PUBMED: PMID: 16620720] ">Niu 2006</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 (0.24 to 2.10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0040" title="PITAGORA Study Investigators, GuliziaM , MangiameliS , OraziS , ChiarandàG , PiccioneG , et al. A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the PITAGORA trial. American Heart Journal2008;155(1):107.e1. [PUBMED: PMID: 18082498] ">PITAGORA 2008</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.86 (0.34 to 100.89)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0057" title="VijayalakshmiK , WhittakerVJ , SuttonA , CampbellP , WrightRA , HallJA , et al. A randomized trial of prophylactic antiarrhythmic agents (amiodarone and sotalol) in patients with atrial fibrillation for whom direct current cardioversion is planned. American Heart Journal2006;151(4):863.e1‐6. [PUBMED: 16569550] ">Vijayalakshmi 2006</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.38 (0.04 to 3.14)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Sotalol vs class I drugs other than quinidine</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0003" title="AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. Journal of the American College of Cardiology2003;42(1):20‐9. [MEDLINE: PMID: 12849654; ISSN: 0735‐1097] ">AFFIRM Substudy 2003</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40 (0.25 to 0.63)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0032" title="KochiadakisGE , IgoumenidisNE , HamilosME , TzerakisPG , KlapsinosNC , ChlouverakisGI , et al. Sotalol versus propafenone for long‐term maintenance of normal sinus rhythm in patients with recurrent symptomatic atrial fibrillation. American Journal of Cardiology2004;94(12):1563‐6. [MEDLINE: PMID: 15589019; ISSN: 0002‐9149] ">Kochiadakis 2004b</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.30 to 3.37)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0044" title="ReimoldSC , CantillonCO , FriedmanPL , AntmanEM . Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. American Journal of Cardiology1993;71(7):558‐63. [MEDLINE: PMID: 8438741; ISSN: 0002‐9149] ">Reimold 1993</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.50 (0.45 to 4.99)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Sotalol vs dofetilide</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0020" title="CambellTJ , GreenbaumRA , ChannerKS , DalrympleHW , KingmaJH , SantiniM , et al. Mortality in patients with atrial fibrillation – 1 year follow up of EMERALD (European and Australian multicenter evaluative research on atrial fibrillation dofetilide). Journal of the American College of Cardiology2000;35(2 Suppl A):154A‐5A. DalrympleHW , CambellTJ , ChannerKS , GreenbaumR , KingmaJH , SantiniM , et al. Maintenance of sinus rhythm by dofetilide improves quality of life. The EMERALD (European and Australian multicenter evaluative research on atrial fibrillation dofetilide) study. Circulation1998;98(Suppl 13‐14):66. GreenbaumR , CampbellTJ , ChannerKS , DalrympleHW , KingmaJH , SantiniM , et al. Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide. The EMERALD (European and Australian multicenter evaluative research on atrial fibrillation dofetilide) study. Circulation1998;98(Suppl I‐633):3326. USFood , DrugAdministration . Drug Approval Package: Tikosyn (Dofetilide). Medical Review: Parts 1 and 2 (Study number 345). www.accessdata.fda.gov/drugsatfda_docs/nda/99/20‐931_Tikosyn.cfm (accessed 10 August 2010). ">EMERALD 2000</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>321</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.16 (1.18 to 3.96)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Sotalol vs other beta‐blockers</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0016" title="DAPHNE Study Investigators, CapucciA , BottoG , MolonG , SpampinatoA , FavaleS , et al. The Drug And Pace Health cliNical Evaluation (DAPHNE) study: a randomized trial comparing sotalol versus beta‐blockers to treat symptomatic atrial fibrillation in patients with brady‐tachycardia syndrome implanted with an antitachycardia pacemaker. American Heart Journal2008;156(2):373.e1‐8. [PUBMED: PMID: 18657671] ">DAPHNE 2008</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.26 (1.21 to 22.84)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0041" title="PlewanA , LehmannG , NdrepepaG , SchreieckJ , AltEU , SchomigA , et al. Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol. European Heart Journal2001;22(16):1504‐10. [MEDLINE: PMID: 11482924; ISSN: 0195‐668X] ">Plewan 2001</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.33 (0.31 to 5.72)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; RR: risk ratio.</p> </div> </div> </section> </section> <section id="CD005049-sec-0107"> <h4 class="title">Proarrhythmia</h4> <p>Virtually all studied antiarrhythmics showed increased proarrhythmic effects (counting both bradyarrhythmias and tachyarrhythmias attributable to treatment). </p> <p>Ventricular arrhythmias (torsades, ventricular tachycardia, ventricular fibrillation, widening QRS or QT leading to stopping treatment, sudden death or unexplained syncope) were the most frequent proarrhythmic events reported with dofetilide (100% of all proarrhythmic events), quinidine (94%) and flecainide (69%), while symptomatic bradyarrhythmias (sinus bradycardia leading to stopping treatment; atrio‐ventricular block) were more frequent with metoprolol (94% of all events) and amiodarone (69%). Other drugs demonstrated both types of proarrhythmic events: propafenone (63% ventricular events, 39% bradycardia), sotalol (61% ventricular events, 39% bradycardia) and dronedarone (41% ventricular events, 59% bradycardia). </p> <section id="CD005049-sec-0108"> <h5 class="title">Quinidine</h5> <p>High‐certainty evidence from seven RCTs showed that the risk of proarrhythmia was twice as high in people the quinidine group compared with people in the placebo or no treatment group, although the CIs did not exclude the possibility of no difference between groups (RR 2.05, 95% CI 0.95 to 4.41; studies = 7, participants = 1676; I<sup>2</sup> = 0%; <a href="./references#CD005049-fig-0017" title="">Analysis 1.12</a>). This represented 11 cases per 1000 people in the control group and 22 (95% CI 10 to 48) cases per 1000 people in the quinidine group. </p> <p>In a way very similar to the analysis of withdrawals due to adverse effects, the results of sensitivity analysis varied depending whether they included mostly older, higher‐dose studies, as the analysis of studies on permanent atrial fibrillation, which showed an increase of proarrhythmia with quinidine (<a href="./references#CD005049-fig-0019" title="">Analysis 1.14</a>); or whether they included mainly the two more recent, lower‐dose studies (<a href="./references#CD005049-bbs2-0039" title="FetschT , BauerP , EngberdingR , KochHP , LuklJ , MeinertzT , et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. European Heart Journal2004;25(16):1385‐94. [MEDLINE: PMID: 15302102; ISSN: 0195‐668X] FetschT , BurschelG , BreithardtG , EngberdingR , KochHP , LuklJ , et al. Medicamentous prevention after electric cardioversion of chronic atrial fibrillation. Goals and design of the PAFAC Study [Die medikamentöse Prophylaxe nach elektronischer Kardioversion von chronischem Vorhofflimmern. Ziele und Design der PAFAC‐Studie]. Zeitschrift fur Kardiologie1999;88(3):195‐207. [MEDLINE: PMID: 10355070; ISSN 0300‐5860] ">PAFAC 2004</a>; <a href="./references#CD005049-bbs2-0053" title="PattenM , KochHP , SonntagF , LuderitzB , MeinertzT . Medicamentous prevention of symptomatic paroxysmal atrial fibrillation/flutter onset. Goals and design of the SOPAT study. Executive committee of the investigators representing trial physicians [Die medikamentose Anfallsprophylaxe bei symptomatischem paroxysmalem Vorhofflimmern/‐flattern. Ziele und Design der SOPAT‐Studie. Investigators in Vertretung der Prufarzte]. Zeitschrift fur Kardiologie1999;88(3):185‐94. [MEDLINE: PMID: 10355069; ISSN: 0300‐5860] PattenM , MaasR , BauerP , LuderitzB , SonntagF , DluzniewskiM , et al. Suppression of paroxysmal atrial tachyarrhythmias – results of the SOPAT trial. European Heart Journal2004;25(16):1395‐404. [MEDLINE: PMID: 15321697; ISSN: 0195‐668X] ">SOPAT 2004</a>), which showed no difference compared with controls (<a href="./references#CD005049-fig-0020" title="">Analysis 1.15</a>; <a href="./references#CD005049-fig-0021" title="">Analysis 1.16</a>). However, a subgroup analysis comparing older studies with more‐recent ones found no difference between groups for this outcome (test for difference between subgroups P = 0.41; <a href="./references#CD005049-fig-0008" title="">Analysis 1.3</a>). </p> </section> <section id="CD005049-sec-0109"> <h5 class="title">Disopyramide</h5> <p>We found no disopyramide studies reporting proarrhythmia.</p> </section> <section id="CD005049-sec-0110"> <h5 class="title">Propafenone</h5> <p>Three RCTs reported proarrhythmia, but the very low‐certainty evidence and wide CIs meant that we were uncertain of the effect of propafenone on this outcome (RR 1.32, 95% CI 0.39 to 4.47; studies = 3, participants = 381; studies = 3; I<sup>2</sup> = 8%; <a href="./references#CD005049-fig-0043" title="">Analysis 3.6</a>). Sensitivity analysis restricted to the only study at low risk of bias showed a lack of evidence for a difference between groups (RR 0.49, 95% CI 0.09 to 2.75; studies = 1, participants = 102; <a href="./references#CD005049-fig-0044" title="">Analysis 3.7</a>). </p> </section> <section id="CD005049-sec-0111"> <h5 class="title">Flecainide</h5> <p>Risk of proarrhythmia was over four times higher among people receiving flecainide than placebo or no treatment (RR 4.80, 95% CI 1.30 to 17.77; studies = 4, participants = 511; I<sup>2</sup> = 0%; moderate‐certainty evidence; <a href="./references#CD005049-fig-0049" title="">Analysis 4.2</a>). This corresponded to a risk of 6 per 1000 among people in the placebo or no treatment group compared with a risk of 30 (95% CI 8 to 112) per 1000 people in the flecainide group. The NNTH for flecainide was 44 (95% CI 10 to 556) participants treated for one year to have one additional proarrhythmic event. </p> <p>All sensitivity analyses suggested an increased risk of proarrhythmia with flecainide, but their CIs were wider and included the possibility of no difference between groups (<a href="./references#CD005049-fig-0050" title="">Analysis 4.3</a>; <a href="./references#CD005049-fig-0051" title="">Analysis 4.4</a>; <a href="./references#CD005049-fig-0052" title="">Analysis 4.5</a>). </p> </section> <section id="CD005049-sec-0112"> <h5 class="title">Metoprolol</h5> <p>High‐certainty evidence showed an important increase of proarrhythmia with metoprolol compared to placebo due mainly to symptomatic bradyarrhythmias (94% of all proarrhythmic events) (RR 18.14, 95% CI 2.42 to 135.66; studies = 2, participants = 562; I<sup>2</sup> = 0%; <a href="./references#CD005049-fig-0070" title="">Analysis 5.10</a>). In the pooled population, proarrhythmic events were reported in no participants in the placebo group and in 60 participants per 1000 people in the metoprolol group. The corresponding NNTH was 19 (95% CI 2 to 235) participants treated for one year to have one additional bradyarrhythmia. </p> <p>All sensitivity analyses showed results similar to the main analysis (<a href="./references#CD005049-fig-0071" title="">Analysis 5.11</a>; <a href="./references#CD005049-fig-0072" title="">Analysis 5.12</a>; <a href="./references#CD005049-fig-0073" title="">Analysis 5.13</a>). </p> </section> <section id="CD005049-sec-0113"> <h5 class="title">Amiodarone</h5> <p>Moderate‐certainty evidence suggested an increase in proarrhythmia with amiodarone compared to placebo or no treatment, but the CIs included the possibility of no difference (or even a reduction) (RR 2.22, 95% CI 0.71 to 6.96; studies = 4, participants = 673; I<sup>2</sup> = 0%; <a href="./references#CD005049-fig-0083" title="">Analysis 6.6</a>). This corresponded to a risk of 8 per 1000 per people with placebo or no treatment and 18 (95% CI 6 to 57) per 1000 people with amiodarone. Symptomatic bradyarrhythmias represented 69% of events with amiodarone. </p> <p>Sensitivity analyses gave similar results, the only difference was that they pooled fewer studies and the CIs were wider (<a href="./references#CD005049-fig-0084" title="">Analysis 6.7</a>; <a href="./references#CD005049-fig-0085" title="">Analysis 6.8</a>; <a href="./references#CD005049-fig-0086" title="">Analysis 6.9</a>). </p> </section> <section id="CD005049-sec-0114"> <h5 class="title">Dofetilide</h5> <p>Moderate‐certainty evidence found a five‐fold increase in proarrhythmic events with dofetilide compared to placebo or no treatment (RR 5.50, 95% CI 1.33 to 22.76; studies = 3, participants = 1183; I<sup>2</sup> = 0%; <a href="./references#CD005049-fig-0102" title="">Analysis 7.9</a>). This corresponded to 2 cases per 1000 people in the control group and 13 (95% CI 3 to 53) cases per 1000 people in the dofetilide group. The NNTH for dofetilide was 111 (95% CI 23 to 1515) participants treated for one year to have one additional proarrhythmic event. </p> <p>Sensitivity analyses did not differ from the main analysis (<a href="./references#CD005049-fig-0103" title="">Analysis 7.10</a>; <a href="./references#CD005049-fig-0104" title="">Analysis 7.11</a>; <a href="./references#CD005049-fig-0105" title="">Analysis 7.12</a>). </p> </section> <section id="CD005049-sec-0115"> <h5 class="title">Dronedarone</h5> <p>Moderate‐certainty evidence from two RCTs suggested an increase of proarrhythmia with dronedarone compared with placebo, but the CIs included the possibility of no difference or even a benefit on this outcome (RR 1.95, 95% CI 0.77 to 4.98; studies = 2, participants = 5872; I<sup>2</sup> = 78%; <a href="./references#CD005049-fig-0115" title="">Analysis 8.6</a>). This represented 18 cases per 1000 people in the placebo group and 36 (95% CI 14 to 91) cases per 1000 people in the dronedarone group. </p> <p>In sensitivity analysis, there was only one study rated at low risk of bias or including more than 200 participants (<a href="./references#CD005049-bbs2-0008" title="ATHENA Investigators, HohnloserSH , CrijnsHJ , vanEickelsM , GaudinC , PageRL , et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. New England Journal of Medicine2009;360(2):668‐78. [PUBMED: PMID: 19213680] ATHENA Investigators, ConnollySJ , CrijnsHJ , Torp‐PedersenC , vanEickelsM , GaudinC , et al. Analysis of stroke in ATHENA: a placebo‐controlled, double‐blind, parallel‐arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death in patients with atrial fibrillation/atrial flutter. Circulation2009;120(13):1174‐80. [PUBMED: PMID: 19752319] ">ATHENA 2009</a>). This study found an increased risk of proarrhythmia with dronedarone compared to placebo (RR 2.94, 95% CI 2.08 to 4.15, participants = 4628; <a href="./references#CD005049-fig-0120" title="">Analysis 8.11</a>; <a href="./references#CD005049-fig-0121" title="">Analysis 8.12</a>). </p> </section> <section id="CD005049-sec-0116"> <h5 class="title">Sotalol</h5> <p>Moderate‐certainty evidence showed increased proarrhythmia rates on sotalol compared to placebo or no treatment (RR 3.55, 95% CI 2.16 to 5.83; studies = 12, participants = 2989; I<sup>2</sup> = 20%; <a href="./references#CD005049-fig-0137" title="">Analysis 9.11</a>). This corresponded to 12 cases per 1000 people in the control group and 41 (95% CI 25 to 68) cases per 1000 people in the sotalol group. The corresponding NNTH was 33 (95% CI 17 to 72) participants treated for one year to have one additional proarrhythmic event. </p> <p>All sensitivity analyses were very similar to the main analysis (<a href="./references#CD005049-fig-0139" title="">Analysis 9.13</a>; <a href="./references#CD005049-fig-0140" title="">Analysis 9.14</a>; <a href="./references#CD005049-fig-0141" title="">Analysis 9.15</a>). </p> </section> <section id="CD005049-sec-0117"> <h5 class="title">Head‐to‐head comparisons</h5> <p>In direct comparisons between antiarrhythmics (<a href="#CD005049-tbl-0013">Table 4</a>), amiodarone seemed to produce fewer proarrhythmic events than class I drugs combined, but showed no clear differences compared with dronedarone or sotalol. There were no other differences between drugs. </p> <div class="table" id="CD005049-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Head‐to‐head trials: proarrhythmia</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Drug 1 vs drug 2</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Drug 1</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Drug 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Disopyramide vs other class I drugs</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0034" title="LloydEA , GershBJ , FormanR . The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation. A double‐blind study comparing quinidine, disopyramide and placebo. South African Medical Journal1984;65(10):367‐9. [MEDLINE: PMID: 6367096; ISSN: 0038‐2469] ">Lloyd 1984</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.32 (0.01 to 7.59)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0042" title="CrijnsHJ , GosselinkAT , LieKI . Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double‐blind study. Cardiovascular Drugs and Therapy1996;10(2):145‐52. [MEDLINE: PMID: 8842506; ISSN: 0920‐3206] ">PRODIS 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.05 to 12.26)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Quinidine vs flecainide</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0035" title="NaccarelliGV , DorianP , HohnloserSH , CoumelP . Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. American Journal of Cardiology1996;77(3):53A‐9A. [MEDLINE: PMID: 8607392; ISSN: 0002‐9149] ">Naccarelli 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>117</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>122</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.49 (0.59 to 3.78)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0054" title="SteinbeckG , DoliwaR , BachP . Therapy of paroxysmal atrial fibrillation. Cardiac glycosides alone or combined with anti‐arrhythmia agents? [Therapie des paroxysmalen Vorhofflimmerns. Herzglykoside allein oder in Kombination mit Antiarrhythmika?]. Deutsche Medizinische Wochenschrift1988;113(48):1867‐71. [MEDLINE: PMID: 3143539; ISSN: 0012‐0472] ">Steinbeck 1988</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.00 (0.20 to 19.78)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Quinidine vs other class I drugs</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0034" title="LloydEA , GershBJ , FormanR . The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation. A double‐blind study comparing quinidine, disopyramide and placebo. South African Medical Journal1984;65(10):367‐9. [MEDLINE: PMID: 6367096; ISSN: 0038‐2469] ">Lloyd 1984</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.10 (0.13 to 73.12)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0035" title="NaccarelliGV , DorianP , HohnloserSH , CoumelP . Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. American Journal of Cardiology1996;77(3):53A‐9A. [MEDLINE: PMID: 8607392; ISSN: 0002‐9149] ">Naccarelli 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>117</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>122</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.49 (0.59 to 3.78)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0045" title="RichiardiE , GaitaF , GrecoC , GaschinoG , Comba CostaG , RosettaniE , et al. Propafenone versus hydroquinidine in long‐term pharmacological prophylaxis of atrial fibrillation [Propafenone versus idrochinidina nella profilassi farmacologica a lungo termine della fibrillazione atriale]. Cardiologia1992;37(2):123‐7. [MEDLINE: PMID: 1600529; ISSN: 0393‐1978] ">Richiardi 1992</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.15 to 7.24)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0054" title="SteinbeckG , DoliwaR , BachP . Therapy of paroxysmal atrial fibrillation. Cardiac glycosides alone or combined with anti‐arrhythmia agents? [Therapie des paroxysmalen Vorhofflimmerns. Herzglykoside allein oder in Kombination mit Antiarrhythmika?]. Deutsche Medizinische Wochenschrift1988;113(48):1867‐71. [MEDLINE: PMID: 3143539; ISSN: 0012‐0472] ">Steinbeck 1988</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.00 (0.20 to 19.78)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Quinidine vs sotalol</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0026" title="HohnloserSH , van deLooA , BaedekerF . Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. Journal of the American College of Cardiology1995;26(4):852‐8. [MEDLINE: PMID: 7560608; ISSN: 0735‐1097] ">Hohnloser 1995</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.00 (0.33 to 26.92)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0027" title="Juul‐MollerS , EdvardssonN , Rehnqvist‐AhlbergN . Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation1990;82(6):1932‐9. [MEDLINE: PMID: 2242519; ISSN: 0009‐7322] ">Juul‐Moller 1990</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 (0.07 to 18.15)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0028" title="KaluscheD , StockingerJ , BetzP , RoskammH . Sotalol and quinidine/verapamil (Cordichin) in chronic atrial fibrillation – conversion and 12‐month follow‐up – a randomized comparison [Sotalol und Chinidin/Verapamil (Cordichin) bei chronischem Vorhoflimmern – Konversion und 12‐Monats‐Follow‐up – ein randomisierter Vergleich]. Zeitschrift fur Kardiologie1994;83 Suppl 5:109‐16. [MEDLINE: PMID: 7846939; ISSN: 0300‐5860] ">Kalusche 1994</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.50 (0.05 to 5.30)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0039" title="FetschT , BauerP , EngberdingR , KochHP , LuklJ , MeinertzT , et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. European Heart Journal2004;25(16):1385‐94. [MEDLINE: PMID: 15302102; ISSN: 0195‐668X] FetschT , BurschelG , BreithardtG , EngberdingR , KochHP , LuklJ , et al. Medicamentous prevention after electric cardioversion of chronic atrial fibrillation. Goals and design of the PAFAC Study [Die medikamentöse Prophylaxe nach elektronischer Kardioversion von chronischem Vorhofflimmern. Ziele und Design der PAFAC‐Studie]. Zeitschrift fur Kardiologie1999;88(3):195‐207. [MEDLINE: PMID: 10355070; ISSN 0300‐5860] ">PAFAC 2004</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>377</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>383</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.46 to 1.62)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0051" title="VelosoHH , dePaolaAA . Analysis of atrial fibrillation recurrence during therapy with sotalol or quinidine. Researchers of +SOCESP [Analise da recorrencia de fibrilacao atrial durante terapia com sotalol ou quinidina. Investigadores da SOCESP]. Arquivos Brasileiros de Cardiologia1998;70(1):43‐9. [MEDLINE: PMID: 9629687; ISSN: 0066‐782X] dePaolaAA , VelosoHH . Efficacy and safety of sotalol versus quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation. SOCESP Investigators. American Journal of Cardiology1999;84(9):1033‐7. [MEDLINE: PMID: 10569659; ISSN: 0002‐9149] ">SOCESP 1999</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61 (0.11 to 3.54)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0053" title="PattenM , KochHP , SonntagF , LuderitzB , MeinertzT . Medicamentous prevention of symptomatic paroxysmal atrial fibrillation/flutter onset. Goals and design of the SOPAT study. Executive committee of the investigators representing trial physicians [Die medikamentose Anfallsprophylaxe bei symptomatischem paroxysmalem Vorhofflimmern/‐flattern. Ziele und Design der SOPAT‐Studie. Investigators in Vertretung der Prufarzte]. Zeitschrift fur Kardiologie1999;88(3):185‐94. [MEDLINE: PMID: 10355069; ISSN: 0300‐5860] PattenM , MaasR , BauerP , LuderitzB , SonntagF , DluzniewskiM , et al. Suppression of paroxysmal atrial tachyarrhythmias – results of the SOPAT trial. European Heart Journal2004;25(16):1395‐404. [MEDLINE: PMID: 15321697; ISSN: 0195‐668X] ">SOPAT 2004</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>518</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>264</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.04 (0.44 to 9.53)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Flecainide vs propafenone</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0005" title="AliotE , DenjoyI , The Flecainide AF French Study Group. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out‐patients with symptomatic paroxysmal atrial fibrillation/flutter. American Journal of Cardiology1996;77(3):66A‐71A. [MEDLINE: PMID: 8607394; ISSN: 0002‐9149] ">Aliot 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.11 (0.01 to 2.05)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0022" title="ChimientiM , CullenMTJr , CasadeiG . Safety of flecainide versus propafenone for the long‐term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. European Heart Journal1995;16(12):1943‐51. [MEDLINE: PMID: 8682031; ISSN: 0195‐668X] ChimientiM , CullenMTJr , CasadeiG . Safety of long‐term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators. American Journal of Cardiology1996;77(3):60A‐75A. [MEDLINE: PMID: 8607393; ISSN: 0002‐9149] ">FAPIS 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.12 (0.20 to 23.05)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Amiodarone vs class I drugs</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0003" title="AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. Journal of the American College of Cardiology2003;42(1):20‐9. [MEDLINE: PMID: 12849654; ISSN: 0735‐1097] ">AFFIRM Substudy 2003</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>154</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.20 (0.08 to 0.51)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0031" title="KochiadakisGE , IgoumenidisNE , HamilosMI , TzerakisPG , KlapsinosNC , ZacharisEA , et al. Long‐term maintenance of normal sinus rhythm in patients with current symptomatic atrial fibrillation: amiodarone vs propafenone, both in low doses. Chest2004;125(2):377‐83. [MEDLINE: PMID: 14769712; ISSN: 0012‐3692] ">Kochiadakis 2004a</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.15 to 7.10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0059" title="VitoloE , TronciM , LarovereMT , RumoloR , MorabitoA . Amiodarone versus quinidine in the prophylaxis of atrial fibrillation. Acta Cardiologica1981;36(6):431‐44. [MEDLINE: PMID: 7039195; ISSN: 0001‐5385] ">Vitolo 1981</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.06 to 14.09)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Amiodarone vs dronedarone</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0018" title="LeHeuzeyJY , DeFerrariGM , RadzikD , SantiniM , ZhuJ , DavyJM . A short‐term, randomized, double‐blind, parallel‐group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. Journal of Cardiovascular Electrophysiology2010;21(6):597‐605. [PUBMED: PMID: 20384650 ] ">DIONYSOS 2010</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>255</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>249</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.95 (0.36 to 10.57)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Amiodarone vs sotalol</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0003" title="AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. Journal of the American College of Cardiology2003;42(1):20‐9. [MEDLINE: PMID: 12849654; ISSN: 0735‐1097] ">AFFIRM Substudy 2003</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>154</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49 (0.17 to 1.42)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0030" title="KochiadakisGE , IgoumenidisNE , MarketouME , KaleboubasMD , SimantirakisEN , VardasPE . Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. Heart2000;84(3):251‐7. [MEDLINE: PMID: 10956284; ISSN 1355‐6037] KochiadakisGE , IgoumenidisNE , MarketouME , SolomouMC , KanoupakisEM , VardasPE . Low‐dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. American Journal of Cardiology1998;81(8):995‐8. [MEDLINE: PMID: 9576159; ISSN: 0002‐9149] KochiadakisGE , MarketouME , IgoumenidisNE , ChrysostomakisSI , MavrakisHE , KaleboubasMD , et al. Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm?. Pacing and Clinical Electrophysiology2000;23(11 Pt 2):1883‐7. [MEDLINE: PMID: 11139949; ISSN 0147‐8389] ">Kochiadakis 2000</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.14 to 6.46)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0046" title="SinghBN , SinghSN , RedaDJ , TangXC , LopezB , HarrisCL , et al. Amiodarone versus sotalol for atrial fibrillation. New England Journal of Medicine2005;352(18):1861‐72. [MEDLINE: PMID: 15872201; ISSN: 0028‐4793] SinghSN , SinghBN , RedaDJ , FyeCL , EzekowitzMD , FletcherRD , et al. Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol‐Amiodarone Fibrillation Efficacy Trial [Safe‐T]). American Journal of Cardiology2003;92(4):468‐72. [MEDLINE: PMID: 12914883; ISSN 0002‐9149] ">SAFE‐T 2005</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>267</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>261</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65 (0.24 to 1.81)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Sotalol vs class I drugs other than quinidine</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0003" title="AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. Journal of the American College of Cardiology2003;42(1):20‐9. [MEDLINE: PMID: 12849654; ISSN: 0735‐1097] ">AFFIRM Substudy 2003</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40 (0.19 to 0.85)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0012" title="CarunchioA , FeraMS , MazzaA , BurattiniM , GrecoG , GalatiA , et al. A comparison between flecainide and sotalol in the prevention of recurrences of paroxysmal atrial fibrillation [Confronto tra flecainide e sotalolo nella profilassi delle recidive di fibrillazione atriale parossistica]. Giornale Italiano di Cardiologia1995;25(1):51‐68. [MEDLINE: PMID: 7642012; ISSN 0046‐5968] ">Carunchio 1995</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.67 (0.46 to 6.06)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0032" title="KochiadakisGE , IgoumenidisNE , HamilosME , TzerakisPG , KlapsinosNC , ChlouverakisGI , et al. Sotalol versus propafenone for long‐term maintenance of normal sinus rhythm in patients with recurrent symptomatic atrial fibrillation. American Journal of Cardiology2004;94(12):1563‐6. [MEDLINE: PMID: 15589019; ISSN: 0002‐9149] ">Kochiadakis 2004b</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.52 (0.26 to 8.86)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0044" title="ReimoldSC , CantillonCO , FriedmanPL , AntmanEM . Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. American Journal of Cardiology1993;71(7):558‐63. [MEDLINE: PMID: 8438741; ISSN: 0002‐9149] ">Reimold 1993</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.50 (0.58 to 3.90)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Sotalol vs dofetilide</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0020" title="CambellTJ , GreenbaumRA , ChannerKS , DalrympleHW , KingmaJH , SantiniM , et al. Mortality in patients with atrial fibrillation – 1 year follow up of EMERALD (European and Australian multicenter evaluative research on atrial fibrillation dofetilide). Journal of the American College of Cardiology2000;35(2 Suppl A):154A‐5A. DalrympleHW , CambellTJ , ChannerKS , GreenbaumR , KingmaJH , SantiniM , et al. Maintenance of sinus rhythm by dofetilide improves quality of life. The EMERALD (European and Australian multicenter evaluative research on atrial fibrillation dofetilide) study. Circulation1998;98(Suppl 13‐14):66. GreenbaumR , CampbellTJ , ChannerKS , DalrympleHW , KingmaJH , SantiniM , et al. Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide. The EMERALD (European and Australian multicenter evaluative research on atrial fibrillation dofetilide) study. Circulation1998;98(Suppl I‐633):3326. USFood , DrugAdministration . Drug Approval Package: Tikosyn (Dofetilide). Medical Review: Parts 1 and 2 (Study number 345). www.accessdata.fda.gov/drugsatfda_docs/nda/99/20‐931_Tikosyn.cfm (accessed 10 August 2010). ">EMERALD 2000</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>321</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.18 to 4.03)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Sotalol vs other beta‐blockers</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0041" title="PlewanA , LehmannG , NdrepepaG , SchreieckJ , AltEU , SchomigA , et al. Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol. European Heart Journal2001;22(16):1504‐10. [MEDLINE: PMID: 11482924; ISSN: 0195‐668X] ">Plewan 2001</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.33 (0.31 to 5.72)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; RR: risk ratio.</p> </div> </div> </section> </section> <section id="CD005049-sec-0118"> <h4 class="title">Stroke</h4> <p>There were limited data for stroke. Only 11 of 41 studies with a control group (placebo or no treatment arm) reported stroke outcomes (<a href="./references#CD005049-bbs2-0008" title="ATHENA Investigators, HohnloserSH , CrijnsHJ , vanEickelsM , GaudinC , PageRL , et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. New England Journal of Medicine2009;360(2):668‐78. [PUBMED: PMID: 19213680] ATHENA Investigators, ConnollySJ , CrijnsHJ , Torp‐PedersenC , vanEickelsM , GaudinC , et al. Analysis of stroke in ATHENA: a placebo‐controlled, double‐blind, parallel‐arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death in patients with atrial fibrillation/atrial flutter. Circulation2009;120(13):1174‐80. [PUBMED: PMID: 19752319] ">ATHENA 2009</a>; <a href="./references#CD005049-bbs2-0010" title="BendittDG , WilliamsJH , JinJ , DeeringTF , ZuckerR , BrowneK , et al. Maintenance of sinus rhythm with oral d,l‐sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. D,L‐Sotalol Atrial Fibrillation/Flutter Study Group. American Journal of Cardiology1999;84(3):270‐7. [MEDLINE: PMID: 10496434; ISSN 0002‐9149] ">Benditt 1999</a>; <a href="./references#CD005049-bbs2-0012" title="CarunchioA , FeraMS , MazzaA , BurattiniM , GrecoG , GalatiA , et al. A comparison between flecainide and sotalol in the prevention of recurrences of paroxysmal atrial fibrillation [Confronto tra flecainide e sotalolo nella profilassi delle recidive di fibrillazione atriale parossistica]. Giornale Italiano di Cardiologia1995;25(1):51‐68. [MEDLINE: PMID: 7642012; ISSN 0046‐5968] ">Carunchio 1995</a>; <a href="./references#CD005049-bbs2-0021" title="BrookesL . Dronedarone on Trial: EURIDIS and ADONIS, 2004. www.medscape.com/viewarticle/489226(accessed January 2007). EURIDIS and ADONIS Investigators, SinghBN , ConnollySJ , CrijnsHJ , RoyD , KoweyPR , et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. New England Journal of Medicine2007;357(10):987‐99. [MEDLINE: PMID: 17804843] HohnloserSH . EURIDIS and ADONIS: maintenance of sinus rhythm with dronedarone in patients with atrial fibrillation or flutter. European Society of Cardiology Congress; 2004 Aug 28 – Sep 1; Munich, Germany. Munich, Germany, 2004. [MEDLINE: none; none] ">EURIDIS ADONIS 2007</a>; <a href="./references#CD005049-bbs2-0023" title="KirchhofP , AndresenD , BoschR , BorggrefeM , MeinertzT , ParadeU , et al. Short‐term versus long‐term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec‐SL): a prospective, randomised, open‐label, blinded endpoint assessment trial. Lancet2012;380(9838):238‐46. [PUBMED: 22713626] ">Flec‐SL 2012</a>; <a href="./references#CD005049-bbs2-0025" title="HillestadL , BjerkelundC , DaleJ , MaltauJ , StorsteinO . Quinidine in maintenance of sinus rhythm after electroconversion of chronic atrial fibrillation. A controlled clinical study. British Heart Journal1971;33(4):518‐21. [MEDLINE: PMID: 4934041; ISSN 0007‐0769] ">Hillestad 1971</a>; <a href="./references#CD005049-bbs2-0029" title="KarlsonBW , TorstenssonI , AbjornC , JanssonSO , PetersonLE . Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo‐controlled one‐year follow‐up study. European Heart Journal1988;9(3):284‐90. [MEDLINE: PMID: 3289932; ISSN 0195‐668X] KarlsonBW , TorstenssonI , AbjornC , KallrydA , JonssonJ , JanssonSO , et al. Preventive disopyramide after electroconversion of atrial fibrillation – a good alternative [Disopyramid som profylax efter elregularisering av formaksflimmer – ett bra alternativ]. Lakartidningen1991;88(24):2242‐5. [MEDLINE: PMID: 2056838; ISSN: 0023‐7205] ">Karlson 1988</a>; <a href="./references#CD005049-bbs2-0034" title="LloydEA , GershBJ , FormanR . The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation. A double‐blind study comparing quinidine, disopyramide and placebo. South African Medical Journal1984;65(10):367‐9. [MEDLINE: PMID: 6367096; ISSN: 0038‐2469] ">Lloyd 1984</a>; <a href="./references#CD005049-bbs2-0046" title="SinghBN , SinghSN , RedaDJ , TangXC , LopezB , HarrisCL , et al. Amiodarone versus sotalol for atrial fibrillation. New England Journal of Medicine2005;352(18):1861‐72. [MEDLINE: PMID: 15872201; ISSN: 0028‐4793] SinghSN , SinghBN , RedaDJ , FyeCL , EzekowitzMD , FletcherRD , et al. Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol‐Amiodarone Fibrillation Efficacy Trial [Safe‐T]). American Journal of Cardiology2003;92(4):468‐72. [MEDLINE: PMID: 12914883; ISSN 0002‐9149] ">SAFE‐T 2005</a>; <a href="./references#CD005049-bbs2-0052" title="SodermarkT , JonssonB , OlssonA , OroL , WallinH , EdhagO , et al. Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter. A multicentre study from Stockholm. British Heart Journal1975;37(5):486‐92. [MEDLINE: PMID: 1093559; ISSN 0007‐0769] ">Sodermark 1975</a>; <a href="./references#CD005049-bbs2-0053" title="PattenM , KochHP , SonntagF , LuderitzB , MeinertzT . Medicamentous prevention of symptomatic paroxysmal atrial fibrillation/flutter onset. Goals and design of the SOPAT study. Executive committee of the investigators representing trial physicians [Die medikamentose Anfallsprophylaxe bei symptomatischem paroxysmalem Vorhofflimmern/‐flattern. Ziele und Design der SOPAT‐Studie. Investigators in Vertretung der Prufarzte]. Zeitschrift fur Kardiologie1999;88(3):185‐94. [MEDLINE: PMID: 10355069; ISSN: 0300‐5860] PattenM , MaasR , BauerP , LuderitzB , SonntagF , DluzniewskiM , et al. Suppression of paroxysmal atrial tachyarrhythmias – results of the SOPAT trial. European Heart Journal2004;25(16):1395‐404. [MEDLINE: PMID: 15321697; ISSN: 0195‐668X] ">SOPAT 2004</a>), and we were uncertain that reporting of stroke was complete. The reported stroke rate was very low (1% to 2% at one year). </p> <section id="CD005049-sec-0119"> <h5 class="title">Drugs with no data on stroke</h5> <p>None of the studies of propafenone, metoprolol or dofetilide reported data on stroke.</p> </section> <section id="CD005049-sec-0120"> <h5 class="title">Drugs with no apparent effect on stroke</h5> <p>Low‐ to very low‐certainty evidence showed no apparent effect on stroke rates, compared to placebo or no treatment, with the following drugs: </p> <p> <ul id="CD005049-list-0007"> <li> <p>quinidine (RR 0.97, 95% CI 0.25 to 3.83; studies = 4, participants = 1107; I<sup>2</sup> = 0%; <a href="./references#CD005049-fig-0022" title="">Analysis 1.17</a>); </p> </li> <li> <p>disopyramide (RR 0.31, 95% CI 0.03 to 2.91; studies = 2, participants = 146; I<sup>2</sup> = 0%; <a href="./references#CD005049-fig-0034" title="">Analysis 2.5</a>); </p> </li> <li> <p>flecainide (RR 2.04, 95% CI 0.11 to 39.00; studies = 1, participants = 362; I<sup>2</sup> = 0%; <a href="./references#CD005049-fig-0053" title="">Analysis 4.6</a>); </p> </li> <li> <p>amiodarone (RR 1.15, 95% CI 0.30 to 4.39; studies = 1, participants = 399; I<sup>2</sup> = 0%; <a href="./references#CD005049-fig-0087" title="">Analysis 6.10</a>). </p> </li> </ul> </p> <p>Moderate‐certainty evidence showed no apparent effect on stroke rates compared to placebo or no treatment with sotalol (RR 1.47, 95% CI 0.48 to 4.51; studies = 3, participants = 1161; I<sup>2</sup> = 0%; <a href="./references#CD005049-fig-0142" title="">Analysis 9.16</a>). </p> <p>The corresponding sensitivity analyses, when these were possible, showed no notable difference with the main analyses. </p> </section> <section id="CD005049-sec-0121"> <h5 class="title">Drugs with an effect on stroke</h5> <section id="CD005049-sec-0122"> <h6 class="title">Dronedarone</h6> <p>High‐certainty evidence from two RCTs suggested that dronedarone may be associated with reduced risk of stroke (RR 0.66, 95% CI 0.47 to 0.95; studies = 2, participants = 5872; I<sup>2</sup> = 0%; <a href="./references#CD005049-fig-0122" title="">Analysis 8.13</a>). This corresponded to a risk of stroke of 27 per 1000 people in the placebo group and 18 per 1000 (13 to 25) people in the dronedarone group. The corresponding NNTB was 109 (95% CI 70 to 741) participants treated for one year to prevent one stroke. </p> <p>However, this result was due to one large study, which accounted for 94.6% of the weight in the meta‐analysis (<a href="./references#CD005049-bbs2-0008" title="ATHENA Investigators, HohnloserSH , CrijnsHJ , vanEickelsM , GaudinC , PageRL , et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. New England Journal of Medicine2009;360(2):668‐78. [PUBMED: PMID: 19213680] ATHENA Investigators, ConnollySJ , CrijnsHJ , Torp‐PedersenC , vanEickelsM , GaudinC , et al. Analysis of stroke in ATHENA: a placebo‐controlled, double‐blind, parallel‐arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death in patients with atrial fibrillation/atrial flutter. Circulation2009;120(13):1174‐80. [PUBMED: PMID: 19752319] ">ATHENA 2009</a>). Sensitivity analysis restricted to studies with more than 200 participants included the same two studies so produced identical results (<a href="./references#CD005049-fig-0123" title="">Analysis 8.14</a>). </p> </section> </section> </section> <section id="CD005049-sec-0123"> <h4 class="title">Recurrence of atrial fibrillation</h4> <p>All antiarrhythmic drugs included in this review, including metoprolol, reduced the risk of recurrence of atrial fibrillation. Recurrence rates of atrial fibrillation at one year were high: 69% to 84% in the control group not receiving antiarrhythmic treatment, reduced to 43% to 67% in participants in the antiarrhythmic group. </p> <section id="CD005049-sec-0124"> <h5 class="title">Quinidine</h5> <p>High‐certainty evidence showed a reduction in atrial fibrillation recurrences with quinidine (RR 0.83, 95% CI 0.78 to 0.88; studies = 7, participants = 1624; I<sup>2</sup> = 0%; <a href="./references#CD005049-fig-0026" title="">Analysis 1.21</a>). Recurrence rates at one year were 80.5% in participants in the placebo or no treatment group and 66.8% (62.8% to 70.8%) in participants in the quinidine group. The NNTB for quinidine was 7 (95% CI 6 to 10) participants treated for one year to avoid one recurrence. </p> <p>Results of sensitivity analyses did not differ from the main analysis (<a href="./references#CD005049-fig-0027" title="">Analysis 1.22</a>; <a href="./references#CD005049-fig-0028" title="">Analysis 1.23</a>; <a href="./references#CD005049-fig-0029" title="">Analysis 1.24</a>). </p> </section> <section id="CD005049-sec-0125"> <h5 class="title">Disopyramide</h5> <p>Evidence for disopyramide was low‐certainty because it consisted of two small RCTs with unclear risk of bias. It suggested disopyramide reduced recurrences of atrial fibrillation (RR 0.77, 95% CI 0.59 to 1.01; studies = 2, participants = 146; I<sup>2</sup> = 0%; <a href="./references#CD005049-fig-0036" title="">Analysis 2.7</a>). This corresponded to a recurrence rate, at six months to one year, of 69.0% in the control group and 53.1% (95% CI 40.7% to 69.7%) in the disopyramide group. Both studies included only people with permanent atrial fibrillation (<a href="./references#CD005049-fig-0037" title="">Analysis 2.8</a>), and no other sensitivity analysis was possible. </p> </section> <section id="CD005049-sec-0126"> <h5 class="title">Propafenone</h5> <p>Moderate‐certainty evidence from five RCTs indicated that propafenone reduced atrial fibrillation recurrences by about a third (RR 0.67, 95% CI 0.61 to 0.74; studies = 5, participants = 1098; I<sup>2</sup> = 0%; <a href="./references#CD005049-fig-0045" title="">Analysis 3.8</a>). Recurrence rate was 73.0% in the control group and 48.9% (44.5% to 54.0%) in the propafenone group. The corresponding NNTB was 4 (95% CI 3 to 5) participants treated for one year to avoid one recurrence. </p> <p>Results from sensitivity analyses were very similar (<a href="./references#CD005049-fig-0046" title="">Analysis 3.9</a>; <a href="./references#CD005049-fig-0047" title="">Analysis 3.10</a>). </p> </section> <section id="CD005049-sec-0127"> <h5 class="title">Flecainide</h5> <p>High‐certainty evidence showed that flecainide reduced atrial fibrillation recurrences by about a third (RR 0.65, 95% CI 0.55 to 0.77; studies = 4, participants = 511; I<sup>2</sup> = 29%; <a href="./references#CD005049-fig-0057" title="">Analysis 4.10</a>). That corresponded to a recurrence rate of 69.8% in people not treated or receiving placebo and 45.4% (38.4% to 53.8%) in people receiving flecainide. The NNTB for flecainide was 4 (95% CI 3 to 6) participants treated for one year to avoid one recurrence. </p> <p>Results from sensitivity analyses did not differ substantially (<a href="./references#CD005049-fig-0058" title="">Analysis 4.11</a>; <a href="./references#CD005049-fig-0059" title="">Analysis 4.12</a>; <a href="./references#CD005049-fig-0060" title="">Analysis 4.13</a>). </p> </section> <section id="CD005049-sec-0128"> <h5 class="title">Metoprolol</h5> <p>Moderate‐certainty evidence from two RCTs suggested that metoprolol reduced recurrences of atrial fibrillation, compared with placebo, but the CI included the possibility of no difference (RR 0.83, 95% CI 0.68 to 1.02; studies = 2, participants = 562; I<sup>2</sup> = 59%; <a href="./references#CD005049-fig-0074" title="">Analysis 5.14</a>). The corresponding recurrence rates were 72.0% in people receiving placebo and 59.7% (49.0% to 73.4%) in people receiving metoprolol. All sensitivity analyses included the same two trials so obtained identical results (<a href="./references#CD005049-fig-0072" title="">Analysis 5.12</a>; <a href="./references#CD005049-fig-0075" title="">Analysis 5.15</a>), except the analysis restricted to studies including more than 200 participants, which included only one study and showed no difference between metoprolol and placebo (<a href="./references#CD005049-fig-0060" title="">Analysis 4.13</a>). </p> </section> <section id="CD005049-sec-0129"> <h5 class="title">Amiodarone</h5> <p>High‐certainty evidence showed a reduction of atrial fibrillation recurrences with amiodarone of about a half, compared to placebo or no treatment (RR 0.52, 95% CI 0.46 to 0.58; studies = 6, participants = 812; I<sup>2</sup> = 33%; <a href="./references#CD005049-fig-0090" title="">Analysis 6.13</a>). This corresponded to a recurrence rate of 81.2% in people not receiving active treatment and 42.2% (95% CI 37.3% to 47.1%) in people receiving amiodarone. The NNTB for amiodarone was 3 (95% CI 2 to 4) participants treated for one year to avoid one recurrence. </p> <p>All sensitivity analyses obtained very similar results (<a href="./references#CD005049-fig-0091" title="">Analysis 6.14</a>; <a href="./references#CD005049-fig-0092" title="">Analysis 6.15</a>; <a href="./references#CD005049-fig-0093" title="">Analysis 6.16</a>). </p> </section> <section id="CD005049-sec-0130"> <h5 class="title">Dofetilide</h5> <p>Moderate‐certainty evidence indicated that dofetilide reduced recurrences of atrial fibrillation, compared to placebo, by about a quarter (RR 0.72, 95% CI 0.61 to 0.85; studies = 3, participants = 1183; I<sup>2</sup> = 79%; <a href="./references#CD005049-fig-0106" title="">Analysis 7.13</a>). Recurrence rates were 84.2% in people receiving placebo and 60.6% (95% CI 51.4% to 71.6%) in people receiving dofetilide. The corresponding NNTB was 4 (95% CI 3 to 8) participants treated for one year to avoid one recurrence. </p> <p>There was substantial heterogeneity between studies on dofetilide for this outcome (I<sup>2</sup> = 79%, P = 0.008). All studies showed the same direction of effect (i.e. a reduction of atrial fibrillation recurrences) and the heterogeneity was probably caused by differences in the characteristics of recruited participants. </p> <p>Sensitivity analyses did not differ from the main analysis (<a href="./references#CD005049-fig-0107" title="">Analysis 7.14</a>; <a href="./references#CD005049-fig-0108" title="">Analysis 7.15</a>; <a href="./references#CD005049-fig-0109" title="">Analysis 7.16</a>). </p> </section> <section id="CD005049-sec-0131"> <h5 class="title">Dronedarone</h5> <p>Moderate‐certainty evidence from two RCTs showed a reduction of recurrences of atrial fibrillation with dronedarone of about 15% (RR 0.85, 95% CI 0.80 to 0.91; studies = 2, participants = 1443; I<sup>2</sup> = 0%; <a href="./references#CD005049-fig-0124" title="">Analysis 8.15</a>). This corresponded to a recurrence rate of 76.6% in people treated with placebo and 65.1% (95% CI 61.3% to 69.7%) in people treated with dronedarone. The NNTB for dronedarone was 9 (95% CI 7 to 15) participants treated for one year to avoid one recurrence. </p> <p>Results from sensitivity analyses were quasi‐identical (<a href="./references#CD005049-fig-0125" title="">Analysis 8.16</a>; <a href="./references#CD005049-fig-0126" title="">Analysis 8.17</a>). </p> </section> <section id="CD005049-sec-0132"> <h5 class="title">Sotalol</h5> <p>High‐certainty evidence found a reduction of atrial fibrillation recurrences of about a fifth with sotalol compared with placebo or no treatment (RR 0.83, 95% CI 0.80 to 0.87; studies = 14, participants = 3179; I<sup>2</sup> = 54%; <a href="./references#CD005049-fig-0146" title="">Analysis 9.20</a>). The corresponding recurrence rates were 78.8% in participants not receiving an antiarrhythmic and 65.4% (95% CI 63.1% to 68.6%) in participants receiving sotalol. The NNTB for sotalol was 7 (95% CI 6 to 10) participants treated for one year to avoid one recurrence. </p> <p>There were no substantial difference with the main analysis in any of the sensitivity analyses (<a href="./references#CD005049-fig-0147" title="">Analysis 9.21</a>; <a href="./references#CD005049-fig-0148" title="">Analysis 9.22</a>; <a href="./references#CD005049-fig-0149" title="">Analysis 9.23</a>). </p> </section> <section id="CD005049-sec-0133"> <h5 class="title">Head‐to‐head comparisons</h5> <p>In direct comparisons between antiarrhythmics (<a href="#CD005049-tbl-0014">Table 5</a>), amiodarone appeared to reduce the recurrence of atrial fibrillation more than the combined class I drugs, more than dronedarone and more than sotalol. There were no other differences in head‐to‐head comparisons between antiarrhythmics. </p> <div class="table" id="CD005049-tbl-0014"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Head‐to‐head trials: recurrence of atrial fibrillation</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Drug 1 vs drug 2</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Drug 1</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Drug 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Disopyramide vs other class I drugs</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0034" title="LloydEA , GershBJ , FormanR . The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation. A double‐blind study comparing quinidine, disopyramide and placebo. South African Medical Journal1984;65(10):367‐9. [MEDLINE: PMID: 6367096; ISSN: 0038‐2469] ">Lloyd 1984</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.61 to 1.53)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0042" title="CrijnsHJ , GosselinkAT , LieKI . Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double‐blind study. Cardiovascular Drugs and Therapy1996;10(2):145‐52. [MEDLINE: PMID: 8842506; ISSN: 0920‐3206] ">PRODIS 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.73 (0.37 to 1.44)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Quinidine vs flecainide</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0035" title="NaccarelliGV , DorianP , HohnloserSH , CoumelP . Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. American Journal of Cardiology1996;77(3):53A‐9A. [MEDLINE: PMID: 8607392; ISSN: 0002‐9149] ">Naccarelli 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>117</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.91 to 1.19)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0054" title="SteinbeckG , DoliwaR , BachP . Therapy of paroxysmal atrial fibrillation. Cardiac glycosides alone or combined with anti‐arrhythmia agents? [Therapie des paroxysmalen Vorhofflimmerns. Herzglykoside allein oder in Kombination mit Antiarrhythmika?]. Deutsche Medizinische Wochenschrift1988;113(48):1867‐71. [MEDLINE: PMID: 3143539; ISSN: 0012‐0472] ">Steinbeck 1988</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.67 (0.81 to 3.41)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Quinidine vs other class I drugs</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0034" title="LloydEA , GershBJ , FormanR . The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation. A double‐blind study comparing quinidine, disopyramide and placebo. South African Medical Journal1984;65(10):367‐9. [MEDLINE: PMID: 6367096; ISSN: 0038‐2469] ">Lloyd 1984</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.65 to 1.64)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0035" title="NaccarelliGV , DorianP , HohnloserSH , CoumelP . Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. American Journal of Cardiology1996;77(3):53A‐9A. [MEDLINE: PMID: 8607392; ISSN: 0002‐9149] ">Naccarelli 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>117</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.91 to 1.19)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0045" title="RichiardiE , GaitaF , GrecoC , GaschinoG , Comba CostaG , RosettaniE , et al. Propafenone versus hydroquinidine in long‐term pharmacological prophylaxis of atrial fibrillation [Propafenone versus idrochinidina nella profilassi farmacologica a lungo termine della fibrillazione atriale]. Cardiologia1992;37(2):123‐7. [MEDLINE: PMID: 1600529; ISSN: 0393‐1978] ">Richiardi 1992</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.87 to 1.44)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0054" title="SteinbeckG , DoliwaR , BachP . Therapy of paroxysmal atrial fibrillation. Cardiac glycosides alone or combined with anti‐arrhythmia agents? [Therapie des paroxysmalen Vorhofflimmerns. Herzglykoside allein oder in Kombination mit Antiarrhythmika?]. Deutsche Medizinische Wochenschrift1988;113(48):1867‐71. [MEDLINE: PMID: 3143539; ISSN: 0012‐0472] ">Steinbeck 1988</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.67 (0.81 to 3.41)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Quinidine vs sotalol</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0026" title="HohnloserSH , van deLooA , BaedekerF . Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. Journal of the American College of Cardiology1995;26(4):852‐8. [MEDLINE: PMID: 7560608; ISSN: 0735‐1097] ">Hohnloser 1995</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58 (0.28 to 1.23)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0027" title="Juul‐MollerS , EdvardssonN , Rehnqvist‐AhlbergN . Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation1990;82(6):1932‐9. [MEDLINE: PMID: 2242519; ISSN: 0009‐7322] ">Juul‐Moller 1990</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13 (0.87 to 1.47)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0028" title="KaluscheD , StockingerJ , BetzP , RoskammH . Sotalol and quinidine/verapamil (Cordichin) in chronic atrial fibrillation – conversion and 12‐month follow‐up – a randomized comparison [Sotalol und Chinidin/Verapamil (Cordichin) bei chronischem Vorhoflimmern – Konversion und 12‐Monats‐Follow‐up – ein randomisierter Vergleich]. Zeitschrift fur Kardiologie1994;83 Suppl 5:109‐16. [MEDLINE: PMID: 7846939; ISSN: 0300‐5860] ">Kalusche 1994</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 (0.43 to 1.18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0039" title="FetschT , BauerP , EngberdingR , KochHP , LuklJ , MeinertzT , et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. European Heart Journal2004;25(16):1385‐94. [MEDLINE: PMID: 15302102; ISSN: 0195‐668X] FetschT , BurschelG , BreithardtG , EngberdingR , KochHP , LuklJ , et al. Medicamentous prevention after electric cardioversion of chronic atrial fibrillation. Goals and design of the PAFAC Study [Die medikamentöse Prophylaxe nach elektronischer Kardioversion von chronischem Vorhofflimmern. Ziele und Design der PAFAC‐Studie]. Zeitschrift fur Kardiologie1999;88(3):195‐207. [MEDLINE: PMID: 10355070; ISSN 0300‐5860] ">PAFAC 2004</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>244</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>377</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>255</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.88 to 1.08)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0051" title="VelosoHH , dePaolaAA . Analysis of atrial fibrillation recurrence during therapy with sotalol or quinidine. Researchers of +SOCESP [Analise da recorrencia de fibrilacao atrial durante terapia com sotalol ou quinidina. Investigadores da SOCESP]. Arquivos Brasileiros de Cardiologia1998;70(1):43‐9. [MEDLINE: PMID: 9629687; ISSN: 0066‐782X] dePaolaAA , VelosoHH . Efficacy and safety of sotalol versus quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation. SOCESP Investigators. American Journal of Cardiology1999;84(9):1033‐7. [MEDLINE: PMID: 10569659; ISSN: 0002‐9149] ">SOCESP 1999</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 (0.72 to 1.84)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0053" title="PattenM , KochHP , SonntagF , LuderitzB , MeinertzT . Medicamentous prevention of symptomatic paroxysmal atrial fibrillation/flutter onset. Goals and design of the SOPAT study. Executive committee of the investigators representing trial physicians [Die medikamentose Anfallsprophylaxe bei symptomatischem paroxysmalem Vorhofflimmern/‐flattern. Ziele und Design der SOPAT‐Studie. Investigators in Vertretung der Prufarzte]. Zeitschrift fur Kardiologie1999;88(3):185‐94. [MEDLINE: PMID: 10355069; ISSN: 0300‐5860] PattenM , MaasR , BauerP , LuderitzB , SonntagF , DluzniewskiM , et al. Suppression of paroxysmal atrial tachyarrhythmias – results of the SOPAT trial. European Heart Journal2004;25(16):1395‐404. [MEDLINE: PMID: 15321697; ISSN: 0195‐668X] ">SOPAT 2004</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>375</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>518</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>198</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.88 to 1.05)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Flecainide vs propafenone</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0005" title="AliotE , DenjoyI , The Flecainide AF French Study Group. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out‐patients with symptomatic paroxysmal atrial fibrillation/flutter. American Journal of Cardiology1996;77(3):66A‐71A. [MEDLINE: PMID: 8607394; ISSN: 0002‐9149] ">Aliot 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75 (0.48 to 1.16)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0022" title="ChimientiM , CullenMTJr , CasadeiG . Safety of flecainide versus propafenone for the long‐term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. European Heart Journal1995;16(12):1943‐51. [MEDLINE: PMID: 8682031; ISSN: 0195‐668X] ChimientiM , CullenMTJr , CasadeiG . Safety of long‐term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators. American Journal of Cardiology1996;77(3):60A‐75A. [MEDLINE: PMID: 8607393; ISSN: 0002‐9149] ">FAPIS 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06 (0.70 to 1.62)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Amiodarone vs class I drugs</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0003" title="AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. Journal of the American College of Cardiology2003;42(1):20‐9. [MEDLINE: PMID: 12849654; ISSN: 0735‐1097] ">AFFIRM Substudy 2003</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>106</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66 (0.55 to 0.80)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0031" title="KochiadakisGE , IgoumenidisNE , HamilosMI , TzerakisPG , KlapsinosNC , ZacharisEA , et al. Long‐term maintenance of normal sinus rhythm in patients with current symptomatic atrial fibrillation: amiodarone vs propafenone, both in low doses. Chest2004;125(2):377‐83. [MEDLINE: PMID: 14769712; ISSN: 0012‐3692] ">Kochiadakis 2004a</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.64 (0.41 to 1.01)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0040" title="PITAGORA Study Investigators, GuliziaM , MangiameliS , OraziS , ChiarandàG , PiccioneG , et al. A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the PITAGORA trial. American Heart Journal2008;155(1):107.e1. [PUBMED: PMID: 18082498] ">PITAGORA 2008</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.66 to 1.06)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0058" title="VillaniR , ZolettiF , VenianiM , LocatiF , NavaS . A comparison between amiodarone and disopyramide in a delayed‐release formulation in the prevention of recurrences of symptomatic atrial fibrillation [Confronto fra amiodarone e disopiramide in formulazione retard nella prevenzione delle recidive di fibrillazione atriale sintomatica]. La Clinica Terapeutica1992;140(1 Pt 2):35‐9. [MEDLINE: PMID: 1559321; ISSN: 0009‐9074] ">Villani 1992</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55 (0.35 to 0.85)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0059" title="VitoloE , TronciM , LarovereMT , RumoloR , MorabitoA . Amiodarone versus quinidine in the prophylaxis of atrial fibrillation. Acta Cardiologica1981;36(6):431‐44. [MEDLINE: PMID: 7039195; ISSN: 0001‐5385] ">Vitolo 1981</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40 (0.18 to 0.88)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Amiodarone vs dronedarone</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0018" title="LeHeuzeyJY , DeFerrariGM , RadzikD , SantiniM , ZhuJ , DavyJM . A short‐term, randomized, double‐blind, parallel‐group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. Journal of Cardiovascular Electrophysiology2010;21(6):597‐605. [PUBMED: PMID: 20384650 ] ">DIONYSOS 2010</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>116</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>255</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>163</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.59 to 0.82)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Amiodarone vs sotalol</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0003" title="AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. Journal of the American College of Cardiology2003;42(1):20‐9. [MEDLINE: PMID: 12849654; ISSN: 0735‐1097] ">AFFIRM Substudy 2003</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>131</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.54 to 0.86)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0030" title="KochiadakisGE , IgoumenidisNE , MarketouME , KaleboubasMD , SimantirakisEN , VardasPE . Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. Heart2000;84(3):251‐7. [MEDLINE: PMID: 10956284; ISSN 1355‐6037] KochiadakisGE , IgoumenidisNE , MarketouME , SolomouMC , KanoupakisEM , VardasPE . Low‐dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. American Journal of Cardiology1998;81(8):995‐8. [MEDLINE: PMID: 9576159; ISSN: 0002‐9149] KochiadakisGE , MarketouME , IgoumenidisNE , ChrysostomakisSI , MavrakisHE , KaleboubasMD , et al. Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm?. Pacing and Clinical Electrophysiology2000;23(11 Pt 2):1883‐7. [MEDLINE: PMID: 11139949; ISSN 0147‐8389] ">Kochiadakis 2000</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65 (0.46 to 0.92)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0037" title="NiuF , HuangCX , JiangH , YangB , GuoWL , ChenYX , et al. Effects of amiodarone versus sotalol in treatment of atrial fibrillation: a random controlled clinical study. Zhonghua Yi Xue Za Zhi2006;86(2):121‐3. [PUBMED: PMID: 16620720] ">Niu 2006</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.67 (0.47 to 0.94)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0040" title="PITAGORA Study Investigators, GuliziaM , MangiameliS , OraziS , ChiarandàG , PiccioneG , et al. A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the PITAGORA trial. American Heart Journal2008;155(1):107.e1. [PUBMED: PMID: 18082498] ">PITAGORA 2008</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78 (0.59 to 1.01)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0046" title="SinghBN , SinghSN , RedaDJ , TangXC , LopezB , HarrisCL , et al. Amiodarone versus sotalol for atrial fibrillation. New England Journal of Medicine2005;352(18):1861‐72. [MEDLINE: PMID: 15872201; ISSN: 0028‐4793] SinghSN , SinghBN , RedaDJ , FyeCL , EzekowitzMD , FletcherRD , et al. Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol‐Amiodarone Fibrillation Efficacy Trial [Safe‐T]). American Journal of Cardiology2003;92(4):468‐72. [MEDLINE: PMID: 12914883; ISSN 0002‐9149] ">SAFE‐T 2005</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>133</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>267</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>183</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 (0.62 to 0.82)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0057" title="VijayalakshmiK , WhittakerVJ , SuttonA , CampbellP , WrightRA , HallJA , et al. A randomized trial of prophylactic antiarrhythmic agents (amiodarone and sotalol) in patients with atrial fibrillation for whom direct current cardioversion is planned. American Heart Journal2006;151(4):863.e1‐6. [PUBMED: 16569550] ">Vijayalakshmi 2006</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.46 (0.16 to 1.32)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Dronedarone vs propafenone</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0014" title="ChunKJ , ByeonK , ImSI , ParkKM , ParkSJ , KimJS , et al. Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion. Clinical Therapeutics2014;36(9):1169‐75. [DOI: 10.1016/j.clinthera.2014.07.013; PUBMED: 25134972] ">Chun 2014</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.77 to 1.24)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Sotalol vs class I drugs other than quinidine</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0003" title="AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. Journal of the American College of Cardiology2003;42(1):20‐9. [MEDLINE: PMID: 12849654; ISSN: 0735‐1097] ">AFFIRM Substudy 2003</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.77 to 1.03)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0012" title="CarunchioA , FeraMS , MazzaA , BurattiniM , GrecoG , GalatiA , et al. A comparison between flecainide and sotalol in the prevention of recurrences of paroxysmal atrial fibrillation [Confronto tra flecainide e sotalolo nella profilassi delle recidive di fibrillazione atriale parossistica]. Giornale Italiano di Cardiologia1995;25(1):51‐68. [MEDLINE: PMID: 7642012; ISSN 0046‐5968] ">Carunchio 1995</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.33 (0.57 to 3.14)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0032" title="KochiadakisGE , IgoumenidisNE , HamilosME , TzerakisPG , KlapsinosNC , ChlouverakisGI , et al. Sotalol versus propafenone for long‐term maintenance of normal sinus rhythm in patients with recurrent symptomatic atrial fibrillation. American Journal of Cardiology2004;94(12):1563‐6. [MEDLINE: PMID: 15589019; ISSN: 0002‐9149] ">Kochiadakis 2004b</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.89 to 1.73)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0044" title="ReimoldSC , CantillonCO , FriedmanPL , AntmanEM . Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. American Journal of Cardiology1993;71(7):558‐63. [MEDLINE: PMID: 8438741; ISSN: 0002‐9149] ">Reimold 1993</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.69 to 1.20)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Sotalol vs dofetilide</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0020" title="CambellTJ , GreenbaumRA , ChannerKS , DalrympleHW , KingmaJH , SantiniM , et al. Mortality in patients with atrial fibrillation – 1 year follow up of EMERALD (European and Australian multicenter evaluative research on atrial fibrillation dofetilide). Journal of the American College of Cardiology2000;35(2 Suppl A):154A‐5A. DalrympleHW , CambellTJ , ChannerKS , GreenbaumR , KingmaJH , SantiniM , et al. Maintenance of sinus rhythm by dofetilide improves quality of life. The EMERALD (European and Australian multicenter evaluative research on atrial fibrillation dofetilide) study. Circulation1998;98(Suppl 13‐14):66. GreenbaumR , CampbellTJ , ChannerKS , DalrympleHW , KingmaJH , SantiniM , et al. Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide. The EMERALD (European and Australian multicenter evaluative research on atrial fibrillation dofetilide) study. Circulation1998;98(Suppl I‐633):3326. USFood , DrugAdministration . Drug Approval Package: Tikosyn (Dofetilide). Medical Review: Parts 1 and 2 (Study number 345). www.accessdata.fda.gov/drugsatfda_docs/nda/99/20‐931_Tikosyn.cfm (accessed 10 August 2010). ">EMERALD 2000</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>196</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.96 to 1.31)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Sotalol vs beta‐blockers</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0016" title="DAPHNE Study Investigators, CapucciA , BottoG , MolonG , SpampinatoA , FavaleS , et al. The Drug And Pace Health cliNical Evaluation (DAPHNE) study: a randomized trial comparing sotalol versus beta‐blockers to treat symptomatic atrial fibrillation in patients with brady‐tachycardia syndrome implanted with an antitachycardia pacemaker. American Heart Journal2008;156(2):373.e1‐8. [PUBMED: PMID: 18657671] ">DAPHNE 2008</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.86 to 1.18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0041" title="PlewanA , LehmannG , NdrepepaG , SchreieckJ , AltEU , SchomigA , et al. Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol. European Heart Journal2001;22(16):1504‐10. [MEDLINE: PMID: 11482924; ISSN: 0195‐668X] ">Plewan 2001</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.74 to 1.55)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; RR: risk ratio.</p> </div> </div> </section> </section> <section id="CD005049-sec-0134"> <h4 class="title">Other outcomes</h4> <p>Chronic anticoagulation with warfarin was mandatory (i.e. every participant received anticoagulation therapy throughout the whole follow‐up period) in only three studies (<a href="./references#CD005049-bbs2-0013" title="ChannerKS , BirchallA , SteedsRP , WaltersSJ , YeoWW , WestJN , et al. A randomized placebo‐controlled trial of pre‐treatment and short‐ or long‐term maintenance therapy with amiodarone supporting DC cardioversion for persistent atrial fibrillation. European Heart Journal2004;25(2):144‐50. [MEDLINE: PMID: 14720531; ISSN 0195‐668X] ">Channer 2004</a>; <a href="./references#CD005049-bbs2-0025" title="HillestadL , BjerkelundC , DaleJ , MaltauJ , StorsteinO . Quinidine in maintenance of sinus rhythm after electroconversion of chronic atrial fibrillation. A controlled clinical study. British Heart Journal1971;33(4):518‐21. [MEDLINE: PMID: 4934041; ISSN 0007‐0769] ">Hillestad 1971</a>; <a href="./references#CD005049-bbs2-0056" title="VanGelderIC , CrijnsHJ , VanGilstWH , VanWijkLM , HamerHP , LieKI . Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. American Journal of Cardiology1989;64(19):1317‐21. [MEDLINE: PMID: 2511744; ISSN: 0002‐9149] VanGelderIC , CrijnsHJ , VanGilstWH , VanWijkLM , HamerHP , LieKI . Efficacy of flecainide to maintain sinus rhythm after cardioversion of chronic atrial fibrillation and flutter. Circulation1988;78(4 Pt 2):III626. [MEDLINE: PMID: 3168202; ISSN: 0009‐7322] ">Van Gelder 1989</a>). In the rest of the studies, the decision on anticoagulation use was left to the judgement of the attending physician. Unfortunately, no trial reported the actual frequency of anticoagulation in the different treatment groups during follow‐up. </p> <p>Seven trials reported some data on the incidence of heart failure, which was low (<a href="./references#CD005049-bbs2-0008" title="ATHENA Investigators, HohnloserSH , CrijnsHJ , vanEickelsM , GaudinC , PageRL , et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. New England Journal of Medicine2009;360(2):668‐78. [PUBMED: PMID: 19213680] ATHENA Investigators, ConnollySJ , CrijnsHJ , Torp‐PedersenC , vanEickelsM , GaudinC , et al. Analysis of stroke in ATHENA: a placebo‐controlled, double‐blind, parallel‐arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death in patients with atrial fibrillation/atrial flutter. Circulation2009;120(13):1174‐80. [PUBMED: PMID: 19752319] ">ATHENA 2009</a>; <a href="./references#CD005049-bbs2-0018" title="LeHeuzeyJY , DeFerrariGM , RadzikD , SantiniM , ZhuJ , DavyJM . A short‐term, randomized, double‐blind, parallel‐group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. Journal of Cardiovascular Electrophysiology2010;21(6):597‐605. [PUBMED: PMID: 20384650 ] ">DIONYSOS 2010</a>; <a href="./references#CD005049-bbs2-0022" title="ChimientiM , CullenMTJr , CasadeiG . Safety of flecainide versus propafenone for the long‐term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. European Heart Journal1995;16(12):1943‐51. [MEDLINE: PMID: 8682031; ISSN: 0195‐668X] ChimientiM , CullenMTJr , CasadeiG . Safety of long‐term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators. American Journal of Cardiology1996;77(3):60A‐75A. [MEDLINE: PMID: 8607393; ISSN: 0002‐9149] ">FAPIS 1996</a>; <a href="./references#CD005049-bbs2-0026" title="HohnloserSH , van deLooA , BaedekerF . Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. Journal of the American College of Cardiology1995;26(4):852‐8. [MEDLINE: PMID: 7560608; ISSN: 0735‐1097] ">Hohnloser 1995</a>; <a href="./references#CD005049-bbs2-0033" title="KuhlkampV , SchirdewanA , StanglK , HombergM , PlochM , BeckOA . Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double‐blind, placebo‐controlled study. Journal of the American College of Cardiology2000;36(1):139‐46. [MEDLINE: PMID: 10898425; ISSN 0735‐1097] ">Kuhlkamp 2000</a>; <a href="./references#CD005049-bbs2-0042" title="CrijnsHJ , GosselinkAT , LieKI . Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double‐blind study. Cardiovascular Drugs and Therapy1996;10(2):145‐52. [MEDLINE: PMID: 8842506; ISSN: 0920‐3206] ">PRODIS 1996</a>; <a href="./references#CD005049-bbs2-0044" title="ReimoldSC , CantillonCO , FriedmanPL , AntmanEM . Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. American Journal of Cardiology1993;71(7):558‐63. [MEDLINE: PMID: 8438741; ISSN: 0002‐9149] ">Reimold 1993</a>). There were no differences in those trials between participants receiving antiarrhythmics and participants receiving placebo or no treatment. </p> </section> <section id="CD005049-sec-0135"> <h4 class="title">Subgroup analysis</h4> <p>Twenty‐three of the studies with a control group (placebo or no treatment) included only people with persistent atrial fibrillation. The mean duration of atrial fibrillation in those studies varied greatly, from three to 36 months. Only four studies exclusively included people with paroxysmal atrial fibrillation. The remaining studies included people with both paroxysmal and persistent atrial fibrillation; none reported outcomes separately by type of atrial fibrillation. </p> <p>It was not possible to compare subgroups of people with permanent and paroxysmal atrial fibrillation for any given antiarrhythmic drug. Therefore, we analysed people with permanent atrial fibrillation separately, for the outcomes and drugs that was possible, but as a sensitivity analysis. </p> <p>Other planned subgroup analyses (people with heart failure, studies where warfarin was mandatory versus those where it was discretionary, people with a structurally normal heart) were not possible as separate data for each group of participants were seldom available. A more detailed analysis by left ventricular function or by the New York Heart Association (NYHA) class was not possible either, for the same reason. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD005049-sec-0136" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD005049-sec-0136"></div> <p>In the third update of this systematic review, we found and included just one new RCT which added little additional information (100 participants, reported only atrial fibrillation recurrence rates). We excluded a previously included study as we become aware its data were already reported in another included study. Additionally, we restructured the analysis of the review to treat each drug separately, in order to present all analyses and results in a clearer way. In the end, some of the results regarding specific antiarrhythmics and conclusions of the review have changed. </p> <section id="CD005049-sec-0137"> <h3 class="title" id="CD005049-sec-0137">Summary of main results</h3> <p>The primary aim of this review was to determine if long‐term treatment with antiarrhythmics carried any clinical benefit to participants in addition to maintenance of sinus rhythm. Consequently, we focused on all‐cause mortality, stroke and potential adverse effects of treatment as the main outcomes. </p> <p>Concerning all‐cause mortality, we found that no antiarrhythmic drug produced a benefit on mortality and that some antiarrhythmics, sotalol and very probably quinidine, were actually associated with an increase in all‐cause mortality. Results for sotalol were particularly strong and the certainty of evidence was high: included studies had a low risk of bias for this outcome; results were consistent in all sensitivity analyses, replicating the results of the main analysis and indicating a clear association with increased mortality. The mortality rate in the pooled population was low, 0.8% in control participants (placebo or no treatment), but it was doubled in participants receiving sotalol. The mean NNTH was estimated at 102 participants treated for one year to have one additional death. </p> <p>The results suggesting an increase in mortality also with quinidine were less solid. The CIs included the possibility of no difference and when the analysis was restricted to more recent, larger and higher‐certainty studies, two studies remained that showed no increase in all‐cause mortality in the active treatment groups (<a href="./references#CD005049-bbs2-0039" title="FetschT , BauerP , EngberdingR , KochHP , LuklJ , MeinertzT , et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. European Heart Journal2004;25(16):1385‐94. [MEDLINE: PMID: 15302102; ISSN: 0195‐668X] FetschT , BurschelG , BreithardtG , EngberdingR , KochHP , LuklJ , et al. Medicamentous prevention after electric cardioversion of chronic atrial fibrillation. Goals and design of the PAFAC Study [Die medikamentöse Prophylaxe nach elektronischer Kardioversion von chronischem Vorhofflimmern. Ziele und Design der PAFAC‐Studie]. Zeitschrift fur Kardiologie1999;88(3):195‐207. [MEDLINE: PMID: 10355070; ISSN 0300‐5860] ">PAFAC 2004</a>; <a href="./references#CD005049-bbs2-0053" title="PattenM , KochHP , SonntagF , LuderitzB , MeinertzT . Medicamentous prevention of symptomatic paroxysmal atrial fibrillation/flutter onset. Goals and design of the SOPAT study. Executive committee of the investigators representing trial physicians [Die medikamentose Anfallsprophylaxe bei symptomatischem paroxysmalem Vorhofflimmern/‐flattern. Ziele und Design der SOPAT‐Studie. Investigators in Vertretung der Prufarzte]. Zeitschrift fur Kardiologie1999;88(3):185‐94. [MEDLINE: PMID: 10355069; ISSN: 0300‐5860] PattenM , MaasR , BauerP , LuderitzB , SonntagF , DluzniewskiM , et al. Suppression of paroxysmal atrial tachyarrhythmias – results of the SOPAT trial. European Heart Journal2004;25(16):1395‐404. [MEDLINE: PMID: 15321697; ISSN: 0195‐668X] ">SOPAT 2004</a>). A possible explanation is that both studies used a lower dose of quinidine than earlier trials and that quinidine was combined with verapamil, which has been shown to reduce some of the proarrhythmic effects of quinidine, such as accelerated atrio‐ventricular conduction. Finally, the proportion of participants having structural heart disease was lower in the <a href="./references#CD005049-bbs2-0039" title="FetschT , BauerP , EngberdingR , KochHP , LuklJ , MeinertzT , et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. European Heart Journal2004;25(16):1385‐94. [MEDLINE: PMID: 15302102; ISSN: 0195‐668X] FetschT , BurschelG , BreithardtG , EngberdingR , KochHP , LuklJ , et al. Medicamentous prevention after electric cardioversion of chronic atrial fibrillation. Goals and design of the PAFAC Study [Die medikamentöse Prophylaxe nach elektronischer Kardioversion von chronischem Vorhofflimmern. Ziele und Design der PAFAC‐Studie]. Zeitschrift fur Kardiologie1999;88(3):195‐207. [MEDLINE: PMID: 10355070; ISSN 0300‐5860] ">PAFAC 2004</a> and <a href="./references#CD005049-bbs2-0053" title="PattenM , KochHP , SonntagF , LuderitzB , MeinertzT . Medicamentous prevention of symptomatic paroxysmal atrial fibrillation/flutter onset. Goals and design of the SOPAT study. Executive committee of the investigators representing trial physicians [Die medikamentose Anfallsprophylaxe bei symptomatischem paroxysmalem Vorhofflimmern/‐flattern. Ziele und Design der SOPAT‐Studie. Investigators in Vertretung der Prufarzte]. Zeitschrift fur Kardiologie1999;88(3):185‐94. [MEDLINE: PMID: 10355069; ISSN: 0300‐5860] PattenM , MaasR , BauerP , LuderitzB , SonntagF , DluzniewskiM , et al. Suppression of paroxysmal atrial tachyarrhythmias – results of the SOPAT trial. European Heart Journal2004;25(16):1395‐404. [MEDLINE: PMID: 15321697; ISSN: 0195‐668X] ">SOPAT 2004</a> studies than in earlier trials. Therefore, the certainty of the evidence pointing to increased all‐cause mortality with quinidine was low. </p> <p>It is important to note that our data do not allow us to exclude a small increase in mortality with other antiarrhythmics, similar to those observed with quinidine and sotalol. Pooled data for other drugs included fewer studies and participants than for quinidine or sotalol and could be underpowered to detect effects that are of small size. In particular, we found very few data on mortality with flecainide. This is concerning because this drug has been shown to induce an excess of mortality in some trials (<a href="./references#CD005049-bbs2-0164" title="EchtDS , LiebsonPR , MitchellLB , PetersRW , Obias‐MannoD , BarkerAH , et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. New England Journal of Medicine1991;324:781‐8. [PMID: 1900101] ">CAST 1991</a>), and it showed a high risk of proarrhythmia in our review, similar to that of sotalol. The combined flecainide data had only a fifth of the participants included for sotalol and, despite the fact that several of the included studies stated that they analysed mortality, there were no deaths in any treatment group. Thus, we are very unsure about what the effect of long‐term treatment with flecainide on mortality might be. Similarly, the combined data for amiodarone for this outcome included four times fewer participants than with sotalol, so our power to detect small increases in mortality was very limited. Amiodarone has a well‐known high toxicity profile, it showed in our analysis one of the highest risk of withdrawing treatment due to adverse effects (RR 6.70, 95% CI 1.91 to 23.45) and was associated, in other meta‐analyses employing different methods, to a possible increase in mortality (<a href="./references#CD005049-bbs2-0176" title="FreemantleN , Lafuente‐LafuenteC , MitchellS , EckertL , ReynoldsM . Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide and propafenone, for the management of atrial fibrillation. Europace2011;13(3):329‐45. [PUBMED: 21227948] ">Freemantle 2011</a>; <a href="./references#CD005049-bbs2-0197" title="PicciniJP , HasselbladV , PetersonED , WashamJB , CaliffRM , KongDF . Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. Journal of the American College of Cardiology2009;54(12):1089‐95. [DOI: 10.1016/j.jacc.2009.04.085] ">Piccini 2009</a>) (see below: <a href="#CD005049-sec-0141">Agreements and disagreements with other studies or reviews</a>). </p> <p>With respect to adverse effects, virtually all the antiarrhythmics showed more withdrawals from treatment due to adverse effects and were associated with increased proarrhythmic events, compared with participants receiving placebo or no treatment. It is important to remember that we employed an extended definition of proarrhythmia that included severe, symptomatic bradycardia and AV blocks. Metoprolol was associated with an increase in proarrhythmia, precisely because of an increased incidence of severe bradycardias. Of all antiarrhythmics, quinidine at higher doses and sotalol appeared to be the drugs with more withdrawals because of adverse events both compared to controls and to other antiarrhythmics. Withdrawal rates with quinidine were as high as 25% in the pooled population analysed. Amiodarone, even if it compared favourably with class I drugs combined, had a very high RR (6.70) for increasing withdrawals compared to placebo. Moreover, these were the results at one‐year follow‐up, and the adverse effects of amiodarone are known to increase in frequency over time (<a href="./references#CD005049-bbs2-0183" title="HarrisL , McKennaWJ , RoxlandE , HoltDW , StoreyGC , KriklerDM . Side effects of long‐term amiodarone therapy. Circulation1983;67(1):45‐51. [MEDLINE: PMID: 6291807; ISSN: 0009‐7322] ">Harris 1983</a>; <a href="./references#CD005049-bbs2-0191" title="Lafuente‐LafuenteC , AlvarezJC , LeenhardtA , MoulyS , ExtramianaF , CaulinC , et al. Amiodarone concentrations in plasma and fat tissue during chronic treatment and related toxicity. British Journal of Clinical Pharmacology2009;67(5):511‐9. [PUBMED: 19552745] ">Lafuente‐Lafuente 2009</a>). </p> <p>Regarding other outcomes, our results showed that all the antiarrhythmic drugs studied reduced the recurrence of atrial fibrillation. However, the effectiveness of antiarrhythmics was limited: they reduced recurrences by 20% to 50% compared to controls, which meant that atrial fibrillation still recurred in many participants (43% to 67%) treated with antiarrhythmics at one year. Amiodarone seemed to be the most effective drug in preventing recurrences as it had the lowest RR and in head‐to‐head comparisons it was better than combined class I drugs, dronedarone or sotalol. In spite of this, atrial fibrillation recurred at one year in 43% of participants treated with amiodarone. </p> <p>Above all, we did not find evidence of any clinical benefit derived from this reduction of recurrences of atrial fibrillation. The results on mortality showed no benefit with any drug, rather the contrary, as we have already discussed. Fewer data existed on stroke or heart failure, but what data we found showed no difference between participants receiving active antiarrhythmic treatment and those not receiving it. The only exception was a single study in which the stroke rate was lower in the dronedarone arm than in the placebo arm (<a href="./references#CD005049-bbs2-0008" title="ATHENA Investigators, HohnloserSH , CrijnsHJ , vanEickelsM , GaudinC , PageRL , et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. New England Journal of Medicine2009;360(2):668‐78. [PUBMED: PMID: 19213680] ATHENA Investigators, ConnollySJ , CrijnsHJ , Torp‐PedersenC , vanEickelsM , GaudinC , et al. Analysis of stroke in ATHENA: a placebo‐controlled, double‐blind, parallel‐arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death in patients with atrial fibrillation/atrial flutter. Circulation2009;120(13):1174‐80. [PUBMED: PMID: 19752319] ">ATHENA 2009</a>). This finding was not confirmed by other studies of dronedarone. This lack of observable clinical benefit from the reduction of atrial fibrillation recurrences could have several explanations: 1. any potential benefit obtained with antiarrhythmics might be erased by the associated toxicity and increased proarrhythmic events; 2. clinical evolution and prognosis might be determined in many participants mostly by their underlying heart disease, rather than by atrial fibrillation itself. </p> <p>An interesting result of this review was that metoprolol, a beta‐blocker, also showed a reduction in atrial fibrillation recurrence, based on the pooled data from two high‐certainty RCTs (<a href="./references#CD005049-bbs2-0033" title="KuhlkampV , SchirdewanA , StanglK , HombergM , PlochM , BeckOA . Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double‐blind, placebo‐controlled study. Journal of the American College of Cardiology2000;36(1):139‐46. [MEDLINE: PMID: 10898425; ISSN 0735‐1097] ">Kuhlkamp 2000</a>; <a href="./references#CD005049-bbs2-0036" title="NergårdhAK , RosenqvistM , NordlanderR , FrickM . Maintenance of sinus rhythm with metoprolol CR initiated before cardioversion and repeated cardioversion of atrial fibrillation: a randomized double‐blind placebo‐controlled study. European Heart Journal2007;28(11):1351‐7. [PUBMED: PMID: 17329409] ">Nergårdh 2007</a>). Besides, there was no difference in preventing recurrences between beta‐blockers and sotalol in two other trials (<a href="./references#CD005049-bbs2-0016" title="DAPHNE Study Investigators, CapucciA , BottoG , MolonG , SpampinatoA , FavaleS , et al. The Drug And Pace Health cliNical Evaluation (DAPHNE) study: a randomized trial comparing sotalol versus beta‐blockers to treat symptomatic atrial fibrillation in patients with brady‐tachycardia syndrome implanted with an antitachycardia pacemaker. American Heart Journal2008;156(2):373.e1‐8. [PUBMED: PMID: 18657671] ">DAPHNE 2008</a> comparing sotalol against metoprolol or atenolol, and <a href="./references#CD005049-bbs2-0041" title="PlewanA , LehmannG , NdrepepaG , SchreieckJ , AltEU , SchomigA , et al. Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol. European Heart Journal2001;22(16):1504‐10. [MEDLINE: PMID: 11482924; ISSN: 0195‐668X] ">Plewan 2001</a> against bisoprolol). The effect of beta‐blockers in reducing the recurrence of atrial fibrillation could be due to their ability to suppress atrial extrasystoles, known to be a frequent precipitant of paroxysmal atrial fibrillation (<a href="./references#CD005049-bbs2-0184" title="HaïssaguerreS , BordierP , JaïsP , ShahDC , HociniM , RaherisonC , et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. New England Journal of Medicine1998;339(10):659‐66. [PUBMED: 9725923] ">Haïssaguerre 1998</a>). Beta‐blocker effects might also relate to antihypertensive and anti‐ischaemic actions or to their effect in reducing cardiac remodelling associated with coronary artery disease or heart failure. Like most of the active drugs we studied, metoprolol was associated with increased withdrawals due to adverse effects and increased cases of severe, symptomatic bradycardia. </p> </section> <section id="CD005049-sec-0138"> <h3 class="title" id="CD005049-sec-0138">Overall completeness and applicability of evidence</h3> <p>Most of the included trials reported data on all‐cause mortality, recurrence of atrial fibrillation and main adverse drug events. We also intended to analyse other clinically relevant outcomes such as the frequency of systemic embolism and use of long‐term anticoagulation, or the influence of heart failure and structural heart disease in the response to treatment. Unfortunately data on those outcomes were sparse, if reported at all. In the few trials where they were reported, the frequencies of stroke and heart failure were very low, perhaps because the populations that were included were low risk. The frequency of use of anticoagulants during follow‐up was not reported in any study. </p> <p>Similarly, we wanted to analyse the influence of structural heart disease on effectiveness, especially with respect to left ventricular ejection fraction and left atrial size, and the influence of duration of atrial fibrillation before cardioversion. These are factors well known to influence the risk of recurrence of atrial fibrillation. Unfortunately this analysis was not possible as separate data were not available for those participants subgroups. </p> <p>This lack of data for some clinical outcomes was the main limitation of our review. Another limitation could be that in many studies participants were followed up until atrial fibrillation recurred, and not thereafter, hence additional events between that point and the complete one year of follow‐up might have been missed. Also, the populations included in most studies were at low risk of events, the mean age of included participants was 64 years old and most of them had a normal left ventricular ejection fraction. We do not know if our results can be extrapolated to other patient populations, especially older people and those with a reduced left ventricular ejection fraction. </p> <p>Finally, it is important to remember that maintaining sinus rhythm using long‐term antiarrhythmic drugs is only one possible step in the more general 'rhythm control' strategy, and antiarrhythmic drugs should be put within the perspective of the global strategy chosen for the patient (<a href="./references#CD005049-bbs2-0156" title="JanuaryCT , WannLS , AlpertJS , CalkinsH , CigarroaJE , ClevelandJCJr , et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Journal American College Cardiology2014;64(21):e1‐76. [DOI: 10.1016/j.jacc.2014.03.022; MEDLINE: PMID: 24685669] ">AHA/ACC/HRS 2014</a>; <a href="./references#CD005049-bbs2-0194" title="National Institute for Health and Care Excellence. Atrial fibrillation: the management of atrial fibrillation. (Clinical Guideline 180), 2014. guidance.nice.org.uk/CG180 (accessed 17 June 2014). ">NICE 2014</a>). Other therapies have proven useful to prevent or reduce recurrence of atrial fibrillation in selected patients, especially catheter ablation (<a href="./references#CD005049-bbs2-0159" title="PapponeC , AugelloG , SalaS , GugliottaF , VicedominiG , GullettaS , et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. Journal of the American College of Cardiology2006;48(11):2340‐7. [DOI: 10.1016/j.jacc.2006.08.037; PUBMED: 17161267] ">APAF 2006</a>; <a href="./references#CD005049-bbs2-0196" title="OralH , PapponeC , ChughA , GoodE , BogunF , PelosiFJr , et al. Circumferential pulmonary‐vein ablation for chronic atrial fibrillation. New England Journal of Medicine2006;354(9):934‐41. [MEDLINE: PMID: 16510747; ISSN: 0028‐4793] ">Oral 2006</a>; <a href="./references#CD005049-bbs2-0206" title="TerasawaT , BalkEM , ChungM , GarlitskiAC , Alsheikh‐AliAA , LauJ , et al. Systematic review: comparative effectiveness of radiofrequency catheter ablation for atrial fibrillation. Annals of Internal Medicine2009;15(3):191‐202. [PUBMED: 19581635] ">Terasawa 2009</a>); and antiarrhythmics have been occasionally used for terminating recurrences (<a href="./references#CD005049-bbs2-0157" title='AlboniP , BottoGL , BaldiN , LuziM , RussoV , GianfranchiL , et al. Outpatient treatment of recent‐onset atrial fibrillation with the "pill‐in‐the‐pocket" approach. New England Journal of Medicine2004;351(23):2384‐91. [MEDLINE: PMID: 15575054; ISSN: 0028‐4793] '>Alboni 2004</a>). However, the effects of these therapies on the important clinical endpoints of all‐cause mortality, stroke and incidence of heart failure are still not well known. A different Cochrane Review has studied the effectiveness of catheter ablation for paroxysmal and persistent atrial fibrillation (<a href="./references#CD005049-bbs2-0168" title="ChenHS , WenJM , WuSN , LiuJP . Catheter ablation for paroxysmal and persistent atrial fibrillation. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD007101.pub2] ">Chen 2012</a>). </p> </section> <section id="CD005049-sec-0139"> <h3 class="title" id="CD005049-sec-0139">Quality of the evidence</h3> <p>Two areas of concern regarding the risk of bias of included studies were present: 1. a lack of details, in about 70% of studies, on the procedures followed for randomisation and for concealing the allocation of participants; and 2. a lack of double‐blinding in approximately 60% of studies. The lack of details on the randomisation and concealing procedures can probably be explained, at least partly, by the fact that many of the studies were conducted in the 1980s and 1990s, when the standards for reporting research methods were less developed. Also, it was very difficult to obtain additional data from authors for studies so old. The lack of blinding particularly concerned studies comparing two antiarrhythmics and much less so those studies comparing an antiarrhythmic with no active treatment. Nevertheless, these concerns did not allow us to consider the evidence as 'high certainty'. </p> <p>In addition to the risk of bias of included studies, another problem was that few data were available for some outcomes, causing imprecision, as analysis produced wide CIs including both the possibility of significant benefit and harm. This problem was more frequent with older drugs (e.g. quinidine, disopyramide, propafenone and flecainide) than newer ones (e.g. metoprolol, dronedarone and sotalol) and affected particularly mortality and, above all, stroke, outcomes that had a low frequency in the studied population. There was occasional inconsistency between studies for some outcomes (e.g. the effect on withdrawals with quinidine and sotalol), but was rare. </p> <p>However, despite those potential limitations, there were two characteristics that increased our confidence in the results of the review. 1. Consistency of results: for each analysis, there were always several studies available and results were very consistent across individual studies, despite their differences in blinding or in the description of the allocation procedures. 2. Objective outcomes: with the only exception of withdrawals because of adverse effects, the outcomes analysed were measured objectively (ECG records) or were objective outcomes (stroke, mortality), which reduced the risk of bias associated to the lack of blinding. </p> <p>In the end, we judged the available evidence for most analysed outcomes (all‐cause mortality, withdrawals due to adverse effects, proarrhythmia and recurrence of atrial fibrillation) as moderate certainty. </p> </section> <section id="CD005049-sec-0140"> <h3 class="title" id="CD005049-sec-0140">Potential biases in the review process</h3> <p>There was asymmetry in the funnel plot of one isolated outcome with sotalol (withdrawals because of adverse effects) but not for the other outcomes or with other drugs. Thus, we think the risk of substantial publication bias was low. </p> <p>There were very few disagreements between authors regarding the inclusion and exclusion of candidate studies. There were also few disagreements regarding the data extracted from included studies. Disagreements were easily resolved by discussion and consensus in all cases. </p> <p>Conflicts of interest could exist as most studies included in the review were funded by the company manufacturing the antiarrhythmic drug tested. </p> </section> <section id="CD005049-sec-0141"> <h3 class="title" id="CD005049-sec-0141">Agreements and disagreements with other studies or reviews</h3> <p>A previous meta‐analysis by <a href="./references#CD005049-bbs2-0172" title="CoplenSE , AntmanEM , BerlinJA , HewittP , ChalmersTC . Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta‐analysis of randomized control trials. Circulation1990;82:1106‐16. [PMID: 2144796] ">Coplen 1990</a> found that quinidine increased all‐cause mortality. A meta‐analysis by <a href="./references#CD005049-bbs2-0195" title="NicholG , McAlisterF , PhamB , LaupacisA , SheaB , GreenM , et al. Meta‐analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation. Heart2002;87:535‐43. [PMID: 12010934] ">Nichol 2002</a> found no difference in all‐cause mortality with any antiarrhythmic, but most of the trials that they pooled had very short follow‐up periods. </p> <p>A more recent network meta‐analysis, using a mixed treatment comparison method (where the estimates obtained from direct and indirect comparisons are combined in a network of trials), also found an increase in all‐cause mortality associated with sotalol (<a href="./references#CD005049-bbs2-0176" title="FreemantleN , Lafuente‐LafuenteC , MitchellS , EckertL , ReynoldsM . Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide and propafenone, for the management of atrial fibrillation. Europace2011;13(3):329‐45. [PUBMED: 21227948] ">Freemantle 2011</a>). This meta‐analysis, as well as a different meta‐analysis that compared amiodarone and dronedarone (<a href="./references#CD005049-bbs2-0197" title="PicciniJP , HasselbladV , PetersonED , WashamJB , CaliffRM , KongDF . Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. Journal of the American College of Cardiology2009;54(12):1089‐95. [DOI: 10.1016/j.jacc.2009.04.085] ">Piccini 2009</a>), raised the possibility of an increase in mortality associated with amiodarone treatment compared with placebo. However, this result appeared in exploratory analysis (restricted to inclusion of larger studies) and not in the main analysis. <a href="./references#CD005049-bbs2-0176" title="FreemantleN , Lafuente‐LafuenteC , MitchellS , EckertL , ReynoldsM . Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide and propafenone, for the management of atrial fibrillation. Europace2011;13(3):329‐45. [PUBMED: 21227948] ">Freemantle 2011</a> did not study quinidine in the meta‐analysis. </p> <p>Another systematic review, published in 2013, employed different methods to ours (RCTs with follow‐up of three months or more, different statistical methods) but found very similar results: antiarrhythmic drugs reduced atrial fibrillation recurrences but increased withdrawals due to adverse effects, serious adverse effects and proarrhythmia (<a href="./references#CD005049-bbs2-0205" title="SullivanSD , OrmeME , MoraisE , MitchellSA . Interventions for the treatment of atrial fibrillation: a systematic literature review and meta‐analysis. International Journal of Cardiology2013;165(2):229‐36. [DOI: 10.1016/j.ijcard.2012.03.070; PUBMED: 22469557] ">Sullivan 2013</a>). This study also found, compared to placebo, an increased mortality in participants receiving sotalol and a trend to increased mortality with amiodarone. It did not study quinidine. </p> <p>Two meta‐analysis, conducted by separate teams but using the same methods, focused on dronedarone and included people with atrial fibrillation but also with heart failure (<a href="./references#CD005049-bbs2-0166" title="ChatterjeeS , GhoshJ , LichsteinE , AikatS , MukherjeeD . Meta‐analysis of cardiovascular outcomes with dronedarone in patients with atrial fibrillation or heart failure. American Journal of Cardiology2012;110(4):607‐13. [DOI: 10.1016/j.amjcard.2012.04.034; PUBMED: 22608952] ">Chatterjee 2012</a>; <a href="./references#CD005049-bbs2-0173" title="DeVecchisR , ArianoC . Effects of dronedarone on all‐cause mortality and on cardiovascular events in patients treated for atrial fibrillation: a meta‐analysis of RCTs. Minerva Cardioangiol2019;67(2):163‐71. [DOI: 10.23736/S0026‐4725.18.04719‐9; PUBMED: 30260141] ">De Vecchis 2019</a>). Both found a trend to increased all‐cause and cardiovascular mortality with dronedarone, compared to placebo, in this population. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD005049-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Selection of studies for inclusion. AF: atrial fibrillation." data-id="CD005049-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Selection of studies for inclusion. AF: atrial fibrillation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/full#CD005049-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 9 Sotalol versus placebo/no treatment, outcome: 9.6 Withdrawals due to adverse effects – main analysis." data-id="CD005049-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Funnel plot of comparison: 9 Sotalol versus placebo/no treatment, outcome: 9.6 Withdrawals due to adverse effects – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/full#CD005049-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD005049-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/full#CD005049-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD005049-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/full#CD005049-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="All‐cause mortality with sotalol compared with placebo/no treatment: main analysis." data-id="CD005049-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>All‐cause mortality with sotalol compared with placebo/no treatment: main analysis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/full#CD005049-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Quinidine versus placebo or no treatment, Outcome 1 All‐cause mortality – main analysis." data-id="CD005049-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Quinidine versus placebo or no treatment, Outcome 1 All‐cause mortality – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Quinidine versus placebo or no treatment, Outcome 2 All‐cause mortality – sensitivity analysis intention to treat (ITT) worse case: missing participants counted as events." data-id="CD005049-fig-0007" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Quinidine versus placebo or no treatment, Outcome 2 All‐cause mortality – sensitivity analysis intention to treat (ITT) worse case: missing participants counted as events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Quinidine versus placebo or no treatment, Outcome 3 All‐cause mortality – subgroup analysis: older and recent studies." data-id="CD005049-fig-0008" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Quinidine versus placebo or no treatment, Outcome 3 All‐cause mortality – subgroup analysis: older and recent studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Quinidine versus placebo or no treatment, Outcome 4 All‐cause mortality – sensitivity analysis: persistent atrial fibrillation." data-id="CD005049-fig-0009" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Quinidine versus placebo or no treatment, Outcome 4 All‐cause mortality – sensitivity analysis: persistent atrial fibrillation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Quinidine versus placebo or no treatment, Outcome 5 All‐cause mortality – sensitivity analysis: low risk of bias studies." data-id="CD005049-fig-0010" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Quinidine versus placebo or no treatment, Outcome 5 All‐cause mortality – sensitivity analysis: low risk of bias studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Quinidine versus placebo or no treatment, Outcome 6 All‐cause mortality – sensitivity analysis: studies &gt; 200 participants." data-id="CD005049-fig-0011" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Quinidine versus placebo or no treatment, Outcome 6 All‐cause mortality – sensitivity analysis: studies &gt; 200 participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Quinidine versus placebo or no treatment, Outcome 7 Withdrawals due to adverse effects – main analysis." data-id="CD005049-fig-0012" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Quinidine versus placebo or no treatment, Outcome 7 Withdrawals due to adverse effects – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Quinidine versus placebo or no treatment, Outcome 8 Withdrawals due to adverse effects – subgroup analysis: older and recent studies." data-id="CD005049-fig-0013" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Quinidine versus placebo or no treatment, Outcome 8 Withdrawals due to adverse effects – subgroup analysis: older and recent studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Quinidine versus placebo or no treatment, Outcome 9 Withdrawals due to adverse effects – sensitivity analysis: persistent atrial fibrillation." data-id="CD005049-fig-0014" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Quinidine versus placebo or no treatment, Outcome 9 Withdrawals due to adverse effects – sensitivity analysis: persistent atrial fibrillation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Quinidine versus placebo or no treatment, Outcome 10 Withdrawals due to adverse effects – sensitivity analysis: low risk of bias studies." data-id="CD005049-fig-0015" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Quinidine versus placebo or no treatment, Outcome 10 Withdrawals due to adverse effects – sensitivity analysis: low risk of bias studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Quinidine versus placebo or no treatment, Outcome 11 Withdrawals due to adverse effects – sensitivity analysis: studies &gt; 200 participants." data-id="CD005049-fig-0016" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Quinidine versus placebo or no treatment, Outcome 11 Withdrawals due to adverse effects – sensitivity analysis: studies &gt; 200 participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Quinidine versus placebo or no treatment, Outcome 12 Proarrhythmia – main analysis." data-id="CD005049-fig-0017" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Quinidine versus placebo or no treatment, Outcome 12 Proarrhythmia – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Quinidine versus placebo or no treatment, Outcome 13 Proarrhythmia – subgroup analysis: older and recent studies." data-id="CD005049-fig-0018" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Quinidine versus placebo or no treatment, Outcome 13 Proarrhythmia – subgroup analysis: older and recent studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Quinidine versus placebo or no treatment, Outcome 14 Proarrhythmia – sensitivity analysis: persistent atrial fibrillation." data-id="CD005049-fig-0019" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Quinidine versus placebo or no treatment, Outcome 14 Proarrhythmia – sensitivity analysis: persistent atrial fibrillation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Quinidine versus placebo or no treatment, Outcome 15 Proarrhythmia – sensitivity analysis: low risk of bias studies." data-id="CD005049-fig-0020" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Quinidine versus placebo or no treatment, Outcome 15 Proarrhythmia – sensitivity analysis: low risk of bias studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Quinidine versus placebo or no treatment, Outcome 16 Proarrhythmia – sensitivity analysis: studies &gt; 200 participants." data-id="CD005049-fig-0021" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Quinidine versus placebo or no treatment, Outcome 16 Proarrhythmia – sensitivity analysis: studies &gt; 200 participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Quinidine versus placebo or no treatment, Outcome 17 Stroke – main analysis." data-id="CD005049-fig-0022" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Quinidine versus placebo or no treatment, Outcome 17 Stroke – main analysis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Quinidine versus placebo or no treatment, Outcome 18 Stroke – sensitivity analysis: persistent atrial fibrillation." data-id="CD005049-fig-0023" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Quinidine versus placebo or no treatment, Outcome 18 Stroke – sensitivity analysis: persistent atrial fibrillation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Quinidine versus placebo or no treatment, Outcome 19 Stroke – sensitivity analysis: low risk of bias studies." data-id="CD005049-fig-0024" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Quinidine versus placebo or no treatment, Outcome 19 Stroke – sensitivity analysis: low risk of bias studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Quinidine versus placebo or no treatment, Outcome 20 Stroke – sensitivity analysis: studies &gt; 200 participants." data-id="CD005049-fig-0025" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 Quinidine versus placebo or no treatment, Outcome 20 Stroke – sensitivity analysis: studies &gt; 200 participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Quinidine versus placebo or no treatment, Outcome 21 Atrial fibrillation recurrence – main analysis." data-id="CD005049-fig-0026" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 Quinidine versus placebo or no treatment, Outcome 21 Atrial fibrillation recurrence – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-001-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-001-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Quinidine versus placebo or no treatment, Outcome 22 Atrial fibrillation recurrence – sensitivity analysis: persistent atrial fibrillation." data-id="CD005049-fig-0027" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1 Quinidine versus placebo or no treatment, Outcome 22 Atrial fibrillation recurrence – sensitivity analysis: persistent atrial fibrillation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-001-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-001-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Quinidine versus placebo or no treatment, Outcome 23 Atrial fibrillation recurrence – sensitivity analysis: low risk of bias studies." data-id="CD005049-fig-0028" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1 Quinidine versus placebo or no treatment, Outcome 23 Atrial fibrillation recurrence – sensitivity analysis: low risk of bias studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-001-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-001-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Quinidine versus placebo or no treatment, Outcome 24 Atrial fibrillation recurrence – sensitivity analysis: studies &gt; 200 participants." data-id="CD005049-fig-0029" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1 Quinidine versus placebo or no treatment, Outcome 24 Atrial fibrillation recurrence – sensitivity analysis: studies &gt; 200 participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-001-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Disopyramide versus placebo or no treatment, Outcome 1 All‐cause mortality – main analysis." data-id="CD005049-fig-0030" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Disopyramide versus placebo or no treatment, Outcome 1 All‐cause mortality – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Disopyramide versus placebo or no treatment, Outcome 2 All‐cause mortality – intention to treat (ITT) worse case: missing participants counted as events." data-id="CD005049-fig-0031" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Disopyramide versus placebo or no treatment, Outcome 2 All‐cause mortality – intention to treat (ITT) worse case: missing participants counted as events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Disopyramide versus placebo or no treatment, Outcome 3 Withdrawals due to adverse effects – main analysis." data-id="CD005049-fig-0032" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Disopyramide versus placebo or no treatment, Outcome 3 Withdrawals due to adverse effects – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Disopyramide versus placebo or no treatment, Outcome 4 Withdrawals due to adverse effects – sensitivity analysis: persistent atrial fibrillation." data-id="CD005049-fig-0033" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Disopyramide versus placebo or no treatment, Outcome 4 Withdrawals due to adverse effects – sensitivity analysis: persistent atrial fibrillation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Disopyramide versus placebo or no treatment, Outcome 5 Stroke – main analysis." data-id="CD005049-fig-0034" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Disopyramide versus placebo or no treatment, Outcome 5 Stroke – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Disopyramide versus placebo or no treatment, Outcome 6 Stroke – subgroup analysis: persistent atrial fibrillation." data-id="CD005049-fig-0035" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Disopyramide versus placebo or no treatment, Outcome 6 Stroke – subgroup analysis: persistent atrial fibrillation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Disopyramide versus placebo or no treatment, Outcome 7 Atrial fibrillation recurrence – main analysis." data-id="CD005049-fig-0036" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Disopyramide versus placebo or no treatment, Outcome 7 Atrial fibrillation recurrence – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Disopyramide versus placebo or no treatment, Outcome 8 Atrial fibrillation recurrence – sensitivity analysis: persistent atrial fibrillation." data-id="CD005049-fig-0037" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Disopyramide versus placebo or no treatment, Outcome 8 Atrial fibrillation recurrence – sensitivity analysis: persistent atrial fibrillation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Propafenone versus placebo or no treatment, Outcome 1 All‐cause mortality – main analysis." data-id="CD005049-fig-0038" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Propafenone versus placebo or no treatment, Outcome 1 All‐cause mortality – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Propafenone versus placebo or no treatment, Outcome 2 All‐cause mortality – intention to treat (ITT) worse case: missing participants counted as events." data-id="CD005049-fig-0039" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Propafenone versus placebo or no treatment, Outcome 2 All‐cause mortality – intention to treat (ITT) worse case: missing participants counted as events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Propafenone versus placebo or no treatment, Outcome 3 All‐cause mortality – sensitivity analysis: low risk of bias studies." data-id="CD005049-fig-0040" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Propafenone versus placebo or no treatment, Outcome 3 All‐cause mortality – sensitivity analysis: low risk of bias studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Propafenone versus placebo or no treatment, Outcome 4 Withdrawals due to adverse effects – main analysis." data-id="CD005049-fig-0041" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Propafenone versus placebo or no treatment, Outcome 4 Withdrawals due to adverse effects – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Propafenone versus placebo or no treatment, Outcome 5 Withdrawals due to adverse effects – sensitivity analysis: studies &gt; 200 participants." data-id="CD005049-fig-0042" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Propafenone versus placebo or no treatment, Outcome 5 Withdrawals due to adverse effects – sensitivity analysis: studies &gt; 200 participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Propafenone versus placebo or no treatment, Outcome 6 Proarrhythmia – main analysis." data-id="CD005049-fig-0043" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Propafenone versus placebo or no treatment, Outcome 6 Proarrhythmia – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Propafenone versus placebo or no treatment, Outcome 7 Proarrhythmia – sensitivity analysis: low risk of bias studies." data-id="CD005049-fig-0044" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Propafenone versus placebo or no treatment, Outcome 7 Proarrhythmia – sensitivity analysis: low risk of bias studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Propafenone versus placebo or no treatment, Outcome 8 Atrial fibrillation recurrence – main analysis." data-id="CD005049-fig-0045" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Propafenone versus placebo or no treatment, Outcome 8 Atrial fibrillation recurrence – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Propafenone versus placebo or no treatment, Outcome 9 Atrial fibrillation recurrence – sensitivity analysis: low risk of bias studies." data-id="CD005049-fig-0046" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Propafenone versus placebo or no treatment, Outcome 9 Atrial fibrillation recurrence – sensitivity analysis: low risk of bias studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Propafenone versus placebo or no treatment, Outcome 10 Atrial fibrillation recurrence – sensitivity analysis: studies &gt; 200 participants." data-id="CD005049-fig-0047" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Propafenone versus placebo or no treatment, Outcome 10 Atrial fibrillation recurrence – sensitivity analysis: studies &gt; 200 participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Flecainide versus placebo or no treatment, Outcome 1 Withdrawals due to adverse effects – main analysis." data-id="CD005049-fig-0048" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Flecainide versus placebo or no treatment, Outcome 1 Withdrawals due to adverse effects – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Flecainide versus placebo or no treatment, Outcome 2 Proarrhythmia – main analysis." data-id="CD005049-fig-0049" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Flecainide versus placebo or no treatment, Outcome 2 Proarrhythmia – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Flecainide versus placebo or no treatment, Outcome 3 Proarrhythmia – sensitivity analysis: persistent atrial fibrillation." data-id="CD005049-fig-0050" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Flecainide versus placebo or no treatment, Outcome 3 Proarrhythmia – sensitivity analysis: persistent atrial fibrillation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Flecainide versus placebo or no treatment, Outcome 4 Proarrhythmia – sensitivity analysis: low risk of bias studies." data-id="CD005049-fig-0051" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Flecainide versus placebo or no treatment, Outcome 4 Proarrhythmia – sensitivity analysis: low risk of bias studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Flecainide versus placebo or no treatment, Outcome 5 Proarrhythmia – sensitivity analysis: studies &gt; 200 participants." data-id="CD005049-fig-0052" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Flecainide versus placebo or no treatment, Outcome 5 Proarrhythmia – sensitivity analysis: studies &gt; 200 participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Flecainide versus placebo or no treatment, Outcome 6 Stroke – main analysis." data-id="CD005049-fig-0053" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Flecainide versus placebo or no treatment, Outcome 6 Stroke – main analysis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Flecainide versus placebo or no treatment, Outcome 7 Stroke – subgroup analysis: persistent atrial fibrillation." data-id="CD005049-fig-0054" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Flecainide versus placebo or no treatment, Outcome 7 Stroke – subgroup analysis: persistent atrial fibrillation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Flecainide versus placebo or no treatment, Outcome 8 Stroke – sensitivity analysis: low risk of bias studies." data-id="CD005049-fig-0055" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Flecainide versus placebo or no treatment, Outcome 8 Stroke – sensitivity analysis: low risk of bias studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Flecainide versus placebo or no treatment, Outcome 9 Stroke – sensitivity analysis: studies &gt; 200 participants." data-id="CD005049-fig-0056" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 Flecainide versus placebo or no treatment, Outcome 9 Stroke – sensitivity analysis: studies &gt; 200 participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-004-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-004-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Flecainide versus placebo or no treatment, Outcome 10 Atrial fibrillation recurrence – main analysis." data-id="CD005049-fig-0057" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-004-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4 Flecainide versus placebo or no treatment, Outcome 10 Atrial fibrillation recurrence – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-004-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-004-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-004-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Flecainide versus placebo or no treatment, Outcome 11 Atrial fibrillation recurrence – sensitivity analysis: persistent atrial fibrillation." data-id="CD005049-fig-0058" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-004-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4 Flecainide versus placebo or no treatment, Outcome 11 Atrial fibrillation recurrence – sensitivity analysis: persistent atrial fibrillation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-004-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-004-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-004-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Flecainide versus placebo or no treatment, Outcome 12 Atrial fibrillation recurrence – sensitivity analysis: low risk of bias studies." data-id="CD005049-fig-0059" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-004-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4 Flecainide versus placebo or no treatment, Outcome 12 Atrial fibrillation recurrence – sensitivity analysis: low risk of bias studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-004-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-004-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-004-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Flecainide versus placebo or no treatment, Outcome 13 Atrial fibrillation recurrence – sensitivity analysis: studies &gt; 200 participants." data-id="CD005049-fig-0060" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-004-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.13</div> <div class="figure-caption"> <p>Comparison 4 Flecainide versus placebo or no treatment, Outcome 13 Atrial fibrillation recurrence – sensitivity analysis: studies &gt; 200 participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-004-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metoprolol versus placebo or no treatment, Outcome 1 All‐cause mortality – main analysis." data-id="CD005049-fig-0061" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Metoprolol versus placebo or no treatment, Outcome 1 All‐cause mortality – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metoprolol versus placebo or no treatment, Outcome 2 All‐cause mortality – intention to treat (ITT) worse case: missing participants counted as events." data-id="CD005049-fig-0062" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Metoprolol versus placebo or no treatment, Outcome 2 All‐cause mortality – intention to treat (ITT) worse case: missing participants counted as events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metoprolol versus placebo or no treatment, Outcome 3 All‐cause mortality – sensitivity analysis: persistent atrial fibrillation." data-id="CD005049-fig-0063" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Metoprolol versus placebo or no treatment, Outcome 3 All‐cause mortality – sensitivity analysis: persistent atrial fibrillation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metoprolol versus placebo or no treatment, Outcome 4 All‐cause mortality – sensitivity analysis: low risk of bias studies." data-id="CD005049-fig-0064" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Metoprolol versus placebo or no treatment, Outcome 4 All‐cause mortality – sensitivity analysis: low risk of bias studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metoprolol versus placebo or no treatment, Outcome 5 All‐cause mortality – sensitivity analysis: studies &gt; 200 participants." data-id="CD005049-fig-0065" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Metoprolol versus placebo or no treatment, Outcome 5 All‐cause mortality – sensitivity analysis: studies &gt; 200 participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metoprolol versus placebo or no treatment, Outcome 6 Withdrawals due to adverse effects – main analysis." data-id="CD005049-fig-0066" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Metoprolol versus placebo or no treatment, Outcome 6 Withdrawals due to adverse effects – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metoprolol versus placebo or no treatment, Outcome 7 Withdrawals due to adverse effects – sensitivity analysis: persistent atrial fibrillation." data-id="CD005049-fig-0067" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 Metoprolol versus placebo or no treatment, Outcome 7 Withdrawals due to adverse effects – sensitivity analysis: persistent atrial fibrillation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-005-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-005-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metoprolol versus placebo or no treatment, Outcome 8 Withdrawals due to adverse effects – sensitivity analysis: low risk of bias studies." data-id="CD005049-fig-0068" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-005-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5 Metoprolol versus placebo or no treatment, Outcome 8 Withdrawals due to adverse effects – sensitivity analysis: low risk of bias studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-005-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-005-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-005-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metoprolol versus placebo or no treatment, Outcome 9 Withdrawals due to adverse effects – sensitivity analysis: studies &gt; 200 participants." data-id="CD005049-fig-0069" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-005-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5 Metoprolol versus placebo or no treatment, Outcome 9 Withdrawals due to adverse effects – sensitivity analysis: studies &gt; 200 participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-005-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-005-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-005-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metoprolol versus placebo or no treatment, Outcome 10 Proarrhythmia – main analysis." data-id="CD005049-fig-0070" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-005-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5 Metoprolol versus placebo or no treatment, Outcome 10 Proarrhythmia – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-005-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-005-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-005-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metoprolol versus placebo or no treatment, Outcome 11 Proarrhythmia – sensitivity analysis: persistent atrial fibrillation." data-id="CD005049-fig-0071" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-005-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.11</div> <div class="figure-caption"> <p>Comparison 5 Metoprolol versus placebo or no treatment, Outcome 11 Proarrhythmia – sensitivity analysis: persistent atrial fibrillation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-005-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-005-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-005-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metoprolol versus placebo or no treatment, Outcome 12 Proarrhythmia – sensitivity analysis: low risk of bias studies." data-id="CD005049-fig-0072" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-005-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.12</div> <div class="figure-caption"> <p>Comparison 5 Metoprolol versus placebo or no treatment, Outcome 12 Proarrhythmia – sensitivity analysis: low risk of bias studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-005-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-005-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-005-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metoprolol versus placebo or no treatment, Outcome 13 Proarrhythmia – sensitivity analysis: studies &gt; 200 participants." data-id="CD005049-fig-0073" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-005-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.13</div> <div class="figure-caption"> <p>Comparison 5 Metoprolol versus placebo or no treatment, Outcome 13 Proarrhythmia – sensitivity analysis: studies &gt; 200 participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-005-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-005-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-005-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metoprolol versus placebo or no treatment, Outcome 14 Atrial fibrillation recurrence – main analysis." data-id="CD005049-fig-0074" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-005-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.14</div> <div class="figure-caption"> <p>Comparison 5 Metoprolol versus placebo or no treatment, Outcome 14 Atrial fibrillation recurrence – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-005-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-005-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-005-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metoprolol versus placebo or no treatment, Outcome 15 Atrial fibrillation recurrence – sensitivity analysis: persistent atrial fibrillation." data-id="CD005049-fig-0075" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-005-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.15</div> <div class="figure-caption"> <p>Comparison 5 Metoprolol versus placebo or no treatment, Outcome 15 Atrial fibrillation recurrence – sensitivity analysis: persistent atrial fibrillation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-005-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-005-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-005-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metoprolol versus placebo or no treatment, Outcome 16 Atrial fibrillation recurrence – sensitivity analysis: low risk of bias studies." data-id="CD005049-fig-0076" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-005-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.16</div> <div class="figure-caption"> <p>Comparison 5 Metoprolol versus placebo or no treatment, Outcome 16 Atrial fibrillation recurrence – sensitivity analysis: low risk of bias studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-005-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-005-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-005-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Metoprolol versus placebo or no treatment, Outcome 17 Atrial fibrillation recurrence – sensitivity analysis: studies &gt; 200 participants." data-id="CD005049-fig-0077" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-005-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.17</div> <div class="figure-caption"> <p>Comparison 5 Metoprolol versus placebo or no treatment, Outcome 17 Atrial fibrillation recurrence – sensitivity analysis: studies &gt; 200 participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-005-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Amiodarone versus placebo or no treatment, Outcome 1 All‐cause mortality – main analysis." data-id="CD005049-fig-0078" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Amiodarone versus placebo or no treatment, Outcome 1 All‐cause mortality – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Amiodarone versus placebo or no treatment, Outcome 2 All‐cause mortality – intention to treat (ITT) worse case: missing participants counted as events." data-id="CD005049-fig-0079" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Amiodarone versus placebo or no treatment, Outcome 2 All‐cause mortality – intention to treat (ITT) worse case: missing participants counted as events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Amiodarone versus placebo or no treatment, Outcome 3 All‐cause mortality – sensitivity analysis: persistent atrial fibrillation." data-id="CD005049-fig-0080" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Amiodarone versus placebo or no treatment, Outcome 3 All‐cause mortality – sensitivity analysis: persistent atrial fibrillation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Amiodarone versus placebo or no treatment, Outcome 4 Withdrawals due to adverse effects – main analysis." data-id="CD005049-fig-0081" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Amiodarone versus placebo or no treatment, Outcome 4 Withdrawals due to adverse effects – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Amiodarone versus placebo or no treatment, Outcome 5 Withdrawals due to adverse effects – sensitivity analysis: low risk of bias studies." data-id="CD005049-fig-0082" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Amiodarone versus placebo or no treatment, Outcome 5 Withdrawals due to adverse effects – sensitivity analysis: low risk of bias studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Amiodarone versus placebo or no treatment, Outcome 6 Proarrhythmia – main analysis." data-id="CD005049-fig-0083" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Amiodarone versus placebo or no treatment, Outcome 6 Proarrhythmia – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-006-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-006-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Amiodarone versus placebo or no treatment, Outcome 7 Proarrhythmia – sensitivity analysis: persistent atrial fibrillation." data-id="CD005049-fig-0084" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-006-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 Amiodarone versus placebo or no treatment, Outcome 7 Proarrhythmia – sensitivity analysis: persistent atrial fibrillation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-006-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-006-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-006-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Amiodarone versus placebo or no treatment, Outcome 8 Proarrhythmia – sensitivity analysis: low risk of bias studies." data-id="CD005049-fig-0085" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-006-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6 Amiodarone versus placebo or no treatment, Outcome 8 Proarrhythmia – sensitivity analysis: low risk of bias studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-006-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-006-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-006-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Amiodarone versus placebo or no treatment, Outcome 9 Proarrhythmia – sensitivity analysis: studies &gt; 200 participants." data-id="CD005049-fig-0086" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-006-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6 Amiodarone versus placebo or no treatment, Outcome 9 Proarrhythmia – sensitivity analysis: studies &gt; 200 participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-006-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-006-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-006-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Amiodarone versus placebo or no treatment, Outcome 10 Stroke – main analysis." data-id="CD005049-fig-0087" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-006-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.10</div> <div class="figure-caption"> <p>Comparison 6 Amiodarone versus placebo or no treatment, Outcome 10 Stroke – main analysis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-006-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-006-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-006-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Amiodarone versus placebo or no treatment, Outcome 11 Stroke – sensitivity analysis: persistent atrial fibrillation." data-id="CD005049-fig-0088" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-006-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.11</div> <div class="figure-caption"> <p>Comparison 6 Amiodarone versus placebo or no treatment, Outcome 11 Stroke – sensitivity analysis: persistent atrial fibrillation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-006-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-006-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-006-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Amiodarone versus placebo or no treatment, Outcome 12 Stroke – sensitivity analysis: studies &gt; 200 participants." data-id="CD005049-fig-0089" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-006-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.12</div> <div class="figure-caption"> <p>Comparison 6 Amiodarone versus placebo or no treatment, Outcome 12 Stroke – sensitivity analysis: studies &gt; 200 participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-006-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-006-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-006-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Amiodarone versus placebo or no treatment, Outcome 13 Atrial fibrillation recurrence – main analysis." data-id="CD005049-fig-0090" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-006-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.13</div> <div class="figure-caption"> <p>Comparison 6 Amiodarone versus placebo or no treatment, Outcome 13 Atrial fibrillation recurrence – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-006-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-006-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-006-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Amiodarone versus placebo or no treatment, Outcome 14 Atrial fibrillation recurrence – sensitivity analysis: persistent atrial fibrillation." data-id="CD005049-fig-0091" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-006-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.14</div> <div class="figure-caption"> <p>Comparison 6 Amiodarone versus placebo or no treatment, Outcome 14 Atrial fibrillation recurrence – sensitivity analysis: persistent atrial fibrillation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-006-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-006-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-006-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Amiodarone versus placebo or no treatment, Outcome 15 Atrial fibrillation recurrence – sensitivity analysis: low risk of bias studies." data-id="CD005049-fig-0092" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-006-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.15</div> <div class="figure-caption"> <p>Comparison 6 Amiodarone versus placebo or no treatment, Outcome 15 Atrial fibrillation recurrence – sensitivity analysis: low risk of bias studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-006-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-006-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-006-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Amiodarone versus placebo or no treatment, Outcome 16 Atrial fibrillation recurrence – sensitivity analysis: studies &gt; 200 participants." data-id="CD005049-fig-0093" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-006-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.16</div> <div class="figure-caption"> <p>Comparison 6 Amiodarone versus placebo or no treatment, Outcome 16 Atrial fibrillation recurrence – sensitivity analysis: studies &gt; 200 participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-006-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Dofetilide versus placebo or no treatment, Outcome 1 All‐cause mortality – main analysis." data-id="CD005049-fig-0094" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Dofetilide versus placebo or no treatment, Outcome 1 All‐cause mortality – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Dofetilide versus placebo or no treatment, Outcome 2 All‐cause mortality – intention to treat (ITT) worse case: missing participants counted as events." data-id="CD005049-fig-0095" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Dofetilide versus placebo or no treatment, Outcome 2 All‐cause mortality – intention to treat (ITT) worse case: missing participants counted as events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Dofetilide versus placebo or no treatment, Outcome 3 All‐cause mortality – sensitivity analysis: persistent atrial fibrillation." data-id="CD005049-fig-0096" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Dofetilide versus placebo or no treatment, Outcome 3 All‐cause mortality – sensitivity analysis: persistent atrial fibrillation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-007-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Dofetilide versus placebo or no treatment, Outcome 4 All‐cause mortality – sensitivity analysis: low risk of bias studies." data-id="CD005049-fig-0097" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 Dofetilide versus placebo or no treatment, Outcome 4 All‐cause mortality – sensitivity analysis: low risk of bias studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-007-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-007-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Dofetilide versus placebo or no treatment, Outcome 5 All‐cause mortality – sensitivity analysis: studies &gt; 200 participants." data-id="CD005049-fig-0098" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-007-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7 Dofetilide versus placebo or no treatment, Outcome 5 All‐cause mortality – sensitivity analysis: studies &gt; 200 participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-007-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-007-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-007-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Dofetilide versus placebo or no treatment, Outcome 6 Withdrawals due to adverse effects – main analysis." data-id="CD005049-fig-0099" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-007-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7 Dofetilide versus placebo or no treatment, Outcome 6 Withdrawals due to adverse effects – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-007-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-007-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-007-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Dofetilide versus placebo or no treatment, Outcome 7 Withdrawals due to adverse effects – sensitivity analysis: persistent atrial fibrillation." data-id="CD005049-fig-0100" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-007-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7 Dofetilide versus placebo or no treatment, Outcome 7 Withdrawals due to adverse effects – sensitivity analysis: persistent atrial fibrillation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-007-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-007-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-007-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Dofetilide versus placebo or no treatment, Outcome 8 Withdrawals due to adverse effects – sensitivity analysis: studies &gt; 200 participants." data-id="CD005049-fig-0101" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-007-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.8</div> <div class="figure-caption"> <p>Comparison 7 Dofetilide versus placebo or no treatment, Outcome 8 Withdrawals due to adverse effects – sensitivity analysis: studies &gt; 200 participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-007-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-007-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-007-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Dofetilide versus placebo or no treatment, Outcome 9 Proarrhythmia – main analysis." data-id="CD005049-fig-0102" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-007-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.9</div> <div class="figure-caption"> <p>Comparison 7 Dofetilide versus placebo or no treatment, Outcome 9 Proarrhythmia – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-007-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-007-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-007-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Dofetilide versus placebo or no treatment, Outcome 10 Proarrhythmia – sensitivity analysis: persistent atrial fibrillation." data-id="CD005049-fig-0103" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-007-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.10</div> <div class="figure-caption"> <p>Comparison 7 Dofetilide versus placebo or no treatment, Outcome 10 Proarrhythmia – sensitivity analysis: persistent atrial fibrillation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-007-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-007-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-007-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Dofetilide versus placebo or no treatment, Outcome 11 Proarrhythmia – sensitivity analysis: low risk of bias studies." data-id="CD005049-fig-0104" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-007-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.11</div> <div class="figure-caption"> <p>Comparison 7 Dofetilide versus placebo or no treatment, Outcome 11 Proarrhythmia – sensitivity analysis: low risk of bias studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-007-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-007-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-007-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Dofetilide versus placebo or no treatment, Outcome 12 Proarrhythmia – sensitivity analysis: studies &gt; 200 participants." data-id="CD005049-fig-0105" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-007-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.12</div> <div class="figure-caption"> <p>Comparison 7 Dofetilide versus placebo or no treatment, Outcome 12 Proarrhythmia – sensitivity analysis: studies &gt; 200 participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-007-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-007-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-007-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Dofetilide versus placebo or no treatment, Outcome 13 Atrial fibrillation recurrence – main analysis." data-id="CD005049-fig-0106" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-007-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.13</div> <div class="figure-caption"> <p>Comparison 7 Dofetilide versus placebo or no treatment, Outcome 13 Atrial fibrillation recurrence – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-007-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-007-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-007-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Dofetilide versus placebo or no treatment, Outcome 14 Atrial fibrillation recurrence – sensitivity analysis: persistent atrial fibrillation." data-id="CD005049-fig-0107" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-007-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.14</div> <div class="figure-caption"> <p>Comparison 7 Dofetilide versus placebo or no treatment, Outcome 14 Atrial fibrillation recurrence – sensitivity analysis: persistent atrial fibrillation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-007-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-007-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-007-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Dofetilide versus placebo or no treatment, Outcome 15 Atrial fibrillation recurrence – sensitivity analysis: low risk of bias studies." data-id="CD005049-fig-0108" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-007-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.15</div> <div class="figure-caption"> <p>Comparison 7 Dofetilide versus placebo or no treatment, Outcome 15 Atrial fibrillation recurrence – sensitivity analysis: low risk of bias studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-007-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-007-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-007-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Dofetilide versus placebo or no treatment, Outcome 16 Atrial fibrillation recurrence – sensitivity analysis: studies &gt; 200 participants." data-id="CD005049-fig-0109" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-007-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.16</div> <div class="figure-caption"> <p>Comparison 7 Dofetilide versus placebo or no treatment, Outcome 16 Atrial fibrillation recurrence – sensitivity analysis: studies &gt; 200 participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-007-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Dronedarone versus placebo or no treatment, Outcome 1 All‐cause mortality – main analysis." data-id="CD005049-fig-0110" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Dronedarone versus placebo or no treatment, Outcome 1 All‐cause mortality – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Dronedarone versus placebo or no treatment, Outcome 2 All‐cause mortality – intention to treat (ITT) worse case: missing participants counted as events." data-id="CD005049-fig-0111" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Dronedarone versus placebo or no treatment, Outcome 2 All‐cause mortality – intention to treat (ITT) worse case: missing participants counted as events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Dronedarone versus placebo or no treatment, Outcome 3 All‐cause mortality – sensitivity analysis: persistent atrial fibrillation." data-id="CD005049-fig-0112" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 Dronedarone versus placebo or no treatment, Outcome 3 All‐cause mortality – sensitivity analysis: persistent atrial fibrillation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Dronedarone versus placebo or no treatment, Outcome 4 All‐cause mortality – sensitivity analysis: low risk of bias studies." data-id="CD005049-fig-0113" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 Dronedarone versus placebo or no treatment, Outcome 4 All‐cause mortality – sensitivity analysis: low risk of bias studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0114"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-008-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-008-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Dronedarone versus placebo or no treatment, Outcome 5 All‐cause mortality – sensitivity analysis: studies &gt; 200 participants." data-id="CD005049-fig-0114" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-008-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8 Dronedarone versus placebo or no treatment, Outcome 5 All‐cause mortality – sensitivity analysis: studies &gt; 200 participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0114">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-008-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0115"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-008-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-008-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Dronedarone versus placebo or no treatment, Outcome 6 Withdrawals due to adverse effects – main analysis." data-id="CD005049-fig-0115" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-008-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8 Dronedarone versus placebo or no treatment, Outcome 6 Withdrawals due to adverse effects – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0115">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-008-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0116"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-008-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-008-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Dronedarone versus placebo or no treatment, Outcome 7 Withdrawals due to adverse effects – sensitivity analysis: persistent atrial fibrillation." data-id="CD005049-fig-0116" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-008-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.7</div> <div class="figure-caption"> <p>Comparison 8 Dronedarone versus placebo or no treatment, Outcome 7 Withdrawals due to adverse effects – sensitivity analysis: persistent atrial fibrillation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0116">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-008-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0117"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-008-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-008-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Dronedarone versus placebo or no treatment, Outcome 8 Withdrawals due to adverse effects – sensitivity analysis: low risk of bias studies." data-id="CD005049-fig-0117" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-008-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.8</div> <div class="figure-caption"> <p>Comparison 8 Dronedarone versus placebo or no treatment, Outcome 8 Withdrawals due to adverse effects – sensitivity analysis: low risk of bias studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0117">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-008-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0118"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-008-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-008-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Dronedarone versus placebo or no treatment, Outcome 9 Withdrawals due to adverse effects – sensitivity analysis: studies &gt; 200 participants." data-id="CD005049-fig-0118" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-008-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.9</div> <div class="figure-caption"> <p>Comparison 8 Dronedarone versus placebo or no treatment, Outcome 9 Withdrawals due to adverse effects – sensitivity analysis: studies &gt; 200 participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0118">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-008-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0119"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-008-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-008-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Dronedarone versus placebo or no treatment, Outcome 10 Proarrhythmia – main analysis." data-id="CD005049-fig-0119" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-008-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.10</div> <div class="figure-caption"> <p>Comparison 8 Dronedarone versus placebo or no treatment, Outcome 10 Proarrhythmia – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0119">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-008-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0120"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-008-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-008-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Dronedarone versus placebo or no treatment, Outcome 11 Proarrhythmia – sensitivity analysis: low risk of bias studies." data-id="CD005049-fig-0120" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-008-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.11</div> <div class="figure-caption"> <p>Comparison 8 Dronedarone versus placebo or no treatment, Outcome 11 Proarrhythmia – sensitivity analysis: low risk of bias studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0120">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-008-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0121"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-008-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-008-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Dronedarone versus placebo or no treatment, Outcome 12 Proarrhythmia – sensitivity analysis: studies &gt; 200 participants." data-id="CD005049-fig-0121" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-008-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.12</div> <div class="figure-caption"> <p>Comparison 8 Dronedarone versus placebo or no treatment, Outcome 12 Proarrhythmia – sensitivity analysis: studies &gt; 200 participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0121">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-008-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0122"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-008-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-008-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Dronedarone versus placebo or no treatment, Outcome 13 Stroke – main analysis." data-id="CD005049-fig-0122" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-008-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.13</div> <div class="figure-caption"> <p>Comparison 8 Dronedarone versus placebo or no treatment, Outcome 13 Stroke – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0122">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-008-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0123"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-008-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-008-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Dronedarone versus placebo or no treatment, Outcome 14 Stroke – sensitivity analysis: studies &gt; 200 participants." data-id="CD005049-fig-0123" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-008-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.14</div> <div class="figure-caption"> <p>Comparison 8 Dronedarone versus placebo or no treatment, Outcome 14 Stroke – sensitivity analysis: studies &gt; 200 participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0123">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-008-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0124"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-008-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-008-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Dronedarone versus placebo or no treatment, Outcome 15 Atrial fibrillation recurrence – main analysis." data-id="CD005049-fig-0124" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-008-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.15</div> <div class="figure-caption"> <p>Comparison 8 Dronedarone versus placebo or no treatment, Outcome 15 Atrial fibrillation recurrence – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0124">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-008-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0125"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-008-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-008-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Dronedarone versus placebo or no treatment, Outcome 16 Atrial fibrillation recurrence – sensitivity analysis: persistent atrial fibrillation." data-id="CD005049-fig-0125" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-008-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.16</div> <div class="figure-caption"> <p>Comparison 8 Dronedarone versus placebo or no treatment, Outcome 16 Atrial fibrillation recurrence – sensitivity analysis: persistent atrial fibrillation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0125">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-008-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0126"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-008-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-008-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Dronedarone versus placebo or no treatment, Outcome 17 Atrial fibrillation recurrence – sensitivity analysis: studies &gt; 200 participants." data-id="CD005049-fig-0126" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-008-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.17</div> <div class="figure-caption"> <p>Comparison 8 Dronedarone versus placebo or no treatment, Outcome 17 Atrial fibrillation recurrence – sensitivity analysis: studies &gt; 200 participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0126">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-008-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0127"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-009-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Sotalol versus placebo or no treatment, Outcome 1 All‐cause mortality – main analysis." data-id="CD005049-fig-0127" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Sotalol versus placebo or no treatment, Outcome 1 All‐cause mortality – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0127">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0128"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Sotalol versus placebo or no treatment, Outcome 2 All‐cause mortality – intention to treat (ITT) worse case: missing participants counted as events." data-id="CD005049-fig-0128" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 Sotalol versus placebo or no treatment, Outcome 2 All‐cause mortality – intention to treat (ITT) worse case: missing participants counted as events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0128">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0129"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-009-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-009-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Sotalol versus placebo or no treatment, Outcome 3 All‐cause mortality – sensitivity analysis: persistent atrial fibrillation." data-id="CD005049-fig-0129" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9 Sotalol versus placebo or no treatment, Outcome 3 All‐cause mortality – sensitivity analysis: persistent atrial fibrillation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0129">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0130"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-009-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-009-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Sotalol versus placebo or no treatment, Outcome 4 All‐cause mortality – sensitivity analysis: low risk of bias studies." data-id="CD005049-fig-0130" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9 Sotalol versus placebo or no treatment, Outcome 4 All‐cause mortality – sensitivity analysis: low risk of bias studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0130">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0131"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-009-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-009-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Sotalol versus placebo or no treatment, Outcome 5 All‐cause mortality – sensitivity analysis: studies &gt; 200 participants." data-id="CD005049-fig-0131" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.5</div> <div class="figure-caption"> <p>Comparison 9 Sotalol versus placebo or no treatment, Outcome 5 All‐cause mortality – sensitivity analysis: studies &gt; 200 participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0131">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0132"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-009-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-009-06.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Sotalol versus placebo or no treatment, Outcome 6 Withdrawals due to adverse effects – main analysis." data-id="CD005049-fig-0132" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.6</div> <div class="figure-caption"> <p>Comparison 9 Sotalol versus placebo or no treatment, Outcome 6 Withdrawals due to adverse effects – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0132">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0133"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-009-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-009-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Sotalol versus placebo or no treatment, Outcome 7 Withdrawals due to adverse effects – sotalol: heterogeneity study." data-id="CD005049-fig-0133" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.7</div> <div class="figure-caption"> <p>Comparison 9 Sotalol versus placebo or no treatment, Outcome 7 Withdrawals due to adverse effects – sotalol: heterogeneity study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0133">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0134"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-009-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-009-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Sotalol versus placebo or no treatment, Outcome 8 Withdrawals due to adverse effects – sensitivity analysis: persistent atrial fibrillation." data-id="CD005049-fig-0134" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.8</div> <div class="figure-caption"> <p>Comparison 9 Sotalol versus placebo or no treatment, Outcome 8 Withdrawals due to adverse effects – sensitivity analysis: persistent atrial fibrillation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0134">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0135"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-009-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-009-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Sotalol versus placebo or no treatment, Outcome 9 Withdrawals due to adverse effects – sensitivity analysis: low risk of bias studies." data-id="CD005049-fig-0135" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.9</div> <div class="figure-caption"> <p>Comparison 9 Sotalol versus placebo or no treatment, Outcome 9 Withdrawals due to adverse effects – sensitivity analysis: low risk of bias studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0135">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0136"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-009-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-009-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Sotalol versus placebo or no treatment, Outcome 10 Withdrawals due to adverse effects – sensitivity analysis: studies &gt; 200 participants." data-id="CD005049-fig-0136" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.10</div> <div class="figure-caption"> <p>Comparison 9 Sotalol versus placebo or no treatment, Outcome 10 Withdrawals due to adverse effects – sensitivity analysis: studies &gt; 200 participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0136">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0137"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-009-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-009-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Sotalol versus placebo or no treatment, Outcome 11 Proarrhythmia – main analysis." data-id="CD005049-fig-0137" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.11</div> <div class="figure-caption"> <p>Comparison 9 Sotalol versus placebo or no treatment, Outcome 11 Proarrhythmia – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0137">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0138"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-009-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-009-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Sotalol versus placebo or no treatment, Outcome 12 Proarrhythmia – sotalol: heterogeneity study." data-id="CD005049-fig-0138" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.12</div> <div class="figure-caption"> <p>Comparison 9 Sotalol versus placebo or no treatment, Outcome 12 Proarrhythmia – sotalol: heterogeneity study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0138">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0139"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-009-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-009-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Sotalol versus placebo or no treatment, Outcome 13 Proarrhythmia – sensitivity analysis: persistent atrial fibrillation." data-id="CD005049-fig-0139" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.13</div> <div class="figure-caption"> <p>Comparison 9 Sotalol versus placebo or no treatment, Outcome 13 Proarrhythmia – sensitivity analysis: persistent atrial fibrillation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0139">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0140"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-009-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-009-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Sotalol versus placebo or no treatment, Outcome 14 Proarrhythmia – sensitivity analysis: low risk of bias studies." data-id="CD005049-fig-0140" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.14</div> <div class="figure-caption"> <p>Comparison 9 Sotalol versus placebo or no treatment, Outcome 14 Proarrhythmia – sensitivity analysis: low risk of bias studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0140">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0141"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-009-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-009-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Sotalol versus placebo or no treatment, Outcome 15 Proarrhythmia – sensitivity analysis: studies &gt; 200 participants." data-id="CD005049-fig-0141" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.15</div> <div class="figure-caption"> <p>Comparison 9 Sotalol versus placebo or no treatment, Outcome 15 Proarrhythmia – sensitivity analysis: studies &gt; 200 participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0141">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0142"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-009-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-009-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Sotalol versus placebo or no treatment, Outcome 16 Stroke – main analysis." data-id="CD005049-fig-0142" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.16</div> <div class="figure-caption"> <p>Comparison 9 Sotalol versus placebo or no treatment, Outcome 16 Stroke – main analysis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0142">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0143"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-009-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-009-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Sotalol versus placebo or no treatment, Outcome 17 Stroke – sensitivity analysis: persistent atrial fibrillation." data-id="CD005049-fig-0143" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.17</div> <div class="figure-caption"> <p>Comparison 9 Sotalol versus placebo or no treatment, Outcome 17 Stroke – sensitivity analysis: persistent atrial fibrillation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0143">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0144"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-009-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-009-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Sotalol versus placebo or no treatment, Outcome 18 Stroke – sensitivity analysis: low risk of bias studies." data-id="CD005049-fig-0144" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.18</div> <div class="figure-caption"> <p>Comparison 9 Sotalol versus placebo or no treatment, Outcome 18 Stroke – sensitivity analysis: low risk of bias studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0144">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0145"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-009-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-009-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Sotalol versus placebo or no treatment, Outcome 19 Stroke – sensitivity analysis: studies &gt; 200 participants." data-id="CD005049-fig-0145" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.19</div> <div class="figure-caption"> <p>Comparison 9 Sotalol versus placebo or no treatment, Outcome 19 Stroke – sensitivity analysis: studies &gt; 200 participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0145">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0146"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-009-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-009-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Sotalol versus placebo or no treatment, Outcome 20 Atrial fibrillation recurrence – main analysis." data-id="CD005049-fig-0146" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.20</div> <div class="figure-caption"> <p>Comparison 9 Sotalol versus placebo or no treatment, Outcome 20 Atrial fibrillation recurrence – main analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0146">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0147"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-009-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-009-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Sotalol versus placebo or no treatment, Outcome 21 Atrial fibrillation recurrence – sensitivity analysis: persistent atrial fibrillation." data-id="CD005049-fig-0147" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.21</div> <div class="figure-caption"> <p>Comparison 9 Sotalol versus placebo or no treatment, Outcome 21 Atrial fibrillation recurrence – sensitivity analysis: persistent atrial fibrillation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0147">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0148"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-009-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-009-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Sotalol versus placebo or no treatment, Outcome 22 Atrial fibrillation recurrence – sensitivity analysis: low risk of bias studies." data-id="CD005049-fig-0148" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.22</div> <div class="figure-caption"> <p>Comparison 9 Sotalol versus placebo or no treatment, Outcome 22 Atrial fibrillation recurrence – sensitivity analysis: low risk of bias studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0148">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005049-fig-0149"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/urn:x-wiley:14651858:media:CD005049:CD005049-CMP-009-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_t/tCD005049-CMP-009-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Sotalol versus placebo or no treatment, Outcome 23 Atrial fibrillation recurrence – sensitivity analysis: studies &gt; 200 participants." data-id="CD005049-fig-0149" src="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.23</div> <div class="figure-caption"> <p>Comparison 9 Sotalol versus placebo or no treatment, Outcome 23 Atrial fibrillation recurrence – sensitivity analysis: studies &gt; 200 participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-fig-0149">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/media/CDSR/CD005049/image_n/nCD005049-CMP-009-23.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD005049-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Quinidine compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Quinidine compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults in sinus rhythm after cardioversion of atrial fibrillation<br/> <b>Setting:</b> hospital/community<br/> <b>Intervention:</b> quinidine<br/> <b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with quinidine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b><br/> follow‐up: median 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.01</b><br/> (0.84 to 4.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1646<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000<br/> (6 to 36) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Withdrawals due to adverse effects</b><br/> follow‐up: median 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.56</b> (0.87 to 2.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1669<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>c,d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Heterogeneity was high for the main analysis (I<sup>2</sup> = 67%), but the test for subgroup differences indicated that the RR was higher in older studies which used a higher dose. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>163 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>254 per 1000 (142 to 452)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proarrhythmia</b><br/> follow‐up: median 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.05</b><br/> (0.95 to 4.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1676<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b><sup>c,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000<br/> (10 to 48) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stroke</b><br/> follow‐up: median 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.97</b><br/> (0.25 to 3.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1107<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000<br/> (1 to 19) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrence of atrial fibrillation</b><br/> follow‐up: median 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.83</b><br/> (0.78 to 0.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1624<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80.5 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66.8 per 100<br/> (62.8 to 70.8) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for study limitations: majority of studies were at low or unclear risk of bias for at least one of the key domains (allocation concealment, blinding, incomplete outcome data).<br/> <sup>b</sup>Downgraded one level for imprecision: confidence interval included no effect, the possibility of a beneficial effect and a strong harmful effect.<br/> <sup>c</sup>Not downgraded for study limitations, as the two studies contributing majority of weight were at low risk for key domains (allocation concealment, blinding, incomplete outcome data).<br/> <sup>d</sup>Not downgraded for inconsistency: although heterogeneity was high for the main analysis, this was partially explained by subgroup analysis.<br/> <sup>e</sup>Downgraded one level for imprecision: confidence interval included possibility of no effect or small beneficial effect as well as harmful effect.<br/> <sup>f</sup>Not downgraded for imprecision, although CI just included null.<br/> <sup>g</sup>Downgraded one level for imprecision: confidence interval included both important benefits and harms, and event rate was very low. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Quinidine compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/full#CD005049-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005049-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Disopyramide compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Disopyramide compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults in sinus rhythm after cardioversion of atrial fibrillation<br/> <b>Setting:</b> hospital/community<br/> <b>Intervention:</b> disopyramide<br/> <b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with disopyramide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b><br/> follow‐up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 5.00</b><br/> (0.25 to 101.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>92<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Anticipated absolute effects per 1000 could not be calculated because there were no deaths in the control group. Risks were the data from the RCT. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0/71</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5/75</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Withdrawals due to adverse effects</b><br/> follow‐up: range 6–12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 3.68</b><br/> (0.95 to 14.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>146<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>104 per 1000<br/> (27 to 401) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proarrhythmia</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stroke</b><br/> follow‐up: range 6–12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.31</b><br/> (0.03 to 2.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>146<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000<br/> (1 to 82) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrence of atrial fibrillation</b><br/> follow‐up: range 6–12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.77</b><br/> (0.59 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>146<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>69.0 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53.1 per 100<br/> (40.7 to 69.7) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for study limitations: both studies had unclear risk of bias for one of the key domains.<br/> <sup>b</sup>Downgraded two levels for imprecision: very small sample size and wide confidence intervals including both important benefits and harms.<br/> <sup>c</sup>Downgraded one level for imprecision: very small sample size. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Disopyramide compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/full#CD005049-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005049-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Propafenone compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Propafenone compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults in sinus rhythm after cardioversion of atrial fibrillation<br/> <b>Setting:</b> hospital/community<br/> <b>Intervention:</b> propafenone<br/> <b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with propafenone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b><br/> follow‐up: range 6–15 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.19</b><br/> (0.02 to 1.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>212<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Very few data available for this outcome: only 2 deaths reported in 5 included RCTs.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000<br/> (1 to 44) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Withdrawals due to adverse effects</b><br/> follow‐up: range 6–15 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.62</b><br/> (1.07 to 2.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1098<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>61 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>99 per 1000<br/> (65 to 150) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proarrhythmia</b><br/> follow‐up: range 6–15 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.32</b><br/> (0.39 to 4.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>381<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000<br/> (5 to 56) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stroke</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrence of atrial fibrillation</b><br/> follow‐up: range 6–15 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.67</b><br/> (0.61 to 0.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1098<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>73.0 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48.9 per 100<br/> (44.5 to 54.0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for study limitations. All studies had unclear or high risk of bias in at least one of the three key domains (allocation concealment, blinding, incomplete outcome data).<br/> <sup>b</sup>Downgraded two levels for imprecision due to small sample size and confidence interval wide enough to include both important benefit and harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Propafenone compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/full#CD005049-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005049-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Flecainide compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Flecainide compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults in sinus rhythm after cardioversion of atrial fibrillation<br/> <b>Setting:</b> hospital/community<br/> <b>Intervention:</b> flecainide<br/> <b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with flecainide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Withdrawals due to adverse effects</b><br/> follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 15.41</b><br/> (0.91 to 260) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>73<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Anticipated absolute effects per 1000 could not be calculated because there were no withdrawals in the control group. Risks were the data from the RCT. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0/37</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7/36</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proarrhythmia</b><br/> follow‐up: range 6–12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 4.80</b><br/> (1.30 to 17.7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>511<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1000<br/> (8 to 112) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stroke</b><br/> follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.04</b><br/> (0.11 to 39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>362<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Anticipated absolute effects per 1000 could not be calculated because there were no strokes in the control group. Risks were the data from the RCT. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0/81</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3/281</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrence of atrial fibrillation</b><br/> follow‐up: range 6–12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.65</b><br/> (0.55 to 0.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>511<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>69.8 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45.4 per 100<br/> (38.4 to 53.8) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Not downgraded for study limitations. the only included study was at high risk of bias for blinding (less relevant for this outcome) but low risk for other key domains.<br/> <sup>b</sup>Downgraded two levels for imprecision due to small sample size and wide confidence interval that included both possible harm and no effect.<br/> <sup>c</sup>Downgraded one level for study limitations; all studies were at high or unclear risk of bias in at least one of the key domains.<br/> <sup>d</sup>Not downgraded for study limitations. Majority of weight came from 2 largest studies which were at high risk of bias for blinding (less relevant for this outcome) but low risk for other key domains. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Flecainide compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/full#CD005049-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005049-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Metoprolol compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Metoprolol compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults in sinus rhythm after cardioversion of atrial fibrillation<br/> <b>Setting:</b> hospital/community<br/> <b>Intervention:</b> metoprolol<br/> <b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Metoprolol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b><br/> follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.02</b><br/> (0.37 to 11.1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>562<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000<br/> (1 to 39) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Withdrawals due to adverse effects</b><br/> follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 3.47</b><br/> (1.48 to 8.1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>562<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000<br/> (31 to 173) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proarrhythmia</b><br/> follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 18.14</b><br/> (2.42 to 135.6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>562<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Anticipated absolute effects per 1000 could not be calculated because there were no events in the control group. Risks are the data from the RCTs. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 / 282</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 / 280</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stroke</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrence of atrial fibrillation</b><br/> follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.83</b> (0.68 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>562<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>72.0 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>59.7 per 100<br/> (49.0 to 73.4) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for imprecision. Confidence intervals included both possible harm and possible benefit.<br/> <sup>b</sup>Downgraded one level for inconsistency: high I<sup>2</sup> statistic (59%) indicated heterogeneity and this could not be explored in subgroup analysis due to only two studies being included. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Metoprolol compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/full#CD005049-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005049-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Amiodarone compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Amiodarone compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults in sinus rhythm after cardioversion of atrial fibrillation<br/> <b>Setting:</b> hospital/community<br/> <b>Intervention:</b> amiodarone<br/> <b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with amiodarone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b><br/> follow‐up: range 6–12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.66</b><br/> (0.55 to 4.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>444<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>43 per 1000<br/> (14 to 129) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Withdrawals due to adverse effects</b><br/> follow‐up: range 6–16 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 6.70</b><br/> (1.91 to 23.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>319<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49 per 1000<br/> (14 to 172) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proarrhythmia</b><br/> follow‐up: range 6–16 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.22</b><br/> (0.71 to 6.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>673<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000<br/> (6 to 57) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stroke</b><br/> follow‐up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.15</b><br/> (0.30 to 4.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>399<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000<br/> (7 to 100) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrence of atrial fibrillation</b><br/> follow‐up: median 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.52</b><br/> (0.46 to 0.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>812<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>81.2 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42.2 per 100<br/> (37.3 to 47.1) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for imprecision: confidence interval included both possible benefit and harm.<br/> <sup>b</sup>Downgraded one level for study limitations: majority of weight was from studies with unclear or high risk of bias in key domains.<br/> <sup>c</sup>Downgraded one level for imprecision: small sample size.<br/> <sup>d</sup>Not downgraded for study limitations, as the majority weight was from studies at low risk of bias in all key domains.<br/> <sup>e</sup>Downgraded two levels for imprecision: small sample size and wide confidence interval which included both possible benefit and harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Amiodarone compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/full#CD005049-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005049-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Dofetilide compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Dofetilide compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults in sinus rhythm after cardioversion of atrial fibrillation<br/> <b>Setting:</b> hospital/community<br/> <b>Intervention:</b> dofetilide<br/> <b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with dofetilide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b><br/> follow‐up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.98</b><br/> (0.76 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1183<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>193 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>189 per 1000<br/> (146 to 245) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Withdrawals due to adverse effects</b><br/> follow‐up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.77</b><br/> (0.75 to 4.2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>677<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>61 per 1000<br/> (26 to 144) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proarrhythmia</b><br/> follow‐up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 5.50</b><br/> (1.33 to 22.8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1183<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000<br/> (3 to 53) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stroke</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrence of atrial fibrillation</b><br/> follow‐up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.72</b> (0.61 to 0.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1183<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>84.2 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60.6 per 100<br/> (51.4 to 71.6) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for study limitations: majority of studies had unclear risk of selection bias.<br/> <sup>b</sup>Downgraded one level for imprecision: confidence interval included both possible benefit and harm.<br/> <sup>c</sup>Not downgraded for study limitations as 51% of weight came from a study with low risk of bias across all domains (but other two studies had unclear risk of selection bias).<br/> <sup>d</sup>Downgraded one level for heterogeneity due to very high I<sup>2</sup> value (79%). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Dofetilide compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/full#CD005049-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005049-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Dronedarone compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Dronedarone compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults in sinus rhythm after cardioversion of atrial fibrillation<br/> <b>Setting:</b> hospital/community<br/> <b>Intervention:</b> dronedarone<br/> <b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with dronedarone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b><br/> follow‐up: range 6–12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.86</b><br/> (0.68 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6071<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>51 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>44 per 1000<br/> (35 to 56) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Withdrawals due to adverse effects</b><br/> follow‐up: range 6–12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.58</b><br/> (1.34 to 1.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6071<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>122 per 1000<br/> (104 to 143) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proarrhythmia</b><br/> follow‐up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.95</b> (0.77 to 4.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5872<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1000<br/> (14 to 91) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stroke</b><br/> follow‐up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.66</b><br/> (0.47 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5872<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000<br/> (13 to 25) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrence of atrial fibrillation</b><br/> follow‐up: range 6–12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.85</b><br/> (0.80 to 0.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1443<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>76.6 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65.1 per 100<br/> (61.3 to 69.7) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for study limitations: 83% of weight came from a study with unclear blinding, which could be relevant to this outcome.<br/> <sup>b</sup>Downgraded one level for inconsistency due to very high I<sup>2</sup> statistic of 78%.<br/> <sup>c</sup>Downgraded one level for study limitations: most weight came from a study with unclear allocation concealment. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Dronedarone compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/full#CD005049-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005049-tbl-0009"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Sotalol compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Sotalol compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults in sinus rhythm after cardioversion of atrial fibrillation<br/> <b>Setting:</b> hospital/community<br/> <b>Intervention:</b> sotalol<br/> <b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with sotalol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b><br/> follow‐up: range 6–12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.23</b><br/> (1.03 to 4.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1882<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000<br/> (9 to 40) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Withdrawals due to adverse effects</b><br/> follow‐up: range 6–19 months; median 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.95</b> (1.23 to 3.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2688<br/> (12 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Heterogeneity was high for the main analysis (I<sup>2</sup> = 56%), but the test for subgroup differences indicated that the RR was higher in older studies with sotalol. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>94 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>183 per 1000<br/> (116 to 293) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Proarrhythmia</b><br/> follow‐up: median 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 3.55</b><br/> (2.16 to 5.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2989<br/> (12 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 1000<br/> (25 to 68) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stroke</b><br/> follow‐up: range 6–12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.47</b><br/> (0.48 to 4.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1161<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/> (3 to 30) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrence of atrial fibrillation</b><br/> follow‐up: range 6–19 months; median 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.83</b><br/> (0.80 to 0.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3179<br/> (14 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b><sup>a,e,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>78.8 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65.4 per 100<br/> (63.1 to 68.6) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Not downgraded for study limitations. Although the majority of studies had unclear or high risk of bias in at least one of the key domains, the majority of the weight was from studies at low risk of bias in key domains.<br/> <sup>b</sup>Not downgraded for inconsistency. I<sup>2</sup> statistic was 56% for the main analysis, but this was partially explained by subgroup analysis.<br/> <sup>c</sup>Downgraded one level for publication bias: forest plot appeared to be asymmetrical.<br/> <sup>d</sup>Downgraded one level for imprecision: confidence interval included both possible benefit and harm.<br/> <sup>e</sup>Not downgraded for publication bias: funnel plot appears to be broadly symmetrical.<br/> <sup>f</sup>Not downgraded for inconsistency. I<sup>2</sup> statistic was 54% but the forest plot had good overlap in confidence intervals, so a fixed‐effect model was used to maintain the weight of the few larger studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Sotalol compared to placebo or no treatment for maintaining sinus rhythm after cardioversion of atrial fibrillation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/full#CD005049-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005049-tbl-0010"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Number of studies assessing each primary outcome</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n trials reporting (n participants)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n trials NOT reporting (n participants)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All‐cause mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 (17,586)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3<sup>a</sup> (393) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same as total mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Same as total mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (9139)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 (8840)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects (proarrhythmia and withdrawals due to adverse effects)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 (16,558)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3<sup>b</sup> (1421) </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>Out of 41 studies comparing an active drug with a control group receiving no antiarrhythmic (total 17,979 participants). </p> <p><sup>a</sup><a href="./references#CD005049-bbs2-0014" title="ChunKJ , ByeonK , ImSI , ParkKM , ParkSJ , KimJS , et al. Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion. Clinical Therapeutics2014;36(9):1169‐75. [DOI: 10.1016/j.clinthera.2014.07.013; PUBMED: 25134972] ">Chun 2014</a>; <a href="./references#CD005049-bbs2-0016" title="DAPHNE Study Investigators, CapucciA , BottoG , MolonG , SpampinatoA , FavaleS , et al. The Drug And Pace Health cliNical Evaluation (DAPHNE) study: a randomized trial comparing sotalol versus beta‐blockers to treat symptomatic atrial fibrillation in patients with brady‐tachycardia syndrome implanted with an antitachycardia pacemaker. American Heart Journal2008;156(2):373.e1‐8. [PUBMED: PMID: 18657671] ">DAPHNE 2008</a>; <a href="./references#CD005049-bbs2-0048" title="SantasE , DominguezE , Martinez‐BrotonsA , Ruiz‐GranellR , RuizV , FerreroA , et al. Early withdrawal of amiodarone after cardioversion in atrial fibrillation patients treated with irbesartan. A prospective randomized study. European Heart Journal2012;33 Suppl 1:380. [DOI: 10.1093/eurheartj/ehs282; PUBMED: 23805432] ">Santas 2012</a>. </p> <p><sup>b</sup><a href="./references#CD005049-bbs2-0004" title="The Atrial Fibrillation Investigation with Bidisomide (AFIB) Investigators. Treatment of atrial fibrillation and paroxysmal supraventricular tachycardia with bidisomide. Circulation1997;96(8):2625‐32. [MEDLINE: PMID: 9355903; ISSN 0009‐7322] ">AFIB 1997</a>; <a href="./references#CD005049-bbs2-0014" title="ChunKJ , ByeonK , ImSI , ParkKM , ParkSJ , KimJS , et al. Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion. Clinical Therapeutics2014;36(9):1169‐75. [DOI: 10.1016/j.clinthera.2014.07.013; PUBMED: 25134972] ">Chun 2014</a>; <a href="./references#CD005049-bbs2-0048" title="SantasE , DominguezE , Martinez‐BrotonsA , Ruiz‐GranellR , RuizV , FerreroA , et al. Early withdrawal of amiodarone after cardioversion in atrial fibrillation patients treated with irbesartan. A prospective randomized study. European Heart Journal2012;33 Suppl 1:380. [DOI: 10.1093/eurheartj/ehs282; PUBMED: 23805432] ">Santas 2012</a>. Others studies did not reported proarrhythmia but reported withdrawals (<a href="./references#CD005049-bbs2-0016" title="DAPHNE Study Investigators, CapucciA , BottoG , MolonG , SpampinatoA , FavaleS , et al. The Drug And Pace Health cliNical Evaluation (DAPHNE) study: a randomized trial comparing sotalol versus beta‐blockers to treat symptomatic atrial fibrillation in patients with brady‐tachycardia syndrome implanted with an antitachycardia pacemaker. American Heart Journal2008;156(2):373.e1‐8. [PUBMED: PMID: 18657671] ">DAPHNE 2008</a>; <a href="./references#CD005049-bbs2-0037" title="NiuF , HuangCX , JiangH , YangB , GuoWL , ChenYX , et al. Effects of amiodarone versus sotalol in treatment of atrial fibrillation: a random controlled clinical study. Zhonghua Yi Xue Za Zhi2006;86(2):121‐3. [PUBMED: PMID: 16620720] ">Niu 2006</a>; <a href="./references#CD005049-bbs2-0058" title="VillaniR , ZolettiF , VenianiM , LocatiF , NavaS . A comparison between amiodarone and disopyramide in a delayed‐release formulation in the prevention of recurrences of symptomatic atrial fibrillation [Confronto fra amiodarone e disopiramide in formulazione retard nella prevenzione delle recidive di fibrillazione atriale sintomatica]. La Clinica Terapeutica1992;140(1 Pt 2):35‐9. [MEDLINE: PMID: 1559321; ISSN: 0009‐9074] ">Villani 1992</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Number of studies assessing each primary outcome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/full#CD005049-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005049-tbl-0011"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Head‐to‐head trials: all‐cause mortality</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Drug 1 vs drug 2</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Drug 1</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Drug 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Disopyramide vs other class I drugs</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0034" title="LloydEA , GershBJ , FormanR . The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation. A double‐blind study comparing quinidine, disopyramide and placebo. South African Medical Journal1984;65(10):367‐9. [MEDLINE: PMID: 6367096; ISSN: 0038‐2469] ">Lloyd 1984</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.19 (0.01 to 3.86)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0042" title="CrijnsHJ , GosselinkAT , LieKI . Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double‐blind study. Cardiovascular Drugs and Therapy1996;10(2):145‐52. [MEDLINE: PMID: 8842506; ISSN: 0920‐3206] ">PRODIS 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.44 (0.10 to 57.37)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Quinidine vs other class I drugs</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0034" title="LloydEA , GershBJ , FormanR . The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation. A double‐blind study comparing quinidine, disopyramide and placebo. South African Medical Journal1984;65(10):367‐9. [MEDLINE: PMID: 6367096; ISSN: 0038‐2469] ">Lloyd 1984</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.17 (0.26 to 103.18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0045" title="RichiardiE , GaitaF , GrecoC , GaschinoG , Comba CostaG , RosettaniE , et al. Propafenone versus hydroquinidine in long‐term pharmacological prophylaxis of atrial fibrillation [Propafenone versus idrochinidina nella profilassi farmacologica a lungo termine della fibrillazione atriale]. Cardiologia1992;37(2):123‐7. [MEDLINE: PMID: 1600529; ISSN: 0393‐1978] ">Richiardi 1992</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.21 (0.01 to 4.28)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Quinidine vs sotalol</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0027" title="Juul‐MollerS , EdvardssonN , Rehnqvist‐AhlbergN . Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation1990;82(6):1932‐9. [MEDLINE: PMID: 2242519; ISSN: 0009‐7322] ">Juul‐Moller 1990</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 (0.07 to 18.15)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0028" title="KaluscheD , StockingerJ , BetzP , RoskammH . Sotalol and quinidine/verapamil (Cordichin) in chronic atrial fibrillation – conversion and 12‐month follow‐up – a randomized comparison [Sotalol und Chinidin/Verapamil (Cordichin) bei chronischem Vorhoflimmern – Konversion und 12‐Monats‐Follow‐up – ein randomisierter Vergleich]. Zeitschrift fur Kardiologie1994;83 Suppl 5:109‐16. [MEDLINE: PMID: 7846939; ISSN: 0300‐5860] ">Kalusche 1994</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.00 (0.13 to 71.56)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0039" title="FetschT , BauerP , EngberdingR , KochHP , LuklJ , MeinertzT , et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. European Heart Journal2004;25(16):1385‐94. [MEDLINE: PMID: 15302102; ISSN: 0195‐668X] FetschT , BurschelG , BreithardtG , EngberdingR , KochHP , LuklJ , et al. Medicamentous prevention after electric cardioversion of chronic atrial fibrillation. Goals and design of the PAFAC Study [Die medikamentöse Prophylaxe nach elektronischer Kardioversion von chronischem Vorhofflimmern. Ziele und Design der PAFAC‐Studie]. Zeitschrift fur Kardiologie1999;88(3):195‐207. [MEDLINE: PMID: 10355070; ISSN 0300‐5860] ">PAFAC 2004</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>377</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>383</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.70 (0.30 to 1.63)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0051" title="VelosoHH , dePaolaAA . Analysis of atrial fibrillation recurrence during therapy with sotalol or quinidine. Researchers of +SOCESP [Analise da recorrencia de fibrilacao atrial durante terapia com sotalol ou quinidina. Investigadores da SOCESP]. Arquivos Brasileiros de Cardiologia1998;70(1):43‐9. [MEDLINE: PMID: 9629687; ISSN: 0066‐782X] dePaolaAA , VelosoHH . Efficacy and safety of sotalol versus quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation. SOCESP Investigators. American Journal of Cardiology1999;84(9):1033‐7. [MEDLINE: PMID: 10569659; ISSN: 0002‐9149] ">SOCESP 1999</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.31 (0.01 to 7.40)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0053" title="PattenM , KochHP , SonntagF , LuderitzB , MeinertzT . Medicamentous prevention of symptomatic paroxysmal atrial fibrillation/flutter onset. Goals and design of the SOPAT study. Executive committee of the investigators representing trial physicians [Die medikamentose Anfallsprophylaxe bei symptomatischem paroxysmalem Vorhofflimmern/‐flattern. Ziele und Design der SOPAT‐Studie. Investigators in Vertretung der Prufarzte]. Zeitschrift fur Kardiologie1999;88(3):185‐94. [MEDLINE: PMID: 10355069; ISSN: 0300‐5860] PattenM , MaasR , BauerP , LuderitzB , SonntagF , DluzniewskiM , et al. Suppression of paroxysmal atrial tachyarrhythmias – results of the SOPAT trial. European Heart Journal2004;25(16):1395‐404. [MEDLINE: PMID: 15321697; ISSN: 0195‐668X] ">SOPAT 2004</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>518</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>264</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51 (0.07 to 3.60)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Flecainide vs propafenone</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0005" title="AliotE , DenjoyI , The Flecainide AF French Study Group. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out‐patients with symptomatic paroxysmal atrial fibrillation/flutter. American Journal of Cardiology1996;77(3):66A‐71A. [MEDLINE: PMID: 8607394; ISSN: 0002‐9149] ">Aliot 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.34 (0.01 to 8.15)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Amiodarone vs class I drugs</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0003" title="AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. Journal of the American College of Cardiology2003;42(1):20‐9. [MEDLINE: PMID: 12849654; ISSN: 0735‐1097] ">AFFIRM Substudy 2003</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>106</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>116</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.42 (0.21 to 0.83)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0040" title="PITAGORA Study Investigators, GuliziaM , MangiameliS , OraziS , ChiarandàG , PiccioneG , et al. A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the PITAGORA trial. American Heart Journal2008;155(1):107.e1. [PUBMED: PMID: 18082498] ">PITAGORA 2008</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.21 (0.67 to 15.40)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Amiodarone vs dronedarone</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0018" title="LeHeuzeyJY , DeFerrariGM , RadzikD , SantiniM , ZhuJ , DavyJM . A short‐term, randomized, double‐blind, parallel‐group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. Journal of Cardiovascular Electrophysiology2010;21(6):597‐605. [PUBMED: PMID: 20384650 ] ">DIONYSOS 2010</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>255</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>249</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.44 (0.48 to 12.47)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Amiodarone vs sotalol</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0003" title="AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. Journal of the American College of Cardiology2003;42(1):20‐9. [MEDLINE: PMID: 12849654; ISSN: 0735‐1097] ">AFFIRM Substudy 2003</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>131</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>125</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60 (0.33 to 1.08)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0040" title="PITAGORA Study Investigators, GuliziaM , MangiameliS , OraziS , ChiarandàG , PiccioneG , et al. A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the PITAGORA trial. American Heart Journal2008;155(1):107.e1. [PUBMED: PMID: 18082498] ">PITAGORA 2008</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.86 (0.34 to 100.89)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0046" title="SinghBN , SinghSN , RedaDJ , TangXC , LopezB , HarrisCL , et al. Amiodarone versus sotalol for atrial fibrillation. New England Journal of Medicine2005;352(18):1861‐72. [MEDLINE: PMID: 15872201; ISSN: 0028‐4793] SinghSN , SinghBN , RedaDJ , FyeCL , EzekowitzMD , FletcherRD , et al. Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol‐Amiodarone Fibrillation Efficacy Trial [Safe‐T]). American Journal of Cardiology2003;92(4):468‐72. [MEDLINE: PMID: 12914883; ISSN 0002‐9149] ">SAFE‐T 2005</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>267</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>261</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.41 to 1.75)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Sotalol vs class I drugs other than quinidine</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0003" title="AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. Journal of the American College of Cardiology2003;42(1):20‐9. [MEDLINE: PMID: 12849654; ISSN: 0735‐1097] ">AFFIRM Substudy 2003</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.43 to 1.60)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0044" title="ReimoldSC , CantillonCO , FriedmanPL , AntmanEM . Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. American Journal of Cardiology1993;71(7):558‐63. [MEDLINE: PMID: 8438741; ISSN: 0002‐9149] ">Reimold 1993</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.00 (0.25 to 101.58)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Sotalol vs dofetilide</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0020" title="CambellTJ , GreenbaumRA , ChannerKS , DalrympleHW , KingmaJH , SantiniM , et al. Mortality in patients with atrial fibrillation – 1 year follow up of EMERALD (European and Australian multicenter evaluative research on atrial fibrillation dofetilide). Journal of the American College of Cardiology2000;35(2 Suppl A):154A‐5A. DalrympleHW , CambellTJ , ChannerKS , GreenbaumR , KingmaJH , SantiniM , et al. Maintenance of sinus rhythm by dofetilide improves quality of life. The EMERALD (European and Australian multicenter evaluative research on atrial fibrillation dofetilide) study. Circulation1998;98(Suppl 13‐14):66. GreenbaumR , CampbellTJ , ChannerKS , DalrympleHW , KingmaJH , SantiniM , et al. Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide. The EMERALD (European and Australian multicenter evaluative research on atrial fibrillation dofetilide) study. Circulation1998;98(Suppl I‐633):3326. USFood , DrugAdministration . Drug Approval Package: Tikosyn (Dofetilide). Medical Review: Parts 1 and 2 (Study number 345). www.accessdata.fda.gov/drugsatfda_docs/nda/99/20‐931_Tikosyn.cfm (accessed 10 August 2010). ">EMERALD 2000</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 (0.04 to 23.99)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>CI: confidence interval; RR: risk ratio.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Head‐to‐head trials: all‐cause mortality</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/full#CD005049-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005049-tbl-0012"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Head‐to‐head trials: withdrawals due to adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Drug 1 vs drug 2</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Drug 1</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Drug 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Disopyramide vs other class I drugs</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0034" title="LloydEA , GershBJ , FormanR . The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation. A double‐blind study comparing quinidine, disopyramide and placebo. South African Medical Journal1984;65(10):367‐9. [MEDLINE: PMID: 6367096; ISSN: 0038‐2469] ">Lloyd 1984</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.48 (0.10 to 2.43)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0042" title="CrijnsHJ , GosselinkAT , LieKI . Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double‐blind study. Cardiovascular Drugs and Therapy1996;10(2):145‐52. [MEDLINE: PMID: 8842506; ISSN: 0920‐3206] ">PRODIS 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40 (0.14 to 1.19)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Quinidine vs flecainide</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0035" title="NaccarelliGV , DorianP , HohnloserSH , CoumelP . Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. American Journal of Cardiology1996;77(3):53A‐9A. [MEDLINE: PMID: 8607392; ISSN: 0002‐9149] ">Naccarelli 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>117</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>122</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.66 (1.04 to 2.65)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0054" title="SteinbeckG , DoliwaR , BachP . Therapy of paroxysmal atrial fibrillation. Cardiac glycosides alone or combined with anti‐arrhythmia agents? [Therapie des paroxysmalen Vorhofflimmerns. Herzglykoside allein oder in Kombination mit Antiarrhythmika?]. Deutsche Medizinische Wochenschrift1988;113(48):1867‐71. [MEDLINE: PMID: 3143539; ISSN: 0012‐0472] ">Steinbeck 1988</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.00 (0.26 to 96.13)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Quinidine vs other class I drugs</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0034" title="LloydEA , GershBJ , FormanR . The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation. A double‐blind study comparing quinidine, disopyramide and placebo. South African Medical Journal1984;65(10):367‐9. [MEDLINE: PMID: 6367096; ISSN: 0038‐2469] ">Lloyd 1984</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.07 (0.41 to 10.43)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0035" title="NaccarelliGV , DorianP , HohnloserSH , CoumelP . Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. American Journal of Cardiology1996;77(3):53A‐9A. [MEDLINE: PMID: 8607392; ISSN: 0002‐9149] ">Naccarelli 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>117</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>122</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.66 (1.04 to 2.65)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0045" title="RichiardiE , GaitaF , GrecoC , GaschinoG , Comba CostaG , RosettaniE , et al. Propafenone versus hydroquinidine in long‐term pharmacological prophylaxis of atrial fibrillation [Propafenone versus idrochinidina nella profilassi farmacologica a lungo termine della fibrillazione atriale]. Cardiologia1992;37(2):123‐7. [MEDLINE: PMID: 1600529; ISSN: 0393‐1978] ">Richiardi 1992</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.39 (1.20 to 4.77)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0054" title="SteinbeckG , DoliwaR , BachP . Therapy of paroxysmal atrial fibrillation. Cardiac glycosides alone or combined with anti‐arrhythmia agents? [Therapie des paroxysmalen Vorhofflimmerns. Herzglykoside allein oder in Kombination mit Antiarrhythmika?]. Deutsche Medizinische Wochenschrift1988;113(48):1867‐71. [MEDLINE: PMID: 3143539; ISSN: 0012‐0472] ">Steinbeck 1988</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.00 (0.26 to 96.13)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Quinidine vs sotalol</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0026" title="HohnloserSH , van deLooA , BaedekerF . Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. Journal of the American College of Cardiology1995;26(4):852‐8. [MEDLINE: PMID: 7560608; ISSN: 0735‐1097] ">Hohnloser 1995</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.00 (1.38 to 72.39)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0027" title="Juul‐MollerS , EdvardssonN , Rehnqvist‐AhlbergN . Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation1990;82(6):1932‐9. [MEDLINE: PMID: 2242519; ISSN: 0009‐7322] ">Juul‐Moller 1990</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.31 (1.19 to 4.47)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0028" title="KaluscheD , StockingerJ , BetzP , RoskammH . Sotalol and quinidine/verapamil (Cordichin) in chronic atrial fibrillation – conversion and 12‐month follow‐up – a randomized comparison [Sotalol und Chinidin/Verapamil (Cordichin) bei chronischem Vorhoflimmern – Konversion und 12‐Monats‐Follow‐up – ein randomisierter Vergleich]. Zeitschrift fur Kardiologie1994;83 Suppl 5:109‐16. [MEDLINE: PMID: 7846939; ISSN: 0300‐5860] ">Kalusche 1994</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.33 (0.65 to 8.40)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0039" title="FetschT , BauerP , EngberdingR , KochHP , LuklJ , MeinertzT , et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. European Heart Journal2004;25(16):1385‐94. [MEDLINE: PMID: 15302102; ISSN: 0195‐668X] FetschT , BurschelG , BreithardtG , EngberdingR , KochHP , LuklJ , et al. Medicamentous prevention after electric cardioversion of chronic atrial fibrillation. Goals and design of the PAFAC Study [Die medikamentöse Prophylaxe nach elektronischer Kardioversion von chronischem Vorhofflimmern. Ziele und Design der PAFAC‐Studie]. Zeitschrift fur Kardiologie1999;88(3):195‐207. [MEDLINE: PMID: 10355070; ISSN 0300‐5860] ">PAFAC 2004</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>377</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>383</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.78 to 1.27)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0051" title="VelosoHH , dePaolaAA . Analysis of atrial fibrillation recurrence during therapy with sotalol or quinidine. Researchers of +SOCESP [Analise da recorrencia de fibrilacao atrial durante terapia com sotalol ou quinidina. Investigadores da SOCESP]. Arquivos Brasileiros de Cardiologia1998;70(1):43‐9. [MEDLINE: PMID: 9629687; ISSN: 0066‐782X] dePaolaAA , VelosoHH . Efficacy and safety of sotalol versus quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation. SOCESP Investigators. American Journal of Cardiology1999;84(9):1033‐7. [MEDLINE: PMID: 10569659; ISSN: 0002‐9149] ">SOCESP 1999</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.32 (0.54 to 3.23)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0053" title="PattenM , KochHP , SonntagF , LuderitzB , MeinertzT . Medicamentous prevention of symptomatic paroxysmal atrial fibrillation/flutter onset. Goals and design of the SOPAT study. Executive committee of the investigators representing trial physicians [Die medikamentose Anfallsprophylaxe bei symptomatischem paroxysmalem Vorhofflimmern/‐flattern. Ziele und Design der SOPAT‐Studie. Investigators in Vertretung der Prufarzte]. Zeitschrift fur Kardiologie1999;88(3):185‐94. [MEDLINE: PMID: 10355069; ISSN: 0300‐5860] PattenM , MaasR , BauerP , LuderitzB , SonntagF , DluzniewskiM , et al. Suppression of paroxysmal atrial tachyarrhythmias – results of the SOPAT trial. European Heart Journal2004;25(16):1395‐404. [MEDLINE: PMID: 15321697; ISSN: 0195‐668X] ">SOPAT 2004</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>518</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>264</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84 (0.62 to 1.14)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Flecainide vs propafenone</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0005" title="AliotE , DenjoyI , The Flecainide AF French Study Group. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out‐patients with symptomatic paroxysmal atrial fibrillation/flutter. American Journal of Cardiology1996;77(3):66A‐71A. [MEDLINE: PMID: 8607394; ISSN: 0002‐9149] ">Aliot 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.23 (0.05 to 1.00)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0022" title="ChimientiM , CullenMTJr , CasadeiG . Safety of flecainide versus propafenone for the long‐term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. European Heart Journal1995;16(12):1943‐51. [MEDLINE: PMID: 8682031; ISSN: 0195‐668X] ChimientiM , CullenMTJr , CasadeiG . Safety of long‐term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators. American Journal of Cardiology1996;77(3):60A‐75A. [MEDLINE: PMID: 8607393; ISSN: 0002‐9149] ">FAPIS 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18 (0.50 to 2.78)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Amiodarone vs class I drugs</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0003" title="AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. Journal of the American College of Cardiology2003;42(1):20‐9. [MEDLINE: PMID: 12849654; ISSN: 0735‐1097] ">AFFIRM Substudy 2003</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>154</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.33 (0.21 to 0.53)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0031" title="KochiadakisGE , IgoumenidisNE , HamilosMI , TzerakisPG , KlapsinosNC , ZacharisEA , et al. Long‐term maintenance of normal sinus rhythm in patients with current symptomatic atrial fibrillation: amiodarone vs propafenone, both in low doses. Chest2004;125(2):377‐83. [MEDLINE: PMID: 14769712; ISSN: 0012‐3692] ">Kochiadakis 2004a</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.74 (2.09 to 36.46)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0040" title="PITAGORA Study Investigators, GuliziaM , MangiameliS , OraziS , ChiarandàG , PiccioneG , et al. A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the PITAGORA trial. American Heart Journal2008;155(1):107.e1. [PUBMED: PMID: 18082498] ">PITAGORA 2008</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11 (0.23 to 5.40)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0058" title="VillaniR , ZolettiF , VenianiM , LocatiF , NavaS . A comparison between amiodarone and disopyramide in a delayed‐release formulation in the prevention of recurrences of symptomatic atrial fibrillation [Confronto fra amiodarone e disopiramide in formulazione retard nella prevenzione delle recidive di fibrillazione atriale sintomatica]. La Clinica Terapeutica1992;140(1 Pt 2):35‐9. [MEDLINE: PMID: 1559321; ISSN: 0009‐9074] ">Villani 1992</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.35 (0.10 to 1.18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0059" title="VitoloE , TronciM , LarovereMT , RumoloR , MorabitoA . Amiodarone versus quinidine in the prophylaxis of atrial fibrillation. Acta Cardiologica1981;36(6):431‐44. [MEDLINE: PMID: 7039195; ISSN: 0001‐5385] ">Vitolo 1981</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.06 to 14.09)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Amiodarone vs dronedarone</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0018" title="LeHeuzeyJY , DeFerrariGM , RadzikD , SantiniM , ZhuJ , DavyJM . A short‐term, randomized, double‐blind, parallel‐group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. Journal of Cardiovascular Electrophysiology2010;21(6):597‐605. [PUBMED: PMID: 20384650 ] ">DIONYSOS 2010</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>255</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>249</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.37 (0.90 to 2.09)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Amiodarone vs sotalol</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0003" title="AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. Journal of the American College of Cardiology2003;42(1):20‐9. [MEDLINE: PMID: 12849654; ISSN: 0735‐1097] ">AFFIRM Substudy 2003</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>154</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.47 to 1.47)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0030" title="KochiadakisGE , IgoumenidisNE , MarketouME , KaleboubasMD , SimantirakisEN , VardasPE . Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. Heart2000;84(3):251‐7. [MEDLINE: PMID: 10956284; ISSN 1355‐6037] KochiadakisGE , IgoumenidisNE , MarketouME , SolomouMC , KanoupakisEM , VardasPE . Low‐dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. American Journal of Cardiology1998;81(8):995‐8. [MEDLINE: PMID: 9576159; ISSN: 0002‐9149] KochiadakisGE , MarketouME , IgoumenidisNE , ChrysostomakisSI , MavrakisHE , KaleboubasMD , et al. Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm?. Pacing and Clinical Electrophysiology2000;23(11 Pt 2):1883‐7. [MEDLINE: PMID: 11139949; ISSN 0147‐8389] ">Kochiadakis 2000</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.44 (1.01 to 11.75)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0037" title="NiuF , HuangCX , JiangH , YangB , GuoWL , ChenYX , et al. Effects of amiodarone versus sotalol in treatment of atrial fibrillation: a random controlled clinical study. Zhonghua Yi Xue Za Zhi2006;86(2):121‐3. [PUBMED: PMID: 16620720] ">Niu 2006</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 (0.24 to 2.10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0040" title="PITAGORA Study Investigators, GuliziaM , MangiameliS , OraziS , ChiarandàG , PiccioneG , et al. A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the PITAGORA trial. American Heart Journal2008;155(1):107.e1. [PUBMED: PMID: 18082498] ">PITAGORA 2008</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.86 (0.34 to 100.89)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0057" title="VijayalakshmiK , WhittakerVJ , SuttonA , CampbellP , WrightRA , HallJA , et al. A randomized trial of prophylactic antiarrhythmic agents (amiodarone and sotalol) in patients with atrial fibrillation for whom direct current cardioversion is planned. American Heart Journal2006;151(4):863.e1‐6. [PUBMED: 16569550] ">Vijayalakshmi 2006</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.38 (0.04 to 3.14)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Sotalol vs class I drugs other than quinidine</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0003" title="AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. Journal of the American College of Cardiology2003;42(1):20‐9. [MEDLINE: PMID: 12849654; ISSN: 0735‐1097] ">AFFIRM Substudy 2003</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40 (0.25 to 0.63)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0032" title="KochiadakisGE , IgoumenidisNE , HamilosME , TzerakisPG , KlapsinosNC , ChlouverakisGI , et al. Sotalol versus propafenone for long‐term maintenance of normal sinus rhythm in patients with recurrent symptomatic atrial fibrillation. American Journal of Cardiology2004;94(12):1563‐6. [MEDLINE: PMID: 15589019; ISSN: 0002‐9149] ">Kochiadakis 2004b</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.30 to 3.37)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0044" title="ReimoldSC , CantillonCO , FriedmanPL , AntmanEM . Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. American Journal of Cardiology1993;71(7):558‐63. [MEDLINE: PMID: 8438741; ISSN: 0002‐9149] ">Reimold 1993</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.50 (0.45 to 4.99)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Sotalol vs dofetilide</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0020" title="CambellTJ , GreenbaumRA , ChannerKS , DalrympleHW , KingmaJH , SantiniM , et al. Mortality in patients with atrial fibrillation – 1 year follow up of EMERALD (European and Australian multicenter evaluative research on atrial fibrillation dofetilide). Journal of the American College of Cardiology2000;35(2 Suppl A):154A‐5A. DalrympleHW , CambellTJ , ChannerKS , GreenbaumR , KingmaJH , SantiniM , et al. Maintenance of sinus rhythm by dofetilide improves quality of life. The EMERALD (European and Australian multicenter evaluative research on atrial fibrillation dofetilide) study. Circulation1998;98(Suppl 13‐14):66. GreenbaumR , CampbellTJ , ChannerKS , DalrympleHW , KingmaJH , SantiniM , et al. Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide. The EMERALD (European and Australian multicenter evaluative research on atrial fibrillation dofetilide) study. Circulation1998;98(Suppl I‐633):3326. USFood , DrugAdministration . Drug Approval Package: Tikosyn (Dofetilide). Medical Review: Parts 1 and 2 (Study number 345). www.accessdata.fda.gov/drugsatfda_docs/nda/99/20‐931_Tikosyn.cfm (accessed 10 August 2010). ">EMERALD 2000</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>321</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.16 (1.18 to 3.96)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Sotalol vs other beta‐blockers</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0016" title="DAPHNE Study Investigators, CapucciA , BottoG , MolonG , SpampinatoA , FavaleS , et al. The Drug And Pace Health cliNical Evaluation (DAPHNE) study: a randomized trial comparing sotalol versus beta‐blockers to treat symptomatic atrial fibrillation in patients with brady‐tachycardia syndrome implanted with an antitachycardia pacemaker. American Heart Journal2008;156(2):373.e1‐8. [PUBMED: PMID: 18657671] ">DAPHNE 2008</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.26 (1.21 to 22.84)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0041" title="PlewanA , LehmannG , NdrepepaG , SchreieckJ , AltEU , SchomigA , et al. Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol. European Heart Journal2001;22(16):1504‐10. [MEDLINE: PMID: 11482924; ISSN: 0195‐668X] ">Plewan 2001</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.33 (0.31 to 5.72)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>CI: confidence interval; RR: risk ratio.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Head‐to‐head trials: withdrawals due to adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/full#CD005049-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005049-tbl-0013"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Head‐to‐head trials: proarrhythmia</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Drug 1 vs drug 2</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Drug 1</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Drug 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Disopyramide vs other class I drugs</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0034" title="LloydEA , GershBJ , FormanR . The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation. A double‐blind study comparing quinidine, disopyramide and placebo. South African Medical Journal1984;65(10):367‐9. [MEDLINE: PMID: 6367096; ISSN: 0038‐2469] ">Lloyd 1984</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.32 (0.01 to 7.59)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0042" title="CrijnsHJ , GosselinkAT , LieKI . Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double‐blind study. Cardiovascular Drugs and Therapy1996;10(2):145‐52. [MEDLINE: PMID: 8842506; ISSN: 0920‐3206] ">PRODIS 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (0.05 to 12.26)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Quinidine vs flecainide</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0035" title="NaccarelliGV , DorianP , HohnloserSH , CoumelP . Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. American Journal of Cardiology1996;77(3):53A‐9A. [MEDLINE: PMID: 8607392; ISSN: 0002‐9149] ">Naccarelli 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>117</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>122</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.49 (0.59 to 3.78)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0054" title="SteinbeckG , DoliwaR , BachP . Therapy of paroxysmal atrial fibrillation. Cardiac glycosides alone or combined with anti‐arrhythmia agents? [Therapie des paroxysmalen Vorhofflimmerns. Herzglykoside allein oder in Kombination mit Antiarrhythmika?]. Deutsche Medizinische Wochenschrift1988;113(48):1867‐71. [MEDLINE: PMID: 3143539; ISSN: 0012‐0472] ">Steinbeck 1988</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.00 (0.20 to 19.78)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Quinidine vs other class I drugs</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0034" title="LloydEA , GershBJ , FormanR . The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation. A double‐blind study comparing quinidine, disopyramide and placebo. South African Medical Journal1984;65(10):367‐9. [MEDLINE: PMID: 6367096; ISSN: 0038‐2469] ">Lloyd 1984</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.10 (0.13 to 73.12)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0035" title="NaccarelliGV , DorianP , HohnloserSH , CoumelP . Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. American Journal of Cardiology1996;77(3):53A‐9A. [MEDLINE: PMID: 8607392; ISSN: 0002‐9149] ">Naccarelli 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>117</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>122</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.49 (0.59 to 3.78)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0045" title="RichiardiE , GaitaF , GrecoC , GaschinoG , Comba CostaG , RosettaniE , et al. Propafenone versus hydroquinidine in long‐term pharmacological prophylaxis of atrial fibrillation [Propafenone versus idrochinidina nella profilassi farmacologica a lungo termine della fibrillazione atriale]. Cardiologia1992;37(2):123‐7. [MEDLINE: PMID: 1600529; ISSN: 0393‐1978] ">Richiardi 1992</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.15 to 7.24)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0054" title="SteinbeckG , DoliwaR , BachP . Therapy of paroxysmal atrial fibrillation. Cardiac glycosides alone or combined with anti‐arrhythmia agents? [Therapie des paroxysmalen Vorhofflimmerns. Herzglykoside allein oder in Kombination mit Antiarrhythmika?]. Deutsche Medizinische Wochenschrift1988;113(48):1867‐71. [MEDLINE: PMID: 3143539; ISSN: 0012‐0472] ">Steinbeck 1988</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.00 (0.20 to 19.78)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Quinidine vs sotalol</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0026" title="HohnloserSH , van deLooA , BaedekerF . Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. Journal of the American College of Cardiology1995;26(4):852‐8. [MEDLINE: PMID: 7560608; ISSN: 0735‐1097] ">Hohnloser 1995</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.00 (0.33 to 26.92)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0027" title="Juul‐MollerS , EdvardssonN , Rehnqvist‐AhlbergN . Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation1990;82(6):1932‐9. [MEDLINE: PMID: 2242519; ISSN: 0009‐7322] ">Juul‐Moller 1990</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 (0.07 to 18.15)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0028" title="KaluscheD , StockingerJ , BetzP , RoskammH . Sotalol and quinidine/verapamil (Cordichin) in chronic atrial fibrillation – conversion and 12‐month follow‐up – a randomized comparison [Sotalol und Chinidin/Verapamil (Cordichin) bei chronischem Vorhoflimmern – Konversion und 12‐Monats‐Follow‐up – ein randomisierter Vergleich]. Zeitschrift fur Kardiologie1994;83 Suppl 5:109‐16. [MEDLINE: PMID: 7846939; ISSN: 0300‐5860] ">Kalusche 1994</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.50 (0.05 to 5.30)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0039" title="FetschT , BauerP , EngberdingR , KochHP , LuklJ , MeinertzT , et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. European Heart Journal2004;25(16):1385‐94. [MEDLINE: PMID: 15302102; ISSN: 0195‐668X] FetschT , BurschelG , BreithardtG , EngberdingR , KochHP , LuklJ , et al. Medicamentous prevention after electric cardioversion of chronic atrial fibrillation. Goals and design of the PAFAC Study [Die medikamentöse Prophylaxe nach elektronischer Kardioversion von chronischem Vorhofflimmern. Ziele und Design der PAFAC‐Studie]. Zeitschrift fur Kardiologie1999;88(3):195‐207. [MEDLINE: PMID: 10355070; ISSN 0300‐5860] ">PAFAC 2004</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>377</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>383</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86 (0.46 to 1.62)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0051" title="VelosoHH , dePaolaAA . Analysis of atrial fibrillation recurrence during therapy with sotalol or quinidine. Researchers of +SOCESP [Analise da recorrencia de fibrilacao atrial durante terapia com sotalol ou quinidina. Investigadores da SOCESP]. Arquivos Brasileiros de Cardiologia1998;70(1):43‐9. [MEDLINE: PMID: 9629687; ISSN: 0066‐782X] dePaolaAA , VelosoHH . Efficacy and safety of sotalol versus quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation. SOCESP Investigators. American Journal of Cardiology1999;84(9):1033‐7. [MEDLINE: PMID: 10569659; ISSN: 0002‐9149] ">SOCESP 1999</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61 (0.11 to 3.54)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0053" title="PattenM , KochHP , SonntagF , LuderitzB , MeinertzT . Medicamentous prevention of symptomatic paroxysmal atrial fibrillation/flutter onset. Goals and design of the SOPAT study. Executive committee of the investigators representing trial physicians [Die medikamentose Anfallsprophylaxe bei symptomatischem paroxysmalem Vorhofflimmern/‐flattern. Ziele und Design der SOPAT‐Studie. Investigators in Vertretung der Prufarzte]. Zeitschrift fur Kardiologie1999;88(3):185‐94. [MEDLINE: PMID: 10355069; ISSN: 0300‐5860] PattenM , MaasR , BauerP , LuderitzB , SonntagF , DluzniewskiM , et al. Suppression of paroxysmal atrial tachyarrhythmias – results of the SOPAT trial. European Heart Journal2004;25(16):1395‐404. [MEDLINE: PMID: 15321697; ISSN: 0195‐668X] ">SOPAT 2004</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>518</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>264</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.04 (0.44 to 9.53)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Flecainide vs propafenone</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0005" title="AliotE , DenjoyI , The Flecainide AF French Study Group. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out‐patients with symptomatic paroxysmal atrial fibrillation/flutter. American Journal of Cardiology1996;77(3):66A‐71A. [MEDLINE: PMID: 8607394; ISSN: 0002‐9149] ">Aliot 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.11 (0.01 to 2.05)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0022" title="ChimientiM , CullenMTJr , CasadeiG . Safety of flecainide versus propafenone for the long‐term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. European Heart Journal1995;16(12):1943‐51. [MEDLINE: PMID: 8682031; ISSN: 0195‐668X] ChimientiM , CullenMTJr , CasadeiG . Safety of long‐term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators. American Journal of Cardiology1996;77(3):60A‐75A. [MEDLINE: PMID: 8607393; ISSN: 0002‐9149] ">FAPIS 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.12 (0.20 to 23.05)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Amiodarone vs class I drugs</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0003" title="AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. Journal of the American College of Cardiology2003;42(1):20‐9. [MEDLINE: PMID: 12849654; ISSN: 0735‐1097] ">AFFIRM Substudy 2003</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>154</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.20 (0.08 to 0.51)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0031" title="KochiadakisGE , IgoumenidisNE , HamilosMI , TzerakisPG , KlapsinosNC , ZacharisEA , et al. Long‐term maintenance of normal sinus rhythm in patients with current symptomatic atrial fibrillation: amiodarone vs propafenone, both in low doses. Chest2004;125(2):377‐83. [MEDLINE: PMID: 14769712; ISSN: 0012‐3692] ">Kochiadakis 2004a</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03 (0.15 to 7.10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0059" title="VitoloE , TronciM , LarovereMT , RumoloR , MorabitoA . Amiodarone versus quinidine in the prophylaxis of atrial fibrillation. Acta Cardiologica1981;36(6):431‐44. [MEDLINE: PMID: 7039195; ISSN: 0001‐5385] ">Vitolo 1981</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 (0.06 to 14.09)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Amiodarone vs dronedarone</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0018" title="LeHeuzeyJY , DeFerrariGM , RadzikD , SantiniM , ZhuJ , DavyJM . A short‐term, randomized, double‐blind, parallel‐group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. Journal of Cardiovascular Electrophysiology2010;21(6):597‐605. [PUBMED: PMID: 20384650 ] ">DIONYSOS 2010</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>255</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>249</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.95 (0.36 to 10.57)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Amiodarone vs sotalol</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0003" title="AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. Journal of the American College of Cardiology2003;42(1):20‐9. [MEDLINE: PMID: 12849654; ISSN: 0735‐1097] ">AFFIRM Substudy 2003</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>154</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49 (0.17 to 1.42)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0030" title="KochiadakisGE , IgoumenidisNE , MarketouME , KaleboubasMD , SimantirakisEN , VardasPE . Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. Heart2000;84(3):251‐7. [MEDLINE: PMID: 10956284; ISSN 1355‐6037] KochiadakisGE , IgoumenidisNE , MarketouME , SolomouMC , KanoupakisEM , VardasPE . Low‐dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. American Journal of Cardiology1998;81(8):995‐8. [MEDLINE: PMID: 9576159; ISSN: 0002‐9149] KochiadakisGE , MarketouME , IgoumenidisNE , ChrysostomakisSI , MavrakisHE , KaleboubasMD , et al. Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm?. Pacing and Clinical Electrophysiology2000;23(11 Pt 2):1883‐7. [MEDLINE: PMID: 11139949; ISSN 0147‐8389] ">Kochiadakis 2000</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.14 to 6.46)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0046" title="SinghBN , SinghSN , RedaDJ , TangXC , LopezB , HarrisCL , et al. Amiodarone versus sotalol for atrial fibrillation. New England Journal of Medicine2005;352(18):1861‐72. [MEDLINE: PMID: 15872201; ISSN: 0028‐4793] SinghSN , SinghBN , RedaDJ , FyeCL , EzekowitzMD , FletcherRD , et al. Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol‐Amiodarone Fibrillation Efficacy Trial [Safe‐T]). American Journal of Cardiology2003;92(4):468‐72. [MEDLINE: PMID: 12914883; ISSN 0002‐9149] ">SAFE‐T 2005</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>267</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>261</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65 (0.24 to 1.81)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Sotalol vs class I drugs other than quinidine</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0003" title="AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. Journal of the American College of Cardiology2003;42(1):20‐9. [MEDLINE: PMID: 12849654; ISSN: 0735‐1097] ">AFFIRM Substudy 2003</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40 (0.19 to 0.85)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0012" title="CarunchioA , FeraMS , MazzaA , BurattiniM , GrecoG , GalatiA , et al. A comparison between flecainide and sotalol in the prevention of recurrences of paroxysmal atrial fibrillation [Confronto tra flecainide e sotalolo nella profilassi delle recidive di fibrillazione atriale parossistica]. Giornale Italiano di Cardiologia1995;25(1):51‐68. [MEDLINE: PMID: 7642012; ISSN 0046‐5968] ">Carunchio 1995</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.67 (0.46 to 6.06)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0032" title="KochiadakisGE , IgoumenidisNE , HamilosME , TzerakisPG , KlapsinosNC , ChlouverakisGI , et al. Sotalol versus propafenone for long‐term maintenance of normal sinus rhythm in patients with recurrent symptomatic atrial fibrillation. American Journal of Cardiology2004;94(12):1563‐6. [MEDLINE: PMID: 15589019; ISSN: 0002‐9149] ">Kochiadakis 2004b</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.52 (0.26 to 8.86)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0044" title="ReimoldSC , CantillonCO , FriedmanPL , AntmanEM . Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. American Journal of Cardiology1993;71(7):558‐63. [MEDLINE: PMID: 8438741; ISSN: 0002‐9149] ">Reimold 1993</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.50 (0.58 to 3.90)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Sotalol vs dofetilide</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0020" title="CambellTJ , GreenbaumRA , ChannerKS , DalrympleHW , KingmaJH , SantiniM , et al. Mortality in patients with atrial fibrillation – 1 year follow up of EMERALD (European and Australian multicenter evaluative research on atrial fibrillation dofetilide). Journal of the American College of Cardiology2000;35(2 Suppl A):154A‐5A. DalrympleHW , CambellTJ , ChannerKS , GreenbaumR , KingmaJH , SantiniM , et al. Maintenance of sinus rhythm by dofetilide improves quality of life. The EMERALD (European and Australian multicenter evaluative research on atrial fibrillation dofetilide) study. Circulation1998;98(Suppl 13‐14):66. GreenbaumR , CampbellTJ , ChannerKS , DalrympleHW , KingmaJH , SantiniM , et al. Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide. The EMERALD (European and Australian multicenter evaluative research on atrial fibrillation dofetilide) study. Circulation1998;98(Suppl I‐633):3326. USFood , DrugAdministration . Drug Approval Package: Tikosyn (Dofetilide). Medical Review: Parts 1 and 2 (Study number 345). www.accessdata.fda.gov/drugsatfda_docs/nda/99/20‐931_Tikosyn.cfm (accessed 10 August 2010). ">EMERALD 2000</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>321</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.18 to 4.03)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Sotalol vs other beta‐blockers</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0041" title="PlewanA , LehmannG , NdrepepaG , SchreieckJ , AltEU , SchomigA , et al. Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol. European Heart Journal2001;22(16):1504‐10. [MEDLINE: PMID: 11482924; ISSN: 0195‐668X] ">Plewan 2001</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.33 (0.31 to 5.72)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>CI: confidence interval; RR: risk ratio.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Head‐to‐head trials: proarrhythmia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/full#CD005049-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005049-tbl-0014"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Head‐to‐head trials: recurrence of atrial fibrillation</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Drug 1 vs drug 2</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Drug 1</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Drug 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Disopyramide vs other class I drugs</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0034" title="LloydEA , GershBJ , FormanR . The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation. A double‐blind study comparing quinidine, disopyramide and placebo. South African Medical Journal1984;65(10):367‐9. [MEDLINE: PMID: 6367096; ISSN: 0038‐2469] ">Lloyd 1984</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.61 to 1.53)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0042" title="CrijnsHJ , GosselinkAT , LieKI . Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double‐blind study. Cardiovascular Drugs and Therapy1996;10(2):145‐52. [MEDLINE: PMID: 8842506; ISSN: 0920‐3206] ">PRODIS 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.73 (0.37 to 1.44)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Quinidine vs flecainide</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0035" title="NaccarelliGV , DorianP , HohnloserSH , CoumelP . Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. American Journal of Cardiology1996;77(3):53A‐9A. [MEDLINE: PMID: 8607392; ISSN: 0002‐9149] ">Naccarelli 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>117</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.91 to 1.19)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0054" title="SteinbeckG , DoliwaR , BachP . Therapy of paroxysmal atrial fibrillation. Cardiac glycosides alone or combined with anti‐arrhythmia agents? [Therapie des paroxysmalen Vorhofflimmerns. Herzglykoside allein oder in Kombination mit Antiarrhythmika?]. Deutsche Medizinische Wochenschrift1988;113(48):1867‐71. [MEDLINE: PMID: 3143539; ISSN: 0012‐0472] ">Steinbeck 1988</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.67 (0.81 to 3.41)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Quinidine vs other class I drugs</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0034" title="LloydEA , GershBJ , FormanR . The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation. A double‐blind study comparing quinidine, disopyramide and placebo. South African Medical Journal1984;65(10):367‐9. [MEDLINE: PMID: 6367096; ISSN: 0038‐2469] ">Lloyd 1984</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.65 to 1.64)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0035" title="NaccarelliGV , DorianP , HohnloserSH , CoumelP . Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. American Journal of Cardiology1996;77(3):53A‐9A. [MEDLINE: PMID: 8607392; ISSN: 0002‐9149] ">Naccarelli 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>117</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 (0.91 to 1.19)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0045" title="RichiardiE , GaitaF , GrecoC , GaschinoG , Comba CostaG , RosettaniE , et al. Propafenone versus hydroquinidine in long‐term pharmacological prophylaxis of atrial fibrillation [Propafenone versus idrochinidina nella profilassi farmacologica a lungo termine della fibrillazione atriale]. Cardiologia1992;37(2):123‐7. [MEDLINE: PMID: 1600529; ISSN: 0393‐1978] ">Richiardi 1992</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.87 to 1.44)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0054" title="SteinbeckG , DoliwaR , BachP . Therapy of paroxysmal atrial fibrillation. Cardiac glycosides alone or combined with anti‐arrhythmia agents? [Therapie des paroxysmalen Vorhofflimmerns. Herzglykoside allein oder in Kombination mit Antiarrhythmika?]. Deutsche Medizinische Wochenschrift1988;113(48):1867‐71. [MEDLINE: PMID: 3143539; ISSN: 0012‐0472] ">Steinbeck 1988</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.67 (0.81 to 3.41)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Quinidine vs sotalol</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0026" title="HohnloserSH , van deLooA , BaedekerF . Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. Journal of the American College of Cardiology1995;26(4):852‐8. [MEDLINE: PMID: 7560608; ISSN: 0735‐1097] ">Hohnloser 1995</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58 (0.28 to 1.23)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0027" title="Juul‐MollerS , EdvardssonN , Rehnqvist‐AhlbergN . Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation1990;82(6):1932‐9. [MEDLINE: PMID: 2242519; ISSN: 0009‐7322] ">Juul‐Moller 1990</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13 (0.87 to 1.47)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0028" title="KaluscheD , StockingerJ , BetzP , RoskammH . Sotalol and quinidine/verapamil (Cordichin) in chronic atrial fibrillation – conversion and 12‐month follow‐up – a randomized comparison [Sotalol und Chinidin/Verapamil (Cordichin) bei chronischem Vorhoflimmern – Konversion und 12‐Monats‐Follow‐up – ein randomisierter Vergleich]. Zeitschrift fur Kardiologie1994;83 Suppl 5:109‐16. [MEDLINE: PMID: 7846939; ISSN: 0300‐5860] ">Kalusche 1994</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 (0.43 to 1.18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0039" title="FetschT , BauerP , EngberdingR , KochHP , LuklJ , MeinertzT , et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. European Heart Journal2004;25(16):1385‐94. [MEDLINE: PMID: 15302102; ISSN: 0195‐668X] FetschT , BurschelG , BreithardtG , EngberdingR , KochHP , LuklJ , et al. Medicamentous prevention after electric cardioversion of chronic atrial fibrillation. Goals and design of the PAFAC Study [Die medikamentöse Prophylaxe nach elektronischer Kardioversion von chronischem Vorhofflimmern. Ziele und Design der PAFAC‐Studie]. Zeitschrift fur Kardiologie1999;88(3):195‐207. [MEDLINE: PMID: 10355070; ISSN 0300‐5860] ">PAFAC 2004</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>244</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>377</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>255</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.88 to 1.08)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0051" title="VelosoHH , dePaolaAA . Analysis of atrial fibrillation recurrence during therapy with sotalol or quinidine. Researchers of +SOCESP [Analise da recorrencia de fibrilacao atrial durante terapia com sotalol ou quinidina. Investigadores da SOCESP]. Arquivos Brasileiros de Cardiologia1998;70(1):43‐9. [MEDLINE: PMID: 9629687; ISSN: 0066‐782X] dePaolaAA , VelosoHH . Efficacy and safety of sotalol versus quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation. SOCESP Investigators. American Journal of Cardiology1999;84(9):1033‐7. [MEDLINE: PMID: 10569659; ISSN: 0002‐9149] ">SOCESP 1999</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 (0.72 to 1.84)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0053" title="PattenM , KochHP , SonntagF , LuderitzB , MeinertzT . Medicamentous prevention of symptomatic paroxysmal atrial fibrillation/flutter onset. Goals and design of the SOPAT study. Executive committee of the investigators representing trial physicians [Die medikamentose Anfallsprophylaxe bei symptomatischem paroxysmalem Vorhofflimmern/‐flattern. Ziele und Design der SOPAT‐Studie. Investigators in Vertretung der Prufarzte]. Zeitschrift fur Kardiologie1999;88(3):185‐94. [MEDLINE: PMID: 10355069; ISSN: 0300‐5860] PattenM , MaasR , BauerP , LuderitzB , SonntagF , DluzniewskiM , et al. Suppression of paroxysmal atrial tachyarrhythmias – results of the SOPAT trial. European Heart Journal2004;25(16):1395‐404. [MEDLINE: PMID: 15321697; ISSN: 0195‐668X] ">SOPAT 2004</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>375</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>518</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>198</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.88 to 1.05)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Flecainide vs propafenone</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0005" title="AliotE , DenjoyI , The Flecainide AF French Study Group. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out‐patients with symptomatic paroxysmal atrial fibrillation/flutter. American Journal of Cardiology1996;77(3):66A‐71A. [MEDLINE: PMID: 8607394; ISSN: 0002‐9149] ">Aliot 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75 (0.48 to 1.16)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0022" title="ChimientiM , CullenMTJr , CasadeiG . Safety of flecainide versus propafenone for the long‐term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. European Heart Journal1995;16(12):1943‐51. [MEDLINE: PMID: 8682031; ISSN: 0195‐668X] ChimientiM , CullenMTJr , CasadeiG . Safety of long‐term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators. American Journal of Cardiology1996;77(3):60A‐75A. [MEDLINE: PMID: 8607393; ISSN: 0002‐9149] ">FAPIS 1996</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06 (0.70 to 1.62)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Amiodarone vs class I drugs</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0003" title="AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. Journal of the American College of Cardiology2003;42(1):20‐9. [MEDLINE: PMID: 12849654; ISSN: 0735‐1097] ">AFFIRM Substudy 2003</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>106</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66 (0.55 to 0.80)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0031" title="KochiadakisGE , IgoumenidisNE , HamilosMI , TzerakisPG , KlapsinosNC , ZacharisEA , et al. Long‐term maintenance of normal sinus rhythm in patients with current symptomatic atrial fibrillation: amiodarone vs propafenone, both in low doses. Chest2004;125(2):377‐83. [MEDLINE: PMID: 14769712; ISSN: 0012‐3692] ">Kochiadakis 2004a</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.64 (0.41 to 1.01)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0040" title="PITAGORA Study Investigators, GuliziaM , MangiameliS , OraziS , ChiarandàG , PiccioneG , et al. A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the PITAGORA trial. American Heart Journal2008;155(1):107.e1. [PUBMED: PMID: 18082498] ">PITAGORA 2008</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83 (0.66 to 1.06)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0058" title="VillaniR , ZolettiF , VenianiM , LocatiF , NavaS . A comparison between amiodarone and disopyramide in a delayed‐release formulation in the prevention of recurrences of symptomatic atrial fibrillation [Confronto fra amiodarone e disopiramide in formulazione retard nella prevenzione delle recidive di fibrillazione atriale sintomatica]. La Clinica Terapeutica1992;140(1 Pt 2):35‐9. [MEDLINE: PMID: 1559321; ISSN: 0009‐9074] ">Villani 1992</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55 (0.35 to 0.85)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0059" title="VitoloE , TronciM , LarovereMT , RumoloR , MorabitoA . Amiodarone versus quinidine in the prophylaxis of atrial fibrillation. Acta Cardiologica1981;36(6):431‐44. [MEDLINE: PMID: 7039195; ISSN: 0001‐5385] ">Vitolo 1981</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.40 (0.18 to 0.88)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Amiodarone vs dronedarone</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0018" title="LeHeuzeyJY , DeFerrariGM , RadzikD , SantiniM , ZhuJ , DavyJM . A short‐term, randomized, double‐blind, parallel‐group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. Journal of Cardiovascular Electrophysiology2010;21(6):597‐605. [PUBMED: PMID: 20384650 ] ">DIONYSOS 2010</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>116</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>255</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>163</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.59 to 0.82)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Amiodarone vs sotalol</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0003" title="AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. Journal of the American College of Cardiology2003;42(1):20‐9. [MEDLINE: PMID: 12849654; ISSN: 0735‐1097] ">AFFIRM Substudy 2003</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>131</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.54 to 0.86)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0030" title="KochiadakisGE , IgoumenidisNE , MarketouME , KaleboubasMD , SimantirakisEN , VardasPE . Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. Heart2000;84(3):251‐7. [MEDLINE: PMID: 10956284; ISSN 1355‐6037] KochiadakisGE , IgoumenidisNE , MarketouME , SolomouMC , KanoupakisEM , VardasPE . Low‐dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. American Journal of Cardiology1998;81(8):995‐8. [MEDLINE: PMID: 9576159; ISSN: 0002‐9149] KochiadakisGE , MarketouME , IgoumenidisNE , ChrysostomakisSI , MavrakisHE , KaleboubasMD , et al. Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm?. Pacing and Clinical Electrophysiology2000;23(11 Pt 2):1883‐7. [MEDLINE: PMID: 11139949; ISSN 0147‐8389] ">Kochiadakis 2000</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65 (0.46 to 0.92)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0037" title="NiuF , HuangCX , JiangH , YangB , GuoWL , ChenYX , et al. Effects of amiodarone versus sotalol in treatment of atrial fibrillation: a random controlled clinical study. Zhonghua Yi Xue Za Zhi2006;86(2):121‐3. [PUBMED: PMID: 16620720] ">Niu 2006</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.67 (0.47 to 0.94)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0040" title="PITAGORA Study Investigators, GuliziaM , MangiameliS , OraziS , ChiarandàG , PiccioneG , et al. A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the PITAGORA trial. American Heart Journal2008;155(1):107.e1. [PUBMED: PMID: 18082498] ">PITAGORA 2008</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78 (0.59 to 1.01)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0046" title="SinghBN , SinghSN , RedaDJ , TangXC , LopezB , HarrisCL , et al. Amiodarone versus sotalol for atrial fibrillation. New England Journal of Medicine2005;352(18):1861‐72. [MEDLINE: PMID: 15872201; ISSN: 0028‐4793] SinghSN , SinghBN , RedaDJ , FyeCL , EzekowitzMD , FletcherRD , et al. Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol‐Amiodarone Fibrillation Efficacy Trial [Safe‐T]). American Journal of Cardiology2003;92(4):468‐72. [MEDLINE: PMID: 12914883; ISSN 0002‐9149] ">SAFE‐T 2005</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>133</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>267</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>183</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 (0.62 to 0.82)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0057" title="VijayalakshmiK , WhittakerVJ , SuttonA , CampbellP , WrightRA , HallJA , et al. A randomized trial of prophylactic antiarrhythmic agents (amiodarone and sotalol) in patients with atrial fibrillation for whom direct current cardioversion is planned. American Heart Journal2006;151(4):863.e1‐6. [PUBMED: 16569550] ">Vijayalakshmi 2006</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.46 (0.16 to 1.32)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Dronedarone vs propafenone</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0014" title="ChunKJ , ByeonK , ImSI , ParkKM , ParkSJ , KimJS , et al. Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion. Clinical Therapeutics2014;36(9):1169‐75. [DOI: 10.1016/j.clinthera.2014.07.013; PUBMED: 25134972] ">Chun 2014</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97 (0.77 to 1.24)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Sotalol vs class I drugs other than quinidine</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0003" title="AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. Journal of the American College of Cardiology2003;42(1):20‐9. [MEDLINE: PMID: 12849654; ISSN: 0735‐1097] ">AFFIRM Substudy 2003</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.77 to 1.03)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0012" title="CarunchioA , FeraMS , MazzaA , BurattiniM , GrecoG , GalatiA , et al. A comparison between flecainide and sotalol in the prevention of recurrences of paroxysmal atrial fibrillation [Confronto tra flecainide e sotalolo nella profilassi delle recidive di fibrillazione atriale parossistica]. Giornale Italiano di Cardiologia1995;25(1):51‐68. [MEDLINE: PMID: 7642012; ISSN 0046‐5968] ">Carunchio 1995</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.33 (0.57 to 3.14)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0032" title="KochiadakisGE , IgoumenidisNE , HamilosME , TzerakisPG , KlapsinosNC , ChlouverakisGI , et al. Sotalol versus propafenone for long‐term maintenance of normal sinus rhythm in patients with recurrent symptomatic atrial fibrillation. American Journal of Cardiology2004;94(12):1563‐6. [MEDLINE: PMID: 15589019; ISSN: 0002‐9149] ">Kochiadakis 2004b</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 (0.89 to 1.73)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0044" title="ReimoldSC , CantillonCO , FriedmanPL , AntmanEM . Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. American Journal of Cardiology1993;71(7):558‐63. [MEDLINE: PMID: 8438741; ISSN: 0002‐9149] ">Reimold 1993</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.69 to 1.20)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Sotalol vs dofetilide</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0020" title="CambellTJ , GreenbaumRA , ChannerKS , DalrympleHW , KingmaJH , SantiniM , et al. Mortality in patients with atrial fibrillation – 1 year follow up of EMERALD (European and Australian multicenter evaluative research on atrial fibrillation dofetilide). Journal of the American College of Cardiology2000;35(2 Suppl A):154A‐5A. DalrympleHW , CambellTJ , ChannerKS , GreenbaumR , KingmaJH , SantiniM , et al. Maintenance of sinus rhythm by dofetilide improves quality of life. The EMERALD (European and Australian multicenter evaluative research on atrial fibrillation dofetilide) study. Circulation1998;98(Suppl 13‐14):66. GreenbaumR , CampbellTJ , ChannerKS , DalrympleHW , KingmaJH , SantiniM , et al. Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide. The EMERALD (European and Australian multicenter evaluative research on atrial fibrillation dofetilide) study. Circulation1998;98(Suppl I‐633):3326. USFood , DrugAdministration . Drug Approval Package: Tikosyn (Dofetilide). Medical Review: Parts 1 and 2 (Study number 345). www.accessdata.fda.gov/drugsatfda_docs/nda/99/20‐931_Tikosyn.cfm (accessed 10 August 2010). ">EMERALD 2000</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>196</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 (0.96 to 1.31)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Sotalol vs beta‐blockers</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0016" title="DAPHNE Study Investigators, CapucciA , BottoG , MolonG , SpampinatoA , FavaleS , et al. The Drug And Pace Health cliNical Evaluation (DAPHNE) study: a randomized trial comparing sotalol versus beta‐blockers to treat symptomatic atrial fibrillation in patients with brady‐tachycardia syndrome implanted with an antitachycardia pacemaker. American Heart Journal2008;156(2):373.e1‐8. [PUBMED: PMID: 18657671] ">DAPHNE 2008</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 (0.86 to 1.18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005049-bbs2-0041" title="PlewanA , LehmannG , NdrepepaG , SchreieckJ , AltEU , SchomigA , et al. Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol. European Heart Journal2001;22(16):1504‐10. [MEDLINE: PMID: 11482924; ISSN: 0195‐668X] ">Plewan 2001</a> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 (0.74 to 1.55)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>CI: confidence interval; RR: risk ratio.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Head‐to‐head trials: recurrence of atrial fibrillation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/full#CD005049-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005049-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Quinidine versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1646</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.01 [0.84, 4.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 All‐cause mortality – sensitivity analysis intention to treat (ITT) worse case: missing participants counted as events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1646</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.12 [0.96, 4.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 All‐cause mortality – subgroup analysis: older and recent studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1646</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.01 [0.84, 4.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Older studies, higher dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>412</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.74 [0.85, 8.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 More recent studies, lower dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.34, 4.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 All‐cause mortality – sensitivity analysis: persistent atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>865</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.82 [0.73, 4.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 All‐cause mortality – sensitivity analysis: low risk of bias studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.34, 4.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 All‐cause mortality – sensitivity analysis: studies &gt; 200 participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.34, 4.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Withdrawals due to adverse effects – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1669</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.87, 2.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Withdrawals due to adverse effects – subgroup analysis: older and recent studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1669</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.87, 2.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Older studies, higher dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>435</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.05 [1.29, 7.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 More recent studies, lower dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.61, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Withdrawals due to adverse effects – sensitivity analysis: persistent atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>877</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.19 [0.99, 4.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Withdrawals due to adverse effects – sensitivity analysis: low risk of bias studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.66, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Withdrawals due to adverse effects – sensitivity analysis: studies &gt; 200 participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.67, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Proarrhythmia – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1676</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.05 [0.95, 4.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Proarrhythmia – subgroup analysis: older and recent studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1677</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.05 [0.96, 4.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Older studies, higher dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.14 [0.87, 11.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 More recent studies, lower dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [0.61, 4.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Proarrhythmia – sensitivity analysis: persistent atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>877</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.64 [0.93, 7.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Proarrhythmia – sensitivity analysis: low risk of bias studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [0.61, 4.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Proarrhythmia – sensitivity analysis: studies &gt; 200 participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [0.61, 4.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Stroke – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.25, 3.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Stroke – sensitivity analysis: persistent atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>338</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.19, 4.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Stroke – sensitivity analysis: low risk of bias studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Stroke – sensitivity analysis: studies &gt; 200 participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Atrial fibrillation recurrence – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1624</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.78, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Atrial fibrillation recurrence – sensitivity analysis: persistent atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>825</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.70, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Atrial fibrillation recurrence – sensitivity analysis: low risk of bias studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.80, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Atrial fibrillation recurrence – sensitivity analysis: studies &gt; 200 participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.80, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Quinidine versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005049-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Disopyramide versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.25, 101.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 All‐cause mortality – intention to treat (ITT) worse case: missing participants counted as events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.55 [0.68, 45.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Withdrawals due to adverse effects – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.68 [0.95, 14.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Withdrawals due to adverse effects – sensitivity analysis: persistent atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.68 [0.95, 14.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Stroke – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.03, 2.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Stroke – subgroup analysis: persistent atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.03, 2.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Atrial fibrillation recurrence – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.59, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Atrial fibrillation recurrence – sensitivity analysis: persistent atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.59, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Disopyramide versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005049-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Propafenone versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.02, 1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 All‐cause mortality – intention to treat (ITT) worse case: missing participants counted as events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.45, 3.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 All‐cause mortality – sensitivity analysis: low risk of bias studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.00, 2.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Withdrawals due to adverse effects – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1098</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [1.07, 2.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Withdrawals due to adverse effects – sensitivity analysis: studies &gt; 200 participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>523</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.79, 2.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Proarrhythmia – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.39, 4.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Proarrhythmia – sensitivity analysis: low risk of bias studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.09, 2.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Atrial fibrillation recurrence – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1098</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.61, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Atrial fibrillation recurrence – sensitivity analysis: low risk of bias studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.50, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Atrial fibrillation recurrence – sensitivity analysis: studies &gt; 200 participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>523</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.63, 0.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Propafenone versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005049-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Flecainide versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Withdrawals due to adverse effects – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.41 [0.91, 260.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Proarrhythmia – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.80 [1.30, 17.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Proarrhythmia – sensitivity analysis: persistent atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>435</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.35 [0.91, 44.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Proarrhythmia – sensitivity analysis: low risk of bias studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>435</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.35 [0.91, 44.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Proarrhythmia – sensitivity analysis: studies &gt; 200 participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Stroke – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.04 [0.11, 39.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Stroke – subgroup analysis: persistent atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Stroke – sensitivity analysis: low risk of bias studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Stroke – sensitivity analysis: studies &gt; 200 participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Atrial fibrillation recurrence – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.55, 0.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Atrial fibrillation recurrence – sensitivity analysis: persistent atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>435</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.60, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Atrial fibrillation recurrence – sensitivity analysis: low risk of bias studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>435</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.60, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Atrial fibrillation recurrence – sensitivity analysis: studies &gt; 200 participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Flecainide versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005049-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Metoprolol versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [0.37, 11.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 All‐cause mortality – intention to treat (ITT) worse case: missing participants counted as events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.41, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 All‐cause mortality – sensitivity analysis: persistent atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [0.37, 11.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 All‐cause mortality – sensitivity analysis: low risk of bias studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [0.37, 11.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 All‐cause mortality – sensitivity analysis: studies &gt; 200 participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.0 [0.36, 134.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Withdrawals due to adverse effects – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.47 [1.48, 8.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Withdrawals due to adverse effects – sensitivity analysis: persistent atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.47 [1.48, 8.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Withdrawals due to adverse effects – sensitivity analysis: low risk of bias studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.47 [1.48, 8.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Withdrawals due to adverse effects – sensitivity analysis: studies &gt; 200 participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.33 [1.37, 8.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Proarrhythmia – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>18.14 [2.42, 135.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Proarrhythmia – sensitivity analysis: persistent atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>18.14 [2.42, 135.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Proarrhythmia – sensitivity analysis: low risk of bias studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>18.14 [2.42, 135.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Proarrhythmia – sensitivity analysis: studies &gt; 200 participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Atrial fibrillation recurrence – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.68, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Atrial fibrillation recurrence – sensitivity analysis: persistent atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.68, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Atrial fibrillation recurrence – sensitivity analysis: low risk of bias studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.68, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Atrial fibrillation recurrence – sensitivity analysis: studies &gt; 200 participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Metoprolol versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005049-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Amiodarone versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [0.55, 4.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 All‐cause mortality – intention to treat (ITT) worse case: missing participants counted as events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.64, 2.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 All‐cause mortality – sensitivity analysis: persistent atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [0.55, 4.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Withdrawals due to adverse effects – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.70 [1.91, 23.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Withdrawals due to adverse effects – sensitivity analysis: low risk of bias studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.98 [0.65, 38.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Proarrhythmia – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>673</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.22 [0.71, 6.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Proarrhythmia – sensitivity analysis: persistent atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>498</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.03 [0.52, 7.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Proarrhythmia – sensitivity analysis: low risk of bias studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Proarrhythmia – sensitivity analysis: studies &gt; 200 participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Stroke – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>399</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.30, 4.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Stroke – sensitivity analysis: persistent atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Stroke – sensitivity analysis: studies &gt; 200 participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Atrial fibrillation recurrence – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>812</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.46, 0.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Atrial fibrillation recurrence – sensitivity analysis: persistent atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>687</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.46, 0.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Atrial fibrillation recurrence – sensitivity analysis: low risk of bias studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>498</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.50, 0.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Atrial fibrillation recurrence – sensitivity analysis: studies &gt; 200 participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Amiodarone versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005049-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Dofetilide versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.76, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 All‐cause mortality – intention to treat (ITT) worse case: missing participants counted as events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.79, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 All‐cause mortality – sensitivity analysis: persistent atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.76, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 All‐cause mortality – sensitivity analysis: low risk of bias studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>506</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.77, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 All‐cause mortality – sensitivity analysis: studies &gt; 200 participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.76, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Withdrawals due to adverse effects – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>677</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [0.75, 4.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Withdrawals due to adverse effects – sensitivity analysis: persistent atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>677</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [0.75, 4.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Withdrawals due to adverse effects – sensitivity analysis: studies &gt; 200 participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>677</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [0.75, 4.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Proarrhythmia – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.50 [1.33, 22.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Proarrhythmia – sensitivity analysis: persistent atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.50 [1.33, 22.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Proarrhythmia – sensitivity analysis: low risk of bias studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>506</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.29 [0.50, 171.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Proarrhythmia – sensitivity analysis: studies &gt; 200 participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.50 [1.33, 22.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Atrial fibrillation recurrence – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.61, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Atrial fibrillation recurrence – sensitivity analysis: persistent atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.61, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Atrial fibrillation recurrence – sensitivity analysis: low risk of bias studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>506</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.54, 0.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Atrial fibrillation recurrence – sensitivity analysis: studies &gt; 200 participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.61, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Dofetilide versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005049-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Dronedarone versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.68, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 All‐cause mortality – intention to treat (ITT) worse case: missing participants counted as events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.67, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 All‐cause mortality – sensitivity analysis: persistent atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.04, 23.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 All‐cause mortality – sensitivity analysis: low risk of bias studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4628</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.66, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 All‐cause mortality – sensitivity analysis: studies &gt; 200 participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5872</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.68, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Withdrawals due to adverse effects – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [1.34, 1.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Withdrawals due to adverse effects – sensitivity analysis: persistent atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.51 [0.90, 234.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Withdrawals due to adverse effects – sensitivity analysis: low risk of bias studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4628</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [1.32, 1.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Withdrawals due to adverse effects – sensitivity analysis: studies &gt; 200 participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5872</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [1.31, 1.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Proarrhythmia – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5872</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [0.77, 4.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Proarrhythmia – sensitivity analysis: low risk of bias studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Proarrhythmia – sensitivity analysis: studies &gt; 200 participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Stroke – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5872</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.47, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Stroke – sensitivity analysis: studies &gt; 200 participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5872</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.47, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Atrial fibrillation recurrence – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1443</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.80, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Atrial fibrillation recurrence – sensitivity analysis: persistent atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Atrial fibrillation recurrence – sensitivity analysis: studies &gt; 200 participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Dronedarone versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005049-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Sotalol versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1882</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.23 [1.03, 4.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 All‐cause mortality – intention to treat (ITT) worse case: missing participants counted as events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2757</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [1.28, 3.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 All‐cause mortality – sensitivity analysis: persistent atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.51 [1.06, 5.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 All‐cause mortality – sensitivity analysis: low risk of bias studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.51 [1.06, 5.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 All‐cause mortality – sensitivity analysis: studies &gt; 200 participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1826</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.65 [1.16, 6.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Withdrawals due to adverse effects – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2688</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [1.23, 3.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Withdrawals due to adverse effects – sotalol: heterogeneity study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2688</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [1.23, 3.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 PAFAC and SOPAT trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.74, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Rest of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1701</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.77 [1.81, 4.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Withdrawals due to adverse effects – sensitivity analysis: persistent atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [1.28, 2.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Withdrawals due to adverse effects – sensitivity analysis: low risk of bias studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1686</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.82, 2.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Withdrawals due to adverse effects – sensitivity analysis: studies &gt; 200 participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1900</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [0.97, 3.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Proarrhythmia – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2989</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.55 [2.16, 5.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Proarrhythmia – sotalol: heterogeneity study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2826</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.43 [2.07, 5.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 PAFAC and SOPAT trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.51, 4.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Rest of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1840</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.32 [2.40, 7.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Proarrhythmia – sensitivity analysis: persistent atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1687</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.37 [2.25, 8.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Proarrhythmia – sensitivity analysis: low risk of bias studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1686</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.05 [1.73, 5.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Proarrhythmia – sensitivity analysis: studies &gt; 200 participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [1.77, 5.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Stroke – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.48, 4.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Stroke – sensitivity analysis: persistent atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>393</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.36, 5.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Stroke – sensitivity analysis: low risk of bias studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>768</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [0.20, 16.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Stroke – sensitivity analysis: studies &gt; 200 participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.48, 4.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Atrial fibrillation recurrence – main analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.80, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Atrial fibrillation recurrence – sensitivity analysis: persistent atrial fibrillation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1743</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.77, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Atrial fibrillation recurrence – sensitivity analysis: low risk of bias studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1686</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.82, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Atrial fibrillation recurrence – sensitivity analysis: studies &gt; 200 participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.81, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Sotalol versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005049.pub5/references#CD005049-tbl-0023">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD005049.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD005049-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD005049-note-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD005049-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD005049-note-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ko#CD005049-note-0006">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD005049-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD005049-note-0001">繁體中文</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD005049-note-0024">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005049\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005049\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005049\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005049\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005049\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005049\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005049\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005049\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005049\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005049\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005049\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005049\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005049\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005049\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005049\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005049\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005049\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005049\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=l7AWCCEw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005049.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005049.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD005049.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD005049.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005049.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726210370"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005049.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726210374"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005049.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e8e148db0f431',t:'MTc0MDcyNjIxMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 